The development, validation and application of analytical methods for the analysis of drugs of abuse. by Maguire, Richard
  
 
 
 
 
 
 
 
 
 
 
THE DEVELOPMENT, VALIDATION AND 
APPLICATION OF ANALYTICAL METHODS FOR THE 
ANALYSIS OF DRUGS OF ABUSE 
 
University of Dublin 
Trinity College 
 
 
 
THE DEVELOPMENT, VALIDATION AND APPLICATION OF 
ANALYTICAL METHODS FOR THE ANALYSIS OF DRUGS OF ABUSE 
 
 
 A thesis submitted in accordance with the requirements of the University of Dublin for the Degree of 
Philosophiae Doctor. 
 
By 
Richard Maguire, B.Sc. (Hons). 
 
Under the supervision of : 
Dr. Desmond Corrigan, B.Sc. (Pharm), M.A., Ph.D., F.P.S.I. 
 
May 2001 
 
 
 
 
Acknowledgements 
 
I would like to thank Dr. Des Corrigan for all his guidance and support over the years. I would also like 
to thank Mrs. Ingrid Hook and Dr. John Walsh for their help and support. I would like to pay a special 
tribute to Dr. Mary Meegan and J.J. Keating for all the hard work they have done, without their efforts, 
completion of this thesis would not have been possible. A big thanks is also due to Dr. Pierce 
Kavanagh for his help and advice.  Thanks also to the technical staff of the School of Pharmacy, but 
especially to Joe Reilly & Co.  
 
I would also like to thank the State Forensic Science Laboratory, especially Dr. Audrey O’Donnell, for 
their help. Thanks are also due to the Garda National Drugs Unit, the Department of Health and 
Children and the Department of Agriculture, Food and Forestry. I would also like to pay tribute to 
everyone in the Laboratory of the Drug Treatment Centre not only for access to client samples, but also 
for making me feel welcome since I began working there. 
 
In addition, I would like to thank the Post-grads in the School of Pharmacy but especially the post-
grads in the Department of Pharmacognosy James, Emmett and Richie and any other Lincoln affiliates. 
Special thanks go to Brendan for all his help academic, not to mention his mandolin purchasing,  skills.  
 
I also want to thank my friends whom I have had the pleasure of knowing; Conor, John, Kevin Mc., 
Kevin C., Dave, Fiona and Seamus. 
 
Many thanks to my Family for their support and encouragement. 
 
I would also like to acknowledge all the heartfelt support shown to me and my family by people who 
were around during the time of my Fathers illness and at the time of his death. I thank you all for just 
being around. 
 
Finally, HUGE  THANKS goes out  Sally-Ann, my long suffering girlfriend. 
  
 
ABSTRACT 
 
There are five chapters presented in this thesis. The first chapter deals with the development and 
validation of an analytical method, incorporating HPLC, for the analysis of MDMA in illicitly 
produced ecstasy tablets. In all 100 tablets were analysed and the MDMA content on average was 
found to be 79.01mg.  
 
The second chapter involved the analysis of route specific compounds (two pyrimidines and N-formyl 
BDB) generated by the synthesis of MBDB that had been synthesised via the Leuckart route. HPLC 
and GC-MS methods were developed and validated of for the analysis of the three target compounds. 
Solid phase extraction and liquid-liquid extraction were assessed as potentially suitable methods for the 
extraction of the three target compounds from MBDB synthesised via the Leuckart route. Street 
samples of MBDB were analysed and it was discovered that three of the tablets were likely to have 
been synthesised via Leuckart route.  
 
The most likely routes of synthesis of MDA, MDMA, MDEA, MBDB and 4-MTA were investigated 
in the Department of Pharmaceutical Chemistry. The third chapter involved subjecting impurities, 
intermediates and products generated by the routes investigated, to GC-MS analysis. Mass spectral data 
recorded was incorporated into a software based library which could be used as a forensic tool for the 
attempted identification of routes of synthesis. Samples licitly prepared Ecstasy and samples of illicitly 
prepared Ecstasy were subjected to GC-MS analysis. Where possible, routes of synthesis were 
identified with the aid of the library. 
 
Chapter IV involved the analysis of the 100 urine samples, taken from clients of the methadone 
programme in the Drug Treatment Centre in Dublin, which had tested positive for amphetamines on 
EMIT screening. A GC-MS method was used to determine whether the type of amphetamines being 
abused were non-ring substituted (amphetamine, methamphetamine), ring-substituted propanamines 
(MDA, MDMA, 4-MTA) or ring-substituted butanamines (MBDB, BDB). Amphetamine and 
methylenedioxy propanamines were found however, there was no abuse of 4-MTA or ring-substituted 
butanamines noted. 
 
The final chapter used GC-FID to determine the cannabinoid content of products of the plant Cannabis 
sativa seized and./or grown in the Republic of Ireland. THC, CBD and CBN levels were determined for 
62 samples of cannabis resin, 5 samples of herbal cannabis and 21 samples hemp. The average levels of 
THC, CBD and CBN in resin were 2.11%, 2.19% and 2.13% respectively. The average levels of THC, 
CBD and CBN in hemp were 0.06%, 1.61% and 0.06% respectively. The average levels of THC, CBD 
and CBN in herb were 0.20%, 0.13% and 0.65% respectively. 
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SUPPLEMENTRAY DISK 
 
 
 
 
 
Section 1.1: Background 
 
 
In the mid-1980’s the methylenedioxyamphetamines became the focus of intense scrutiny and 
controversy in the media, not only because of their association with previously discredited models of 
psychedelic psychotherapy, but because of their increasing recreational use by young people (Grob,  
1998). The compound 3,4-methylenedioxyamphetamine or MDA (4), is the parent compound of a 
series of methylenedioxyamphetamines which have come to be generally known as ecstasy. MDA (4) 
was first synthesised in 1910 by Mannich and Jacobson  (Mannich, 1910) and the N-methylated 
analogue of MDA, 3,4-methylenedioxymethamphetamaine or MDMA (5) has been known and 
patented since 1914 (Anon., 1914).  
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Figure 1.1:Mescaline (1), Phenylalkylamine backbone (2), amphetamine (3), 3,4-Methylenedioxyamphetamine (MDA) (4), 3,4-
Methylenedioxymethylamphetamine (MDMA) (5), 3,4-Methylenedioxyethylamphetamine (MDEA) (6), 3,4-
Methylenedioxyphenyl-2-butylamine (BDB)  (7), N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) (8), 4-
Methylthioamphetamine (4-MTA) (9) and Para-methoxyamphetamine (PMA) (10). 
 MDA (4) was the first hallucinogenic amphetamine derivative to show popularity as a recreational 
drug. MDA (4) is a phenethylamine resembling amphetamine (3) and mescaline (1) (Figure 1.1, 
above). MDA (4) is reported to act as a central nervous system stimulant that may be hallucinogenic in 
large doses (Naranjo, 1967). On methylation the MDMA (5) analogue is formed (Figure 1.1). Most of 
the known psychedelic drugs suffer a major loss of potency on N-methylation (Anderson, 1978). 
MDMA (5) is the exception to this rule as it, like amphetamine (3), maintains potency as the N-methyl 
homologue (Shulgin, 1986). Methylation does however produce significant changes in the 
pharmacological effects, resulting in a shorter duration of action, a decrease in potency and elimination 
of the hallucinogenic properties (Dal Cason, 1990; Shulgin, 1978).  
 
As a result of this observation Nichols et al. (1986a) describe these compounds as representing a new 
pharmacological class, known as the ‘’Entactogens’’. The word ‘’entactogen’’ is derived from the 
Greek roots ‘’en’’ meaning within, ‘’gen’’ meaning to produce and the Latin root ‘’tactus’’ for touch 
(to touch within ones self). Entactogens produce their unique behavioural effects without profound 
sensory experiences or distortion as observed with hallucinogenic or psychedelic drugs, such as 
Lysergic acid diethylamide (LSD) or Mescaline (1) (Naranjo, 1967). Thus, entactogens continue to be 
proposed as potential therapeutic agents in facilitating psychotherapy (Nichols, 1986a). 
 
Throughout the 1990’s, new ring substituted amphetamines appeared on the illicit drug market. The 
motivation for the supply of the new pharmacologically similar analogues was born out of attempts to 
elude legislative control. MDMA (5) and MDA (4) have been subject to control internationally, under 
the terms of the United Nations Convention on Psychotropic Substances 1971, since 1986 and 1990 
respectively (United Nations URL). However N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine 
(MBDB) (8), methylenedioxyethylamphetamine (MDEA) (6) , 4-methylthioamphetamine (4-MTA) (9) 
and para-methoxyamphetamine (PMA) (10) have appeared on the international drug market and have 
subsequently been scheduled as controlled substances. These compounds have not received the same 
attention in the literature as MDA (4) or MDMA (5). This observation may be an indication that these 
drugs have been abused to a lesser extent than MDA (4) and MDMA (5). However, they are still a 
major cause of concern for the relevant authorities and it does not seem to matter which of the 
compounds appears in an illicit tablet as it is still referred to as ecstasy. MDEA (6) and MBDB (8) 
appear to possess pharmacological activities comparable to MDA (4) and MDMA (5) (Nichols, 1986; 
Braun, 1980). It is of interest that MBDB (8) is found to be only slightly less toxic than MDMA (5) in 
one study (Johnson, 1989) and slightly less potent in another (Nichols, 1986a).  There is very little 
literature available for 4-MTA (9) and PMA (10), however both drugs have been linked to fatalities 
(Elliot, 2000; Felgate, 1998) and would therefore be considered toxic under certain conditions.  
 
The acute and chronic toxicity of the methylenedioxyamphetamines is an area of much controversy, 
however numerous animal studies which have shown toxicity, have been reviewed (Steele, 1994; 
McCann, 1996). Clinical observations were reported after MDMA (5) or MDEA (6) intoxications, 
including loss of appetite, nausea, muscle pain and/or cramps, ataxia (Greer, 1986), mental confusion, 
depression, anxiety (Strafer, 1985), hypothermia, convulsions and cardiac disrythmias (Johnson, 1989) 
which dispel any theory that these drugs are harmless. There are also a significant number of accounts 
of ecstasy related deaths published in the scientific arena involving MDA (4) or MDMA (5) 
(Chadwick, 1991; Campkin, 1992; Felgenhauer, 1999 and O’Connor, 1999), MDEA (6) (Tsatsakis, 
1997) and MBDB (8) (Carter, 2000). These fatalities serve to highlight the risks associated with the 
illegal use of these drugs. A review of 32 deaths related to amphetamine derivatives in Spain from 
1993 to 1995 show high blood levels of methylenedioxyamphetamine and paramethoxy amphetamine 
derivatives (Lora-Tamayo, 1997). 
 
Section 1.2: Qualitative and quantitative considerations 
 
Given that the term ‘’Ecstasy’’ can refer to anyone of a series of drugs including MDA (4), MDMA 
(5), MDEA (6), and MBDB (8)  (Figure 1.1), it is important to be able to distinguish between these 
compounds when analysing tablets purportedly containing ‘’Ecstasy’’. The quantity of active material 
in these tablets is quite variable, but the dosage is reported to be around 100mg for MDA (4), MDMA 
(5) and MDEA (6) (King, 1997). The expected MBDB (8) content in illicit tablets was also reported to 
be around 100mg (Van Aerts, 2000).  The content of MDMA (5) in a number of tablets analysed was 
reported to vary from trace amounts to 180mg (O’Connell, 1999). A recent communication from the 
European Monitoring Centre for Drugs and Drug Addiction warned of 4 tablets, seized in France, 
which contained extremely high levels of MDMA (5) (>200mg MDMA) (Wallon, 2000). It is 
important to be able to detect, not only, the identity of the main ingredient and/or ingredients but also 
to accurately estimate the amount of active(s) in the dosage form.  Higher doses of MDMA (5) seem to 
be linked with many of the unpleasant side effects reported (Solowij, 1992) 
 
There are many well established techniques available when analysing illicitly prepared tablets for 
Ecstasy content. Many of the established methods are targeted at some or all of the methylenedioxy 
compounds, and some also target the non-ring substituted amphetamine type compounds like 
amphetamine (3) itself and methamphetamine, but methods for only the methylenedioxy compounds 
are described here.  
 
Gas Chromatography 
 
Gas chromatography-mass spectrometry (GC-MS) seems to be the method of choice for the analysis of 
methylenedioxyamphetamines, where electron ionisation (EI) is the favoured ionisation mode 
(O’Connell, 1999; Furnari, 1998; Dawson, 1997; de Boer, 1997; King, 1994; Noggle, 1988; Borth, 
2000 and de Ruiter, 1995). This is most likely because the mass spectral data allows the possibility of 
unequivocal identification of an unknown analyte. GC-MS has also been extensively used in the 
analysis of ecstasy type compounds and their metabolites in biological fluids (Helmlin, 1996; Maurer, 
1996; Kintz, 1997; Fallon, 1999; Garret, 1991; Bogusz, 2000 and Valentine, 2000). MDA (4), MDMA 
(5), and MDEA (6) were successfully separated by Noggle et al.  (1988), and by O’Connell et al. 
(1999). BDB (7) and MBDB (8) were the focus of another GC-MS separation (Kintz 1997), while 
Dawson et al. (Dawson, 1997) analysed only MDEA (6). The separation of MDMA (5) and MBDB (8) 
was the subject of another GC-MS procedure (Noggle, 1991). Enantiomeric separation has also been 
achieved for MDMA (5) (de Boer, 1997).  Borth et al. analysed a series 2,3-
methylenedioxyamphetamines and 3,4-methylenedioxyamphetamines using tandem GC-MS or GC-
MS-MS (Borth, 2000). 
 
MDA (4) and MDMA (5) have been analysed by Gas chromatography with flame ionisation detection 
(GC-FID) (Gupta, 1977), as have MDA (4), MDMA (5) and MDEA (6) (McAvoy, 1999). MDA (4), 
MDMA (5), MDEA (6) and MBDB (8) have also been separated by this technique (Furnari, 1998). 
GC-FID is not as popular as GC-MS, as no spectral information is supplied by this method.  
 
High Performance Liquid Chromatography 
 
High performance liquid chromatography (HPLC) has also been used extensively in the analysis of 
methylenedioxyamphetamine type compounds. The chromatographic system that is normally employed 
involves the use of a reverse phase system with ultra-violet-visible (UV–Vis) detection (McAvoy, 
1999; Sadeghipour, 1997a; Sadeghipour, 1997b; Longo, 1994; Pok Phak Rop, 1995; Clark, 1995; 
Noggle, 1991 & Noggle, 1988). Some methods focus only on the separation of MDA (4) and MDMA 
(5), as these were the first of the methylenedioxyamphetamines to appear on the illicit drug market 
(Garret, 1991). Others include the separation of MDA (4), MDMA (5) and MDEA (6) (Noggle, 1988; 
Noggle, 1987; McAvoy, 1999; Sadeghipour, 1997b & Longo, 1994). Other than Sadeghipour et al.  
(1997a), who used a fluorimetric detection system, none of the other workers seem to focus on the 
separation of MDA (4), MDMA (5), MDEA (6) and MBDB (8) from one another, however Clarke et 
al. (1995) describe a method that may be applicable to the analysis of all four compounds. Other 
methods focus solely on MDEA (6) and MDMA (5) (Pok Phak Rop, 1995) or MBDB (8) and MDMA 
(5) (Noggle, 1991) with the exclusion of all other Ecstasy type compounds.  
 
Other HPLC systems employed cyclodextrin stationary phases which allowed the separation of MDA 
(4), MDMA (5), MDEA (6) and MBDB (8), and also achieved separation of their enantiomers. These 
methods are generally used in the analysis of biological fluids (Sadeghipour, 1998). Other workers 
focused only on the enantiomeric separation of R- and S- MDMA (5) (Fallon, 1999).  
 
Many different detection systems have also been employed. In most cases a fixed wavelength UV-Vis 
detector (Noggle, 1988; Noggle, 1991; Noggle, 1987; Sadeghipour, 1997b; Clark, 1995 and Garret, 
1991) was used. Diode Array Detectors (DAD) (McAvoy, 1999; Pok Phak Rop, 1995 and Longo, 
1994) and fluorimetric detectors (Sadeghipour, 1997a; Sadeghipour, 1998 and Pok Phak Rop, 1995) 
have also been used. The fluorimetric detector is possibly the best choice, as the methylenedioxy-
bridge is a fluorescent moiety and as such is the detected unit. The background interference compared 
to that from a conventional UV-Vis detector is drastically reduced and in essence the sensitivity is 
increased. These detectors also have the added advantage of allowing more rapid analysis as the 
selectivity increases dramatically and as such co-eluting interfering compounds are not a problem as 
they are invisible to the detector unless they fluoresce over the same specific range as the 
methylenedioxy bridge. 
 
Miscellaneous Chromatographic Methods 
 
Other separation methods that have been proposed as potentially useful techniques for the analysis of 
the methylenedioxyamphetamines include Capillary Zone Electrophoresis (CZE) and Super Critical 
Fluid Chromatography (SFC). MDA (4), MDMA (5) and MDEA (6) were analysed using CZE, which 
showed potential as both a qualitative and quantitative analytical method for these compounds 
(McAvoy, 1999 and Sadeghipour, 1997b). McAvoy et al. also investigated the use of SFC as a 
qualitative and quantitative method (McAvoy, 1999). 
 
 Thin Layer Chromatography (TLC) has found application in the analysis of the ring-substituted 
amphetamines  (Munro, 1995; Martel, 1986 and O’Brien, 1982) but has been overshadowed by HPLC 
and GC-MS.  TLC can be useful however as it is very quick to set up, it is also very cheap, so it can 
often be used as a preliminary analytical step before other more sophisticated chromatographic 
techniques are used. Furnari et al. employed a TLC system for the analysis of various sugars used as 
excipients in Ecstasy tablets (Furnari, 1998). 
 
Immunoassays such as Radioimmunoassay, Elisa, Fluorescence polarisation immunoassay and 
competitive binding assays, (Baker 1995; Ruangyultikarn, 1998; Wu,  1993 and Dasgupta, 1993) have 
also been employed in the analysis of ring-substituted amphetamines.  
 
 
 
 
 
Spectroscopic Methods 
 
Nuclear magnetic resonance (NMR), which is the most important tool available with respect to the 
structural elucidation of unknown molecules, has been used in the analysis of the ring-substituted 
amphetamines. However it is difficult to obtain good NMR spectra if there is more than one compound 
in an illicit sample. Because of this, some preparative chromatographic step would be used or else a 
hyphenated chromatographic technique such as GC-MS would find favour. Dal Cason et al. (1997) 
detailed the proton (H1) and carbon (C13) NMR assignments for MDA (4), MDMA (5) and MDEA (6) 
and other analogues of MDA (4). NMR has been used in the identification of MDEA (6) in an illicit 
tablet after liquid-liquid extraction (Dawson, 1997) and also in the identification of MDMA (5) 
(Bailey, 1975). Noggle et al.  (1987) used NMR to good effect for the identification of MDA (4), 
MDMA (5), MDEA (6) and a variety of N-alkyl derivatives of MDA (4) after synthesis. Lee et al. used 
NMR to identify MDEA (6) and MDMA (5) in illicit tablets using solid state NMR, and also to identify 
a variety of excipients (Lee, 2000). 
 
Raman spectroscopy is a new technique which may well find favour in the future but which is having 
its progress as a routine method stifled as it has to compete with well established GC-MS techniques. 
Raman spectroscopy has been successfully used in the analysis of ring-substituted amphetamines (Bell, 
2000; Ryder, 1999 and Dawson, 1997) but problems can arise when mixtures of drugs are analysed.  
However if the excipients are poor Raman scatterers then this technique can be quite useful as it 
involves little or no sample preparation and the results are rapidly available. Sonderamann et al. (1999) 
used Near Infra-Red (NIR) spectroscopy in the analysis of these compounds. Infra-red and UV-Vis 
spectroscopy have also been used, but are not considered as useful when compared to GC-MS. HPLC 
with suitable spectroscopic detection and GC-MS seem to be the mainstay of ring-substituted 
amphetamine analysis. 
 
Sample Extraction 
 
The extraction of the methylenedioxy amphetamines from illicitly produced tablets prior to 
chromatographic analysis is not complicated. Some approach the extraction by simply mixing an 
aliquot of a homogenised tablet in a polar organic solvent (O’Connell, 2000; Pop Phak Rop, 1995) or 
dilute acid (Sadeghipour, 1997b; Longo, 1994). The mixture is agitated, by vortex mixing and/or 
sonication, and any undissolved material is then removed by filtration or centrifugation. This method is 
suitable for HPLC and GC-MS analysis where the resultant extract can be directly injected into the 
chromatographic system, however in the case of GC-MS care must be taken as polar organic solvents 
can sometimes cause bad peak tailing, especially where methanol is used (Furnari, 1998). Sometimes in 
GC-MS analysis the preferred technique is to dissolve an aliquot of powdered tablet in an alkaline 
solution and then to extract using an immiscible solvent (Furnari, 1998; Dawson, 1997).  
 
Section 1.3: Objectives  
The objective of the work presented in this chapter was to design a HPLC separation for the analysis of 
a mixture of MDA (4), MDMA (5), MDEA (6) and MBDB (8). The precision and selectivity of this 
was assessed, in order that a reliable qualitative method could be established for each of the 
compounds. The linearity was assessed using external standardisation, so that the method could be used 
for quantitative determinations of MDMA (5). Once established the method was used in quantitative 
determinations of MDMA (5) in illicitly produced tablets seized in the Republic of Ireland. 
 
An extraction procedure was investigated and validated for accuracy (i.e. recovery of MDMA (5)). 
Once a suitable extraction procedure was established it was intended that this method be used in 
conjunction with the previously established quantitative HPLC procedure in the analysis of illicitly 
prepared tablets.  
 
A batch of 100 illicitly prepared tablets confiscated by the Garda National Drugs Unit (GNDU) bearing 
a Mitsubishi logo and purported to contain MDMA (5) was supplied for analysis (see Figure 1.2). The 
main active compound in the batch of 100 Mitsubishi tablets was to be identified using retention time 
data for the already established HPLC method. This method would further be used with the validated 
extraction protocol for the quantitative analysis of uniformity of MDMA (5) content in the batch of 
tablets. A number of miscellaneous tablets, also supplied by the GNDU, were also analysed 
qualitatively using the HPLC method. Finally any unusual samples (containing compounds other than 
MDA (4), MDMA (5), MDEA (6) and MBDB (8)) which were available were subjected to GC-MS 
analysis.  
 
Figure 1.2:Image of Mitsubishi tablets analysed. 
 
 
 
Section 2.1: Instrumentation 
HPLC-UV 
The HPLC system consisted of a Waters 600 controller and pump, a Waters 2487 Dual λ absorbance 
UV detector. The integrator was a Waters 746 data module. The chromatographic column used was a 
Waters Spherisorb® 5µm ODS1 (4.6mm × 250mm) analytical column. Samples were introduced into 
the system using a Rheodyne model 7125.  
 
GC-MS 
The GC-MS consisted of a Varian 3800 GC coupled to a Varian Saturn 2000 Ion Trap Mass 
Spectrometer (mass range 50-650). Varian Saturn Workstation Software was used to control the 
system.  The column used was a 30M Varian DB-35 (35%-phenyl-65%-dimethylsiloxane copolymer), 
which had a 0.25mm internal diameter and a 0.1µm film thickness. 
 
Miscellaneous Instruments 
The centrifuge used was a Sanyo Harrier 18/80 benchtop centrifuge. The ultrasonic bath was a Decon 
FS4006.  The pH meter used was a Metrohm 744 pH meter, equipped with a Metrohm 6.0228.000 
glass pH electrode. All weighing was carried out using a Sartorius BP110 S analytical weighing 
balance. 
 
Section 2.2: Preparation of buffer solutions and mobile phases 
 
Preparation of buffers 
The pH 3 phosphate buffer was prepared by adding 34g of KH2PO4 to 800 ml of HPLC grade water 
and adjusting to pH 3.0 using phosphoric acid.  
 
Preparation of Mobile Phases 
All organic solvents used for chromatographic purposes were HPLC grade. All buffers were filtered 
through a Millipore filtration apparatus (42µm cut-off).  After the mobile phase was prepared by 
adding the correct ratio of each component to the mixture, the solutions were subjected to 
ultrasonication for 20 minutes, in order to degas. 
Section 2.3: Development of a chromatographic system for analysis of MDA (4), MDMA (5), MDEA (6) and MBDB (8) using 
HPLC-UV. 
 
Preparation of analytical solutions 
All reference solutions were prepared by dissolving 0.1 mg in 1 ml of methanol unless otherwise 
stated. 
Reference solution 1: MDA (4). 
Reference solution 2: MDMA (5). 
Reference solution 3: MDEA (6). 
Reference solution 4: MBDB (8). 
Reference solution 5: A mixture containing 0.1 mg/ml each of MDA (4), MDMA (5), MDEA (6) and 
MBDB (8) dissolved in methanol. 
 
Chromatographic system 
The chromatographic systems investigated are outlined below in Table 2.3.1 
System Mobile Phase Constituents Proportions Flow Rate  Wavelength  
1 pH 3.0 Phosphate Buffer : 
MeOH: ACN : Triethylamine 
600 : 100 : 25 : 1 1.5 ml/min 280 nm 
2 pH 3.0 Phosphate Buffer : 
ACN : Triethylamine 
600 : 100 : 1 1.5 ml/min 280 nm 
3 pH 3.0 Phosphate Buffer : 
ACN : Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.3.1: Chromatographic conditions used for the analysis of MDMA (5). 
 
Analysis 
An aliquot (20 µl) of each reference solutions was analysed separately under the above 
chromatographic conditions outlined for system 1, 2 and 3. For results and discussion see section 3.1. 
  
Section 2.4 Assessment of precision of the selected chromatographic method. 
 
Preparation of analytical solutions 
Reference solution 5: A mixture containing 0.1 mg/ml each of MDA (4), MDMA (5), MDEA (6) and 
MBDB (8) dissolved in methanol. 
 
Chromatographic conditions 
The chromatographic system used is outlined below in Table 2.4.1  
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.4.1: Chromatographic conditions used for the analysis of MDMA (5). 
 
 
Analysis 
 
Six replicate injections (20µl) were chromatographed. This data generated was then used to 
test the precision of the method. For results and discussion see section 3.2. 
 
 
Section 2.5 Assessment of selectivity of the selected chromatographic method. 
 
Preparation of analytical solutions 
All standard solutions 7-12 of potentially interfering compounds were prepared by dissolving 1.0mg 
aliquots of the respective compound in 1ml of acetonitrile, unless otherwise stated. 
Reference solution 7: BDB (7). 
Reference solution 8: 4-MTA (9). 
Reference solution 9: Ketamine (27). 
Reference solution 10: Amphetamine (3). 
Reference solution 11: Caffeine (28). 
Reference solution 12: Paracetamol (29). 
 Chromatographic conditions 
The HPLC conditions used in the analysis are outlined in Table 2.5.1. 
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.5.1: Chromatographic conditions used for the analysis of MDA (4), MDMA (5), MDEA (6) and MBDB (8). 
 
 
Analysis 
The selectivity of the above chromatographic system was tested by a series of 5µl injections of 
reference solutions 7-12 inclusive. For results and discussion see section 3.3. 
 
Section 2.6: Assessment of linearity of response for MDMA in the selected 
chromatographic system. 
 
Preparation of the analytical solutions 
Reference solution 13: A 0.25 mg/ml MDMA (5) standard was prepared by dissolving 2.97mg of 
MDMA•HCl in methanol. 
Reference solution 14: A 0.50 mg/ml MDMA (5) standard was prepared by dissolving 5.95mg of 
MDMA•HCl in methanol. 
Reference solution 15: A 0.75 mg/ml MDMA (5) standard was prepared by dissolving 8.92mg of 
MDMA•HCl in methanol. 
Reference solution 16: A 1.0 mg/ml MDMA (5) standard was prepared by dissolving 11.90mg of 
MDMA•HCl in methanol. 
 
Chromatographic conditions 
The chromatographic system used is outlined below in Table 2.6.1  
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.6.1: Chromatographic conditions used for the analysis of MDMA (5). 
 
Analysis 
 
Each of the solutions 13, 14, 15 and 16, were injected (20µl) in duplicate, into the chromatographic 
system with aid of a microlitre syringe. The peak areas, determined by integration, were averaged and 
plotted against concentration in order to assess the linearity of the method. For results and discussion 
see section 3.4. 
 
Section 2.7: GC-MS analysis of reference MDMA (5) standard. 
 
MDMA (5) Standard 
MDMA (5) synthesised in the Department of Pharmaceutical Chemistry in the School of Pharmacy 
was used as standard (Keating, 2001).  
 
Preparation of solution 17 
Powdered MDMA•HCl (10mg) was dissolved in 1 ml of water, in a test tube. Aliquots of conc. 
ammonia (100 µl) and petroleum ether (1 ml) were added and the contents of the test tube were shake 
for circa (ca.) 1minute. The supernatant petroleum ether was transferred to a glass vial and evaporated 
under a stream of nitrogen. The residue was re-dissolved in acetonitrile (500 µl) and labelled test 
solution 17. 
 
 
 
 
 
 
 
  
 
 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 2.7.1. 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent Methanol 
 
Table 2.7.1: GC-MS conditions used for the qualitative analysis of Standard MDMA (5). 
 
 
Analysis 
 
Test solution 17 was analysed using the above chromatographic conditions. The results and discussion 
can be found in Section 3.5. 
 
 
 
 
 
Section 2.8: Determination of the active compound 
contained in ‘’Mitsubishi’’ tablets 
 
HPLC analysis of  ‘’Mitsubishi’’ tablet 
 
Tablet Analysed 
One ‘’Mitsubishi’’ tablet from a batch of 100 tablets supplied by the GNDU was analysed. The tablets 
were bi-convex, slightly off white tablets bearing a ‘’Mitsubishi’’ logo on one side.  
 
Extraction 
Powdered tablet (10mg) was dissolved in 1 ml of methanol. The supernatant was removed and labelled 
test solution 18. 
 
Chromatographic conditions 
The chromatographic system used is outlined below in Table  2.8.1 
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.8.1: Chromatographic conditions used for the analysis of ‘’Mitsubishi’’ tablet. 
 
Analysis 
A volume (20 µl) of test solution 18 was introduced into the chromatographic system outlined above. 
For results and discussion see section 2.8.1. 
 
GC-MS analysis of ‘’Mitsubishi’’ Tablet 
 
Tablet Analysed 
One ‘’Mitsubishi’’ tablet from a batch of 100 tablets supplied by the GNDU was analysed.  
 
 
Extraction 
Powdered tablet (10mg) was dissolved in 1 ml of water, in a test tube. Aliquots of conc. ammonia (100 
µl) and petroleum ether (1 ml) were added and the contents of the test tube were shaken for ca. 
1minute. The supernatant petroleum ether was transferred to a glass vial and evaporated under a stream 
of nitrogen. The residue was re-dissolved in acetonitrile (500 µl) and labelled test solution 19. 
 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 2.8.2 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Impact 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent Methanol 
 
 
Table 2.8.2: GC-MS conditions used for the qualitative analysis of ‘’Mitsubishi’’ tablet. 
 
 
 
 
Analysis 
 
Test solution 19 was analysed using the above chromatographic conditions. The results and discussion 
can be found in Section 10.6. 
 
Section 2.9: Validation of extraction of MDMA (5) from 
illicitly produced tablets using liquid extraction. 
 Extraction protocol 
To 25 mg of powdered homogenised ‘’Mitsubishi’’ tablet in a centrifuge tube, was added 8mls of 
methanol. This solution was vortex mixed for 10 seconds before being sonicated for 10 minutes. The 
tubes were then centrifuged at 1000 rpm for 10 minutes. After centrifugation the supernatant was added 
to a 25ml volumetric flask, the contents made up to volume with methanol and the flask was marked 
test solution 20. The pellet remaining in the centrifuge tube after removal of the supernatant was re-
extracted in 8mls of methanol and vortex mixed. The solution was sonicated for a further 10 minutes, 
after which time it was centrifuged for 10 minutes at 1000rpm. The supernatant was then transferred to 
a 25ml volumetric and made up to volume with methanol and the flask was marked test solution 21. 
The pellet was re-extracted in 8mls of methanol. Homogenisation was achieved by vortex mixing. The 
solution was sonicated and then subjected to centrifugation (1000rpm, 10minutes). The supernatant 
was then transferred to a 25ml volumetric flask. The volumetric flask was made up to volume with 
methanol.  The flask was labelled solution 22. 
 
The above procedure was repeated so the analysis could be carried out in duplicate giving test solutions 
23-25 respectively. 
 
 
 
 
 
 
 
 
Chromatographic conditions 
 
The chromatographic system used is outlined below in Table 2.9.1 
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.9.1: Chromatographic conditions used for the analysis of MDMA (5). 
 Analysis 
Test solution 20,21, 22, 23, 24 and 25 were analysed, in duplicate, by injecting them into the HPLC 
system (20µl). The peak areas estimated by the integrator were recorded and graphed against extraction 
number. For results and discussion see section 3.7. 
 
Section 2.10: Determination of uniformity of content in 
suspected MDMA (5) containing tablets using HPLC-UV. 
 
Preparation of the analytical solutions 
 
Reference solution 13: A 0.25 mg/ml MDMA (5) standard was prepared by dissolving 2.97mg of 
MDMA•HCl in HPLC. 
Reference solution 14: A 0.50 mg/ml MDMA (5) standard was prepared by dissolving 5.95mg of 
MDMA•HCl in HPLC. 
Reference solution 15: A 0.75 mg/ml MDMA (5) standard was prepared by dissolving 8.92mg of 
MDMA•HCl in HPLC. 
Reference solution 16: A 1.00 mg/ml MDMA (5) standard was prepared by dissolving 11.90mg of 
MDMA•HCl in HPLC. 
 
Tablets analysed 
A batch of 100 tablets supplied by the Garda National Drugs Unit were extracted and analysed as 
outlined below. The tablets were bi-convex, slightly off white tablets bearing a ‘Mitsubishi’ logo on 
one side (see Figure 2.10.1 below). The tablets were well made and not chipped to any extent on 
inspection. Tablet weights were recorded for the tablets. 
 Figure 2.10.1: Image of Mitsubishi tablets analysed. 
 
A further twenty miscellaneous tablets were analysed. Physical descriptions of these tablets are 
outlined in Table 2.10.1 below. 
 
Tablet Number Logo/Shape Tablet Number Logo/Shape 
1a No logo/Cross shaped 11a Bird/round 
2a No logo/Cross shaped 12a Bird/round 
3a Mitsubishi/round 13a Bird/round 
4a Mitsubishi/round 14a Bird/round 
5a Mitsubishi/round 15a Bird/round 
6a $/round 16a Bird/round 
7a $/round 17a Bird/round 
8a Bird/round 18a Bird/round 
9a Bird/round 19a Bird/round 
10a Bird/round 20a Bird/round 
 
Table 2.10.1: Description of miscellaneous tablets analysed by HPLC 
  
Extraction protocol 
To 25 mg of powdered homogenised tablet in a centrifuge tube, was added 8mls of methanol. This 
solution was vortex mixed for 10 seconds before being sonicated for 10 minutes. The tubes were then 
centrifuged at 1000 rpm for 10 minutes. After centrifugation the supernatant was added to a 25ml 
volumetric flask. The pellet remaining in the centrifuge tube after removal of the supernatant was re-
dissolved in 8mls of methanol and vortex mixed. The solution was sonicated for a further 10 minutes, 
after which time it was centrifuged for 10 minutes at 1000rpm. The supernatant was then added to the 
previously extracted supernatant in the 25ml volumetric flask. The flask was then made up to volume 
with methanol.  This procedure was carried out in duplicate for each of the tablets analysed. 
Chromatographic conditions 
The chromatographic system used is outlined below in Table 2.10.2  
Mobile Phase Constituents Proportions Flow Rate  Wavelength  
pH 3.0 Phosphate Buffer : ACN : 
Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 2.10.2: Chromatographic conditions used for the analysis of MDMA (5). 
 
 
Analysis 
Each of the reference solutions 13, 14, 15 and 16, were injected in duplicate (20µl). Peak areas were 
calculated by the integrator. The average of the areas for duplicate injections were calculated and 
plotted against concentration. Each of the tablet extracts was injected in duplicate in the 
chromatographic system outlined above (20 µl). The peak areas were estimated and concentrations of 
MDMA were calculated from the standard curve. For results and discussion see Section 3.8. 
 
Section 2.11 Analysis of tablet 3a by GC-MS 
 
Preparation of analytical solutions 
Reference solution 26: 0.1 mg/ml solution ketamine (27) in methanol. 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 2.11.1. 
 
 
 
 
 
 
 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent Methanol 
 
Table 2.11.1: GC-MS conditions used for the qualitative analysis of  illicitly prepared tablets. 
 
 
 
Analysis 
 
Reference solution 26 was analysed under the above chromatographic conditions. The extract of 
sample 3a extracted by the method described in section 9.8 was chromatographed in the system 
outlined above. The mass spectrum for the most significant peak was compared to the Varian reference 
library, which is part of the Varian Saturn software. The unknown was also compared to the spectrum 
obtained from reference solution 26. For results and discussion see section 3.9. 
 
 
 
Section 3.1: Development of a chromatographic system for analysis of MDA (4), 
MDMA (5), MDEA (6) and MBDB (8) using HPLC-UV. 
 
Three chromatographic systems were investigated in the separation MDA (4), MDMA (5), MDEA (6) 
and MBDB (8)  (Table 3.1.1). 
 
System Mobile Phase Constituents Proportions Flow Rate  Wavelength  
1 pH 3.0 Phosphate Buffer : 
MeOH: ACN : Triethylamine 
600 : 100 : 25 : 1 1.5 ml/min 280 nm 
2 pH 3.0 Phosphate Buffer : 
ACN : Triethylamine 
600 : 100 : 1 1.5 ml/min 280 nm 
3 pH 3.0 Phosphate Buffer : 
ACN : Triethylamine 
600 : 100 : 1 2.0 ml/min 280 nm 
 
Table 3.1.1: Chromatographic conditions used for the analysis of MDMA (5). 
 
Clark et al. used system 2 as a means of separating MDA (4), MDMA (5) and MDEA (6) and in a 
separate experiment used the same system to separate a series of methylenedioxybutanamines such as 
BDB (7) and MBDB (8) (Clark, 1995). Clark et al did not attempt a separation of MDA (4), MDMA 
(5), MDEA (6) and MBDB (8). By injecting aliquots of reference solution 5 (containing all four 
compounds) chromatographic data was acquired for each of the three systems. A chromatogram 
obtained under the conditions outlined in system 3 (Table 3.1.1) is shown below (Figure 3.1.2).  
 
 
 
 
 
 
 
 Figure 3.1.2: Chromatographic profile obtained for a 0.1 mg/ml mixture of MDA (4), MDMA (5), MDEA (6) and MBDB (8). 
 
Chromatographic parameters such as capacity factors, resolution, peak tailing and column 
efficiency were calculated manually and are tabulated below (Table 3.1.3). For details of the 
formulae used see appendix I. Visual inspection of a typical chromatogram shows separation was 
achieved and the peaks are symmetrical. The order of elution was determined by sequentially 
injecting reference solutions 1-4 containing MDA (4), MDMA (5), MDEA (6) and MBDB (8) 
respectively. The retention times were compared with those of the chromatographed mixture and 
the identities of the peaks were determined. The retention time relative to MDMA (5) were also 
calculated (Table 3.1.3). The first compound to elute was MDA (4) at ca. 4.37 minutes followed by 
the more polar MDMA (5) at ca. 5.72 minutes. MDEA (6) eluted at ca. 7.66 minutes and its isomer 
MBDB (8) at ca. 9.43 minutes was the last compound to elute.  
 
 
 
 
 
Peak Peak 
Identity 
tR tR Relative 
to MDMA 
Width Capacity 
Factor 
Resolution Asymmetry Theoretical 
Plates 
1 MDA (4) 4.37 mins 0.76 0.15 mins 3.37 -- 1.1 13,580 
2 MDMA (5) 5.72 mins 1.00 0.15 mins 4.72 9.00MDA/MDMA 1.1 23,266 
3 MDEA (6) 7.66 mins 1.34 0.25 mins 6.66 11.08MDMA/MDEA 1.1 19,397 
4 MBDB (8) 9.43 mins 1.65 0.30 mins 8.43 6.60MDEA/MBDB 1.1 15,809 
 
Table 10.1.3 Table of chromatographic parameters calculated from the HPLC trace recorded for the 
separation of MDA (4), MDMA (5), MDEA (6), MBDB (8). 
 
In each case the tailing factors were within acceptable  limits (Dolan, 2000) and the resolution 
between the peaks was excellent, where all calculated resolution values exceeded 6.60. The 
calculated theoretical plate values were high enough to indicate the column was performing 
satisfactorily. The capacity factors of the analytes were within acceptable limits (2-10 ideally; 
Dolan, 2000). The wavelength of 280 nm, a common wavelength used in the analysis of aromatic 
compounds seemed to be suitable, as there was a relatively good response from the detector and 
little or no background at the 0.10 mg/ml level investigated.  
 
The conclusion, that system 3 was the best, was arrived at on the basis that the chromatography was 
acceptable (i.e. tailing, resolution and column efficiency). Another reason for this conclusion was 
that the compounds eluted from the column under the conditions of system three more quickly that 
from either of the other two chromatographic systems, which would keep the run-time to a 
minimum.  
 
Section 3.2: Assessment of precision of the chromatographic method 
 
Chromatographic parameters, such as, retention time and area (for six replicate injections) were 
determined using the integrator (see Table 3.2.1) for the four peaks in the chromatograms resulting 
from injections of reference solution 5. Chromatographic parameters such as retention times and peak 
areas, from the replicate injection of a standard mixture containing MDA (4), MDMA (5), MDEA (6) 
and MBDB (8), were acquired via electronic integration for all of the peaks (see Table 3.2.1) 
 
Compound Average 
Retention 
Time  
Relative 
Standard 
Deviation 
Average 
Peak Area 
Relative 
Standard 
Deviation 
MDA (minutes) 4.38 mins 0.52 % 1554207 7.36 % 
MDMA (minutes) 5.79 mins 0.71 % 1948065 7.24 % 
MDEA (minutes) 7.74 mins 0.74 % 1535068 6.99 % 
MBDB (minutes) 9.51mins 0.75 % 2289160 6.94 % 
 
Table 3.2.1: Chromatographic parameters for peaks in six replicate injections of reference solution 5 
 
 
The relative standard deviations (R.S.D) (see Appendix I) of the retention times for all four compounds 
were low enough for the precision to be considered good. The relative standard deviation is a term 
often used to describe the precision (Riley, 1996). Ideally one strives to minimise the relative standard 
deviation as much as possible, but values of less than two are usually considered very good (Riley, 
1996). The peak area deviated more than the retention time, however the deviation was acceptable. 
This deviation could have been reduced by the use of an internal standard and it is advisable that any 
future work would use a suitable internal standard. The precision of the method was considered to be 
good, as there was little deviation in the retention time and the peak areas as estimated by the 
integrator. 
 
Section 3.3: Assessment of selectivity of the chromatographic method. 
 
The selectivity of chromatographic system 3 (see Section 2.3) was assessed by injecting various 
potential interfering compounds, such as caffeine (28), paracetamol (29), ketamine (27), 
amphetamine (3), BDB (7) and 4-MTA (9) (reference solutions 7-12) into the system. If one 
includes MDA (4), MDMA (5), MDEA (6) and MBDB (8) were 10 compounds. The resolution 
between the chromatographic peak of these 10 compounds should ideally be greater than 1. The 
retention time and resolution between all of these compounds, with respect to each other was 
calculated and is shown below (see Figure 3.3.1). 
 
 
Compound Retention Time (minutes) Resolution 
Paracetamol 2.87 minutes 10.27 (Paracetamol, MDA) 
MDA 4.31minutes 5.19 (MDA, MDMA) 
MDMA 5.63 minutes 3.36 (MDMA, BDB) 
BDB 6.77minutes 2.18 (BDB, MDEA) 
MDEA 7.51 minutes 1.70 (MDEA, Caffeine) 
Caffeine 8.09 minutes 0.94 (Caffeine, Ketamine) 
Ketamine 8.41 minutes 2.09 (Ketamine, MBDB) 
MBDB 9.21 minutes 1.52 (MBDB, 4-MTA) 
4-MTA 9.84 minutes  
Amphetamine No peak recorded at 280nm  
 
Figure 3.3.1: Retention times, and resolution values estimated for the analysis of selectivity of chromatographic system 3. 
 
The selectivity of the method with respect to other methylenedioxyamphetamines, (MDA (4), 
MDMA (5), MDEA (6) and MBDB (8)) was adequate, this was clearly shown in section 3.1 where 
the resolution values were acceptable. Amphetamine (3) did not give a signal at 280 nm over the 15 
minute period monitored. Caffeine (28) did not interfere with the method as it eluted before MBDB 
(8).  4-MTA (9) eluted just after the MBDB (8) peak at ca. 9.84 minutes. The resolution between 
the two peaks was calculated to be circa 1.52, which would indicate, that the peaks did not interfere 
with each other and that this method would be suitable for the analysis of 4-MTA (9). Ketamine 
(27) eluted between MDMA (5) and MDEA (6) in the chromatogram but as there was particularly 
good resolution between these compounds to begin with ketamine (27) did not interfere. Hence the 
method is considered selective for the methylenedioxyamphetamines and also may be an 
appropriate method for the analysis of ketamine (27) and 4-MTA (9) also.  
  
 
 
 
Section 3.4: Assessment of linearity of the chromatographic method for MDMA (5). 
 
The linearity of the method for MDMA (5) was tested by performing external standardisation. Using a 
series of standards, reference solutions 13-16, varying in concentration (0.25 mg/ml, 0.50 mg/ml, 0.75 
mg/ml and 0.10 mg/ml respectively) the peak area was used to plot a standard curve. The average peak 
area for two injections of each of the aforementioned standards can be seen in Table 3.4.1. A plot of the 
average peak area for two injections versus the concentration can also be seen below. (see Figure 
3.4.1). 
 
Solution Number Standard Concentration Average Peak Area 
4 0.25 mg/ml 5600990 
5 0.50 mg/ml 9904739 
6 0.75 mg/ml 1408798 
7 0.10 mg/ml 19738837 
 
Table 3.4.1: Average peak area for two injections of MDMA (5) standards 
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Figure 3.4.1: Plot of average peak area versus concentration of MDMA (5) standard. 
 
One can clearly see from the above plot that the relationship between MDMA (5) concentration and 
peak area is linear. The R2 value as calculated with the aid of Microsoft Excel was found to be 0.99 
(Microsoft®, 1997). The R2   parameter is a correlation coefficient  which is a measure of goodness of 
fit of a set data points to a linear trend. A value of +1 indicates perfect correlation and a positive slope 
(Riley, 1996). Values of greater than 0.9 are considered very good. The equation of the line was 
estimated to be y = 18647x + 683941. The linearity test conducted indicated that relationship between 
the absorbance of MDMA (5) and concentration obeyed Beer’s law (Appendix I) and hence it was 
acceptable to use this method in the quantitation of MDMA (5) in illicit tablets provided that a suitable 
extraction technique could be established. 
 
Section 3.5: GC-MS analysis of reference MDMA (5) standard 
 
A  GC-MS of the standard MDMA (5) was run. This would help prove the identity and purity of the 
standard MDMA (5) which had been synthesised in the Department of Pharmaceutical Chemistry in 
the School of Pharmacy, T.C.D.  It was found that only one peak eluted for MDMA (5) in the 
chromatogram at 6.4 minutes, indicating that there were no other impurities present in the standard (see 
Figure 3.5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1: GC-MS trace for the MDMA (5) standard. 
Section 3.6: Determination of the active compound contained in ‘’Mitsubishi’’ tablets using HPLC and GC-MS 
 The GC-MS procedure outlined in section 2.8 was used to assess the type of compound contained 
in the ‘Mitsubishi’’ tablets. The tablet analysed was found to contain MDMA (5) as the peak 
eluted at 6.5 minutes (the same retention time as that of the standard MDMA, discussed above, 
Section 3.5). The GC-MS chromatogram of the tablet extract is shown below (Fig 3.6.1a). As can 
be seen MDMA (5) was the main peak in the chromatogram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.6.1a:GC-MS chromatogram of the ‘’Mitsubishi’’ tablet extract. 
The mass spectrum was also a good match with that of the standard MDMA (5) when searched 
against the National Institute of Standards and Technology (NIST) mass spectral library (see 
Figure 3.6.1b) (NIST, 1995). The NIST library is an electronic database containing thousands of 
reference EI mass spectra. 
 
Figure 3.6.1b: NIST library comparison of standard MDMA (5) from library and compound found in  ‘’Mitsubishi’’ tablet. 
The uppermost spectrum represents the NIST library spectrum, including the structure of MDMA (5). The lowermost 
spectrum was the spectrum acquired when the standard extract was chromatographed The middle spectrum represents the 
difference spectrum between the uppermost and the lowermost spectrum in the figure. 
 
A tablet extract was also chromatographed using the HPLC system described earlier (see Section 
2.3). It was found that the only peak to elute under the chromatographic conditions described in 
section 2.8 did so at 5.72 minutes, which was the same time as the standard (see Figure 3.6.2). 
 
 
 
 
 
 
 
Figure 3.6.2: HPLC chromatogram of ‘’Mitsubishi’’ tablet extract. 
 Section 3.7: Extraction of MDMA (5) from illicitly produced 
tablets using liquid extraction. 
 
It was established that the tablet to be used in the validation of the extraction of MDMA (5) actually 
contained MDMA (5) by a simple methanol extraction followed by HPLC analysis and GC-MS see 
Section 2.8). In order to determine the recovery of MDMA (5) from illicitly prepared tablets an 
experiment was designed. This experiment involved the extraction of MDMA (5) from an illicitly 
prepared tablet with methanol with the aid of sonication and centrifugation. The supernatant was 
removed (test solution 20). The pellet left after the first extraction was re-extracted (test solution 21). 
Finally the pellet from the second extraction was re-extracted again (test solution 22). This procedure 
was carried out in duplicate (test solutions 23, 24 and 25 respectively). Each extract was made up to 
25mls and subjected to HPLC analysis. The averaged peak areas returned for the duplicate procedure 
were plotted and are shown below (see Figure 3.7.1).  
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Figure 3.6.1: Plot of peak area versus MDMA (5) recovery (peak area) used to establish the best method for the extraction of 
MDMA (5) form illicitly prepared tablets. 
 
As can be seen from the above graph the majority of MDMA (5) is extracted after the first extraction 
but there is still MDMA (5) extracted with the second extraction. The third extraction seemed 
unnecessary as there did not seem to be any MDMA (5) left to extract. Hence it was decided that 
maximum recovery of MDMA (5) from illicitly prepared tablets could be achieved with two 
extractions using methanol.  
 
Section 3.8: Analysis of suspected MDMA (5) containing 
tablets using HPLC-UV. 
 
A new standard curve was prepared each day and as sample extracts became available they were 
subjected to the HPLC analysis outlined in system 3, section 2.3. Samples, which had been extracted in 
duplicate, were chromatographed in duplicate and average peak areas were calculated from integrator 
data. These peak areas were then interpolated from the standard curve and the amount of MDMA (5) 
per tablet was estimated by substituting the values in the formula below with experimental values. 
 
 
The estimated amounts of MDMA (5), as calculated from HPLC data for the 100 ‘Mitsubishi’ tablets 
are shown below (see Table 3.8.1). 
Tablet 
Number 
MDMA 
(mg) 
Tablet 
Number 
MDMA 
(mg) 
Tablet 
Number 
MDMA 
(mg) 
Tablet 
Number 
MDMA 
(mg) 
1 85.67mg 26 75.74mg 51 76.40mg 76 86.90mg 
2 74.40mg 27 76.90mg 52 76.13mg 77 85.00mg 
3 73.62mg 28 70.56mg 53 87.89mg 78 84.95mg 
4 72.36mg 29 78.16mg 54 83.93mg 79 89.91mg 
5 79.02mg 30 82.39mg 55 75.90mg 80 85.70mg 
6 59.24mg 31 73.91mg 56 76.95mg 81 98.18mg 
7 73.31mg 32 69.63mg 57 78.16mg 82 66.51mg 
8 77.30mg 33 74.31mg 58 72.04mg 83 83.43mg 
9 90.94mg 34 70.41mg 59 76.51mg 84 77.29mg 
10 89.73mg 35 82.44mg 60 79.65mg 85 78.01mg 
11 79.62mg 36 75.17mg 61 79.41mg 86 77.96mg 
12 88.07mg 37 83.66mg 62 62.05mg 87 82.00mg 
13 68.54mg 38 77.84mg 63 68.12mg 88 78.94mg 
14 76.06mg 39 76.77mg 64 70.44mg 89 76.92mg 
15 80.21mg 40 77.43mg 65 79.01mg 90 81.63mg 
16 97.64mg 41 80.92mg 66 76.29mg 91 76.87mg 
17 84.09mg 42 78.83mg 67 75.23mg 92 76.51mg 
18 77.69mg 43 78.40mg 68 79.17mg 93 82.15mg 
19 63.39mg 44 76.52mg 69 78.25mg 94 71.95mg 
20 76.64mg 45 94.88mg 70 74.30mg 95 72.09mg 
21 80.33mg 46 76.46mg 71 75.96mg 96 81.36mg 
22 78.04mg 47 87.88mg 72 84.65mg 97 78.01mg 
23 80.05mg 48 89.02mg 73 78.72mg 98 79.47mg 
24 90.17mg 49 80.82mg 74 90.41mg 99 72.24mg 
25 83.79mg 50 84.01mg 75 89.72mg 100 78.93mg 
 
Table 3.8.1: MDMA (5) content (mg) estimated for a batch of 100 Mitsubishi tablets analysed by HPLC 
 
The average amount of MDMA (5) calculated for the 100 tablets analysed was 79.01mg, with a 
standard deviation of 6.91mg. The relative standard deviation was calculated and found to be 8.74%. 
The lowest concentration was 59.24 mg and the highest concentration was 98.18 mg. The tablets were 
obviously not made to pharmaceutical grade but it was of interest to compare the British 
Pharmacopoeia (BP) requirements for Uniformity of Content of tablets to the batch analysed in this 
case. The BP general monograph (BP, 2000) concerning uniformity of content states, that if one or 
more tablets out of 10 analysed are outside the limit of 85%-115% of the stated amount but within the 
limit 75%-125%, then 20 more tablets should be analysed. Then if out of the 30 analysed there is not 
more than one individual tablet outside the 85%-115% and none are outside the limits 75%-125% the 
batch can be accepted, otherwise the batch must be rejected. If we consider the batch here and say the 
target content is the average we can see whether the tablets conform to the BP monograph. Table 3.8.2 
shows the uniformity of content values calculated with 79.01 mg as the target concentration, solving 
the equation below arrived at the percentage values. 
 
None of the tablets were outside the wider interval, 75%-125%. However tablets 6 (75%), 16 (124%), 
19 (80%), 45 (120%) and 81 (124%) were outside the narrower range. 
 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
1 108 26 96 51 97 76 110 
2 94 27 97 52 96 77 108 
3 93 28 89 53 111 78 108 
4 92 29 99 54 106 79 114 
5 100 30 104 55 96 80 108 
6 75 31 94 56 97 81 124 
7 93 32 88 57 99 82 84 
8 98 33 94 58 91 83 106 
9 115 34 89 59 97 84 98 
10 114 35 104 60 101 85 99 
11 101 36 95 61 101 86 99 
12 111 37 106 62 79 87 104 
13 87 38 99 63 86 88 100 
14 96 39 97 64 89 89 97 
15 102 40 98 65 100 90 103 
16 124 41 102 66 97 91 97 
17 106 42 100 67 95 92 97 
18 98 43 99 68 100 93 104 
19 80 44 97 69 99 94 91 
20 97 45 120 70 94 95 91 
21 102 46 97 71 96 96 103 
22 99 47 111 72 107 97 99 
23 101 48 113 73 100 98 101 
24 114 49 102 74 114 99 91 
25 106 50 106 75 114 100 100 
 
Table 3.8.2: Uniformity of content for batch of 100 Mitsubishi tablets analysed by HPLC 
 
If it was a pharmaceutical product the batch would therefore be rejected. It is worth noting however 
that in this instance the majority of the tablets, 95%, are within the limits, indicating that the tablets are 
reasonably well made. 
 
The average weight of tablets was 0.305g, with a standard deviation of 0.017%. The relative standard 
deviation was 5.73%. The BP also has a monograph for the uniformity of weight of uncoated tablets. 
The tablets analysed were uncoated. The monograph states that out of 20 tablets, randomly chosen and 
weighed, not more than two tablets may deviate from the target weight by more than 5%, and no tablets 
at all should deviate by more than 10%. Table 3.8.3 shows the uniformity of weight data for tablets. 
 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
Tablet 
Number 
MDMA 
(%) 
1 110 26 99 51 99 76 105 
2 108 27 101 52 97 77 100 
3 96 28 99 53 106 78 103 
4 93 29 93 54 105 79 109 
5 95 30 109 55 105 80 106 
6 87 31 91 56 104 81 99 
7 100 32 88 57 104 82 100 
8 96 33 91 58 96 83 103 
9 96 34 85 59 103 84 103 
10 103 35 103 60 97 85 99 
11 105 36 101 61 106 86 101 
12 105 37 95 62 80 87 106 
13 103 38 102 63 90 88 99 
14 97 39 93 64 99 89 100 
15 104 40 98 65 100 90 105 
16 105 41 98 66 98 91 98 
17 103 42 100 67 100 92 98 
18 99 43 99 68 106 93 104 
19 90 44 96 69 107 94 91 
20 105 45 105 70 98 95 96 
21 106 46 91 71 93 96 102 
22 98 47 105 72 99 97 102 
23 104 48 110 73 101 98 99 
24 107 49 97 74 106 99 97 
25 101 50 95 75 108 100 105 
 
Table 3.8.3: Uniformity of weight for batch of 100 Mitsubishi tablets analysed by HPLC 
 
Solving the equation below arrived at the values in Table 3.8.3. 
 
 
Looking at the uniformity of content (Table 3.8.3) it appears that the samples vary significantly in 
weight and would certainly not comply with the monograph.  Graphs of Uniformity of Content and 
Uniformity of Weight were plotted versus ‘’Mitsubishi’’ tablet number (see Figure 3.8.4).  
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Figure 3.8.4 continued: Graphs of Uniformity of Content and Uniformity of Weight plotted against ‘’Mitsubishi’’ Tablet number. 
(a) tablets 51-75, (b) tablets 76-100. 
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Figure 3.8.4 continued: Graphs of Uniformity of Content and Uniformity of Weight plotted against ‘’Mitsubishi’’ Tablet number. 
(c) tablets 51-75, (d) tablets 76-100. 
 
The plots were made for every 25 samples such that the spread could be seen. As can be seen from 
visual inspection of the graphs there seems to be a link between the uniformity of content and the 
uniformity of weight.  
 
In conclusion the tablets analysed would appear to be reasonably well made based on the appearance 
and the uniformity of content data. An MDMA (5) concentration of 79.01mg is the low end of the 
scale, if one considers the average concentration to be ca. 100mg. The underground text ‘Secrets of 
Methamphetamine Manufacture’  (Uncle Fester, 1996) advocates the use of 100mg. Shulgin 
experimented with 100mg and 120mg  (Shulgin, 1991) and many laboratory investigations have proved 
that the concentration of MDMA (5) in illicitly prepare tablets range from trace (O’Connell, 2000)-
300mg (Wallon, 2000) 
. 
The miscellaneous samples, which were analysed (Table 2.10.1) had the concentration of MDMA (5) 
calculated from a standard curve and the above equation in the same way as the batch of 
aforementioned ‘Mitsubishi’ tablets. Table 2.8.4 below details the results of the analysis. 
 
Tablet Number Logo/Shape Tablet Weight (g ) MDMA (mg) 
1a No logo/Cross shaped 0.3758g 77.60mg 
2a No logo/Cross shaped 0.3882g 77.14mg 
3a Pink mottled/round 0.5471g ----- 
4a Mitsubishi/round 0.2910g 78.45mg 
5a Mitsubishi/round 0.3020g 82.68mg 
6a Mitsubishi/round 0.3099g 80.44mg 
7a $/round 0.3070g ---- 
8a $/round 0.2866g ---- 
9a Bird/round 0.2617g 108.75mg 
10a Bird/round 0.2525g 114.93mg 
11a Bird/round 0.2135g 114.80mg 
12a Bird/round 0.2343g 115.39mg 
13a Bird/round 0.2135g 97.88mg 
14a Bird/round 0.2343g 99.68mg 
15a Bird/round 0.2701g 111.77mg 
16a Bird/round 0.2612g 123.56mg 
17a Bird/round 0.2751g 117.56mg 
18a Bird/round 0.2711g 110.51mg 
19a Bird/round 0.2703g 111.16mg 
20a Bird/round 0.2550g 93.15mg 
 
Table 3.8.4: Physical appearance & MDMA (5) content of miscellaneous tablets analysed by HPLC-UV. 
 
Tablets 1a and 2a were cross-shaped tablets, which were nicknamed shamrocks when introduced to the 
Irish market (see Figure 3.8.5). 
 
 
 
 
Figure 3.8.5: Image of  ‘’Shamrock’’ MDMA tablet. 
These tablets were reported by the Irish media to contain twice the normal amount of MDMA (5) 
(Williams, 1999). In the case of our analysis the two tablets which were analysed were found to contain 
ca. 77mg of MDMA (5) in each. The Mitsubishi tablets analysed, which were not part of the batch that 
was analysed earlier, contained a similar level to the amount observed in the larger batch. The average 
of the three tablets was 80.52mg, with a standard deviation of 1.73mg.  Whether these tablets were 
from the same batch or not, isn’t known, but this result backs up the theory that the tablets may have 
been intended to contain ca. 80mg MDMA (5). It was not known whether the tablets bearing the bird 
logo were from the same batch or not (see Figure 3.8.6). 
 
 
Figure 3.8.6: Image of  MDMA tablet bearing a Bird logo. 
 
 These tablets varied greatly in MDMA (5) content where the average was 109.92mg MDMA (5), with 
standard deviation of 8.47mg. The relative standard deviation was 7.7%. The MDMA (5) concentration 
is certainly higher in the case of these tablets when compared to the ‘Mitsubishi’ tablets. 
 
The other tablets analysed did not contain MDMA (5). Tablets 7a and 8a contained MBDB (8), which 
was confirmed in section 3.8. The amounts of MBDB (8) in found in tablets were discussed in section 
3.9 as estimated by HPLC-UV analysis.  
 
Section 3.9: Analysis of tablet 3a by GC-MS 
 
The large pink speckled tablet, 3a, did not appear to contain any of the methyelendioxyamphetamines 
when analysed by HPLC, it did however have a compound eluting from the chromatographed extract at 
ca. 4.7minutes which may indicate that the compound was ketamine (see Section 3.3 above). The tablet 
extraction mixture was subjected to GC-MS analysis and was found to contain ketamine (27) eluting at 
8.8 minutes, when compared to the NIST mass spectral library. The library spectrum and the sample 
spectrum are shown below (Figure 3.9.1). The difference between the two spectra is also included and 
one can see that there is little difference between the two spectra from Figure 3.9.1. The quality of the 
hit in the NIST library was found to be 793, which is reasonable. The structure of ketamine (27) is 
shown below (Figure 3.9.2). A reference solution of ketamine (27) was analysed, where ketamine was 
found to elute at 8.8 minutes. The spectrum of the standard and tablet extract were also a good match 
which confirm that the tablet 3a contained ketamine (27). 
 
 
 
Figure 3.9.1: The uppermost spectrum represents the NIST library spectrum, including the structure of ketamine (27). The 
lowermost spectrum was the spectrum acquired when the sample of 3a extract was chromatographed The middle spectrum 
represents the difference spectrum between the uppermost and the lowermost spectrum in the figure. 
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Figure 3.9.2: Structure of ketamine (27), the compound found to be eluting at 8.8 minutes in the GC-MS trace of the extract of 
sample 3a. 
Section 3.10: Conclusion 
 
A valid method for the extraction of MDMA (5) from illicit tablets followed by analysis via HPLC-UV 
was successfully established. The HPLC-UV method was considered to be useful as a qualitative 
method for the analysis of MDA (4), MDMA (5), MDEA (6), MBDB (8), 4-MTA (9) and ketamine 
(27), however this was not fully validated. The method may well also be suitable for the quantitation of 
the aforementioned compounds but again this was not the subject of validation. The batch of 100 
tablets bearing the Mitsubishi logo appeared to be well made and would possibly pass the some of the 
BP requirements for manufactured tablets. The miscellaneous tablets for the most part contained 
MDMA (5), however samples containing ketamine (27) and MBDB (8) were also identified. 
 
 
Section 5.1: Instrumentation 
HPLC 
The HPLC consisted of a Shimadzu LC-6A isocratic pump and a Shimadzu SPD-M10AVP diode array 
detector (DAD). The chromatographic system was controlled using Shimadzu CLASS-VP software 
(version 5.032). The chromatographic column used was a Waters Spherisorb® 5µm ODS1 (4.6mm × 
250mm) analytical column. Samples were introduced into the system using a Rheodyne model 7125.  
 
GC-MS 
The GC-MS consisted of a Varian 3800 GC coupled to a Varian Saturn 2000 Ion Trap Mass 
Spectrometer (mass range 50-650 m/z). Varian Saturn Workstation software was used to control the 
system. The column used was a 30M Varian DB-35 (35%-phenyl-65%-dimethylsiloxane copolymer), 
which had a 0.25mm internal diameter and a 0.1µm film thickness. 
 
Miscellaneous Instruments 
The centrifuge used was a Sanyo Harrier 18/80 benchtop centrifuge. The ultrasonic bath was a Decon 
FS4006.  The pH meter used was a Metrohm 744 pH meter, equipped with a Metrohm 6.0228.000 
glass pH electrode. All weighing was carried out using a Sartorius BP110 S analytical weighing 
balance. 
 
Section 5.2: Preparation of buffer solutions and mobile phases 
pH 3.0 buffer 
The pH 3 phosphate buffer was prepared by adding 34g of KH2PO4 to 800mls of HPLC grade water 
and adjusting to pH 3.0 using phosphoric acid.  
 
pH 4.0 buffer 
The pH 4.0 buffer was prepared by dissolving 5.04 g Na2HPO4 and 3.01 g of KH2PO4 in sufficient 
HPLC grade water to produce 1000ml. The solution was then adjusted to pH 4.0 with glacial acetic 
acid. 
 
pH 4.9 buffer 
The pH 4.9 buffer was prepared by dissolving 40 g Na2HPO4 and 1.2 g of NaOH in sufficient HPLC 
grade water to produce 100 ml. If necessary the pH was adjusted to 4.9 with 1M H2SO4 or 1M NaOH as 
required. 
 
pH 6.0 buffer 
Phosphate buffer of pH 6.0 was prepared by mixing 50 ml of 0.2M potassium dihydrogen (volumetric 
solution) orthophosphate with 5.70 ml of sodium hydroxide 0.2M (volumetric solution). 
 
pH 7.0 buffer 
Phosphate buffer of pH 7.0 was prepared by mixing 50 ml of 0.2M potassium dihydrogen 
orthophosphate (volumetric solution) with 29.6 ml of sodium hydroxide 0.2M (volumetric solution). 
 
Preparation of Mobile Phases 
All organic solvents used were HPLC grade. All buffers were filtered through a Millipore filtration 
apparatus (42µm cut-off).  After the mobile phase was prepared by adding the correct ratio of each 
component to the mixture the solutions were subjected to ultrasonication for 20 minutes, in order to 
degas them. 
 
Section 5.3: Liquid chromatographic separation of seven Leuckart specific 
impurities derived from the synthesis of MBDB (8) 
   
Preparation of Analytical Solutions: 
All standard impurity solutions 1-7 were prepared by dissolving 0.5 mg aliquots of the relevant 
compound(s) in 1ml of acetonitrile (ACN) unless otherwise stated. 
Reference Solution 1: N-formyl BDB (17). 
Reference Solution 2: 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20).  
Reference Solution 3: 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21). 
Reference Solution 4: 2,6-diethyl-3,5-di(3,4-metyhylenedioxyphenyl)pyridine (22). 
Reference Solution 5: 2,6-dimethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine (23). 
Reference Solution 6: 2-ethyl-5-methyl-3-(3,4-methylenedioxyphenyl)-6-(3,4-methylenedioxybenzyl) 
pyridine (25). 
Reference Solution 7: 2,4-diethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine (26). 
Reference Solution 8: A combined standard solution (ca. 0.5mg/ml) of compounds 17, 20, 21, 22, 23, 
25 & 26 in acetonitrile. 
 
Chromatographic conditions 
The chromatographic conditions used are outlined in Table 5.3.1 below. A waters 5 ODS1column 
(4.6mm × 250mm) was used in all HPLC analysis.  
 
System Mobile Phase Constituents Proportions Flow Rate  Wavelength Range 
1 pH 3.0 Phosphate Buffer : ACN  60:40 1.0 ml/min 190-370 nm 
2 pH 3.0 Phosphate Buffer : ACN : THF* 66 : 25 : 13 1.0 ml/min 190-370 nm 
3 pH 3.0 Phosphate Buffer : ACN : THF* 66 : 25 : 13 1.5 ml/min 190-370 nm 
 
Table 5.3.1: Chromatographic conditions used in the analysis of seven Leuckart impurities  (17, 20, 21, 22, 23, 25 & 26)  derived 
from the synthesis of MBDB (8).  (*Tetrahydrofuran (THF). 
 
Analysis 
The mixture containing all of the standards (reference solution 8) was analysed using the mobile phase 
conditions shown in Table 5.3.1. Each of the individual peaks was identified using reference solutions 
1-7. The retention times, column efficiency, resolution and tailing factor were determined using the 
equations in appendix I. The results of these experiments are shown in section 6.1. 
 
 
 
 
 
 
Section 5.4: HPLC-DAD separation of three Leuckart impurities derived from 
the synthesis of MBDB (8) 
 
Three experiments were carried out including, section 5.4.1 the development of the liquid 
chromatographic separation, section 5.4.2 the assessment of the precision of the most suitable system 
and section 5.4.3 assessment of the selectivity of the most suitable system. 
 
Section 5.4.1 Development of HPLC-DAD separation of three Leuckart impurities derived from 
the synthesis of MBDB (8) 
 
Preparation of analytical solutions 
All standard impurity solutions 9-11 were prepared by dissolving 0.15 mg aliquots of the respective 
compound in 1ml of acetonitrile unless otherwise stated. 
 
Reference Solution 9: N-formyl BDB (17). 
Reference Solution 10: 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20). 
Reference Solution 11: 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21). 
Reference Solution 12: A combined standard containing three impurities, N-formyl MBDB (17), 4-
ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) 
pyrimidine (21)   was prepared by dissolving 0.15 mg of each in 1 ml of acetonitrile. 
 
Chromatographic conditions 
The various chromatographic systems investigated are outlined below in Table 5.4.1.1. In all cases a 
Waters 5 ODS1column (4.6 mm × 250 mm) and a wavelength range of 190 nm-370 nm. The results are 
shown in section 6.2. 
 
 
 
 
System Number Constituents Proportions Flow Rate 
1 ACN : H2O : TE* 50 : 50: 1 1.0 ml/min 
2 ACN : H2O : TE 50 : 50: 1 1.5 ml/min 
3 ACN : H2O : TE 50 : 50: 1 2.0 ml/min 
4 ACN : H2O : Formic Acid 50 : 50: 1 2.0 ml/min 
5 MeOH : H2O : TE 45 : 55 : 1 1.0 ml/min 
6 ACN : H2O : THF 45 : 50 : 5 1.0 ml/min 
7 pH 3.0 Phosphate Buffer : ACN  66 : 30 1.0 ml/min 
8 pH 3.0 Phosphate Buffer : ACN :THF 66 : 33 : 1 1.0 ml/min 
9 pH 3.0 Phosphate Buffer : ACN : THF 66 : 33 : 1 2.0 ml/min 
10 pH 3.0 Phosphate Buffer : ACN : THF 66 : 30 : 3 1.5 ml/min 
11 pH 3.0 Phosphate Buffer : ACN : THF 66 : 25 : 13 1.5 ml/min 
12 pH 3.0 Phosphate Buffer : ACN : THF 66 : 30 : 5 2.0 ml/min 
 
Table 5.4.1.1: Chromatographic conditions used in the attempted separation of N-formyl BDB (17) and pyrimidine (20, 21) 
Leuckart impurities derived from the synthesis of MBDB (8). ( * Triethylamine (TE)) 
 
Analysis 
A composite mixture containing all three standards, N-formyl MBDB (17), 4-ethyl-5-(3,4-methylene 
dioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine (21)   (reference 
solution 12) was analysed using the mobile phase conditions shown in Table 5.4.1.1. Each peak was 
identified using reference solutions 9-11. The results are discussed in section 6.2. 
 
Section 5.4.2: Assessment of precision of HPLC-DAD separation of three Leuckart impurities 
derived from the synthesis of MBDB (8) 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard containing the three impurities, N-formyl MBDB (17), 4-
ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) 
pyrimidine (21)   was prepared by dissolving 0.15mg of each in 1ml of acetonitrile. 
 
Chromatographic conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined in Table 5.4.2.1 
 
Constituents Proportions Column Flow Rate Analytical 
Wavelength  
Injection 
Volume 
pH 3.0 Phosphate 
Buffer : ACN : THF 
66 : 30 : 5 5 ODS  
(4.6 mm × 250 mm) 
2.0 ml/min 190nm-370nm 20 µl 
 
Table 5.4.2.1: Chromatographic conditions used for the assessment of precision of HPLC-DAD separation of three Leuckart 
impurities (17, 20 & 2 1) derived from the synthesis of MBDB (8). 
 
Analysis 
Five replicate injections, 20µl each, of reference solution 12 were introduced into the chromatographic 
system outlined above. The results are shown in section 6.2. 
 
Section 5.4.3: Assessment of selectivity of HPLC-DAD separation of three Leuckart impurities 
derived from the synthesis of MBDB (8) 
 
Preparation of analytical solutions 
All standard impurity solutions 13-23 were prepared by dissolving 1.0mg aliquots of the respective 
compound in 1ml of acetonitrile, unless otherwise stated. 
 
Reference solution 13: MBDB (8). 
Reference solution 14: BDB (7). 
Reference solution 15: MDA (4). 
Reference solution 16: MDMA (5). 
Reference solution 17: MDEA (6). 
Reference solution 18: 4-methylthioamphetamine (9). 
Reference solution 19: Ketamine (27). 
Reference solution 20: Amphetamine (3). 
Reference solution 21: Caffeine (28). 
Reference solution 22: Paracetamol (29). 
Reference solution 23: Piperonyl Ethyl Ketone (16). 
 
Chromatographic conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined in Table 5.4.3.1. 
 
Constituents Proportions Column Flow Rate Analytical 
Wavelength  
Injection 
Volume 
pH 3.0 Phosphate 
Buffer : ACN : THF 
66 : 30 : 5 5 ODS  
(4.6 mm × 250 mm) 
2.0 ml/min 190nm-370nm 20 µl 
 
Table 5.4.3.1: Chromatographic conditions used in the assessment of selectivity of HPLC-DAD separation of three Leuckart 
impurities (17, 20 & 2 1) derived from the synthesis of MBDB (8). 
 
Analysis 
The selectivity of system 12 (section 5.4.1) was tested by a series of 5µl injections of reference 
solutions 13-23 inclusive, into that particular chromatographic system. The results are shown in section 
6.2. 
 
Section 5.5: Construction of UV-Vis spectral library of Leuckart impurities, 
derived from the synthesis of MBDB (8), and related compounds. 
 
The software that controlled the diode array detector, was entitled Shimadzu CLASS-VP version 5.032. 
This software allowed for the construction of a customised UV-Vis spectral library. Compounds were 
entered into the spectral library from chromatographic data files generated during the experiments 
described in Section 6.3 and 6.4. The following compounds were included in the library; amphetamine 
(3), MDA (4), MDMA (5), MDEA (6), BDB (7), MBDB (8), 4-MTA (9), PEK (16), N-formyl BDB 
(17), N-formyl MBDB (18), 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20), 5-methyl-4-(3,4-
methylenedioxybenzyl)pyrimidine (21), 2,6-diethyl-3,5-di(3,4-metyhylenedioxyphenyl) pyridine (22), 
2,6-dimethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine (23),  2-ethyl-5-methyl-3-(3,4-methylene 
dioxyphenyl)-6-(3,4-methylenedioxybenzyl) pyridine (25), 2,4-diethyl-3,5-di(3,4-methylene 
dioxyphenyl)pyridine (26) ,  ketamine (27), caffeine (28) and paracetamol (29). 
 
 Library creation using CLASS-VP is fully explained in the help tool, which is part of the software 
(Varian 1997). An electronic copy of this library, called LW3.lib, can be found on the supplementary 
disk at the back of this thesis (see Appendix II). This electronic copy requires Shimadzu CLASS-VP  
software or some other compatible software in order to function. The results are shown in Section 6.3. 
 
Section 5.6 GC-MS separation of three Leuckart impurities derived from the 
synthesis of MBDB (8) 
 
Three experiments were carried out including, section 5.6.1 the development of the liquid 
chromatographic separation, section 5.6.2 the assessment of the precision of the chosen system and 
section 5.6.3 the assessment of the selectivity of the chosen method. 
 
Section 5.6.1 Development of GC-MS separation of three Leuckart impurities derived from the 
synthesis of MBDB (8) 
 
Preparation of analytical solutions 
All standard impurity solutions (solutions 9-11) were prepared by dissolving 0.15 mg aliquots of the 
respective compound in 1ml of acetonitrile unless otherwise stated. 
 
Reference Solution 9: N-formyl BDB (17). 
Reference Solution 10: 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20). 
Reference Solution 11: 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21). 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15 mg of each impurity in 1ml of acetonitrile. 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 5.6.1.1  
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 (35%-phenyl-65%- 
dimethyl siloxane-copolymer) 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm  
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1µl 
Injection Solvent ACN 
 
Table 5.6.1.1: Chromatographic conditions used in the development of a GC-MS separation of N-formyl (17) and pyrimidine 
Leuckart impurities (20 & 21) derived from the synthesis of MBDB (8). 
 
The temperature programme conditions were varied in an attempt to optimise the separation. The 
various temperature programmes investigated are outlined in Table 5.6.1.2. 
 
 
 
 
 
 
System No. Initial Temperature Hold Time Final Temperature Ramp Rate Final Hold Time  Total Run Time 
1 90°C 1 minute 300°C 15°C/min 10 minutes 25 minutes 
2 200°C 25 minutes 200°C 0°C/min 0 minutes 25 minutes 
3 250°C 25 minutes 250°C 0°C/min 0 minutes 25 minutes 
4 90°C 1 minute 300°C 10°C/min 15 minutes 37 minutes 
5 90°C 1minute 200°C 5°C/min 10 minutes 33 minutes 
6 90°C 5 minutes 300°C 25°C/min 5 minutes 18.4 minutes 
7 90°C 1minute 150°C 10°C/min 10 minutes 17 minutes 
 
Table 5.6.1.2: Various temperature programs used in the attempted development of a separation of N-formyl  (17) and 
pyrimidine Leuckart impurities (20 & 21) derived from the synthesis of MBDB (8). 
 
Analysis 
An aliquot (1µl) of the composite mixture of N-formyl MBDB (17), 4-ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine (21) 
i.e. reference solution 12, was injected into the chromatographic system and separation was attempted 
using the various temperature programme, outlined in table 5.6.1.2 above. Reference solutions 9, 10 
and 11 were used to identify the retention times of compounds 17, 20 and 21 respectively, for the 
various temperature program runs attempted.  The results of the analysis are shown in section 6.4. 
 
Section 5.6.2 Assessment of precision of GC-MS separation of three Leuckart impurities derived 
from the synthesis of MBDB (8) 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15mg of each in 1ml of acetonitrile. 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 5.6.2.1.  
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm  
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1µl 
Injection Solvent ACN 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 300°C (10minutes) 
Total Run Time 25 minutes 
 
Table 5.6.2.1: Chromatographic conditions used for the assessment of the precision of GC-MS separation of three Leuckart 
impurities (17, 20 & 21) derived from the synthesis of MBDB (8). 
 
Analysis 
Five replicate injections of reference solution 12 were injected, under the conditions outlined in system 
1, in order to assess the precision of the method.  The results are shown in section 6.4. 
 
 
 
 
Section 5.6.3 Assessment of selectivity of GC-MS separation of three Leuckart impurities derived 
from the synthesis of MBDB (8) 
 
Preparation of analytical solutions 
All standard impurity solutions 13-23 were prepared by dissolving 1.0mg aliquots of the respective 
compound in 1ml of acetonitrile unless otherwise stated. 
 
Reference solution 13: MBDB (8). 
Reference solution 14: BDB (7). 
Reference solution 15: MDA (4). 
Reference solution 16: MDMA (5). 
Reference solution 17: MDEA (6). 
Reference solution 18: 4-methylthioamphetamine (9). 
Reference solution 19: Ketamine (27). 
Reference solution 20: Amphetamine (3). 
Reference solution 21: Caffeine (28). 
Reference solution 22: Paracetamol (29). 
Reference solution 23: Piperonyl Ethyl Ketone (16). 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 5.6.3.1 (overleaf).  
 
 
 
 
 
 
 
 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm  
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1µl 
Injection Solvent ACN 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 300°C (10minutes) 
Total Run Time 25 minutes 
 
Table 5.6.3.1: Chromatographic conditions used for the assessment of the selectivity of the GC-MS separation of three Leuckart 
impurities (17, 20 & 21) derived from the synthesis of MBDB (8). 
 
Analysis 
The selectivity of programme 1 was checked by injecting a series of 1µl aliquots of solutions 13-23 
inclusive into the GC-MS system. The results are shown in section 6.4. 
 
 
 
 
Section 5.7: Construction of Mass spectral library of Leuckart impurities, 
derived from the synthesis of MBDB (8), and related compounds. 
 
The Saturn Workstation version 5.2.1 software that controlled the mass spectral detector allowed for 
the construction of mass spectral libraries (Varian 1989-1998). Compounds were entered into the 
custom spectral library from chromatographic data generated in section 5.6.  
 
The compounds that were included in the library were: amphetamine (3), MDA (4), MDMA (5), 
MDEA (6), BDB (7), MBDB (8), 4-MTA (9), PEK (16), N-formyl BDB (17), N-formyl MBDB (18), 
4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20), 5-methyl-4-(3,4-methylenedioxybenzyl) 
pyrimidine (21), 2,6-diethyl-3,5-di(3,4-metyhylenedioxyphenyl) pyridine (22), 2,6-dimethyl-3,5-di(3,4-
methylenedioxyphenyl)pyridine (23),  2-ethyl-5-methyl-3-(3,4-methylene dioxyphenyl)-6-(3,4-
methylenedioxybenzyl) pyridine (25), 2,4-diethyl-3,5-di(3,4-methylene dioxyphenyl)pyridine (26) ,  
ketamine (27), caffeine (28), paracetamol (29).  
 
Library creation using the Saturn Workstation is fully explained in the software help tool (Varian 1989-
1998). An electronic copy of this library called LW3.msp is available on the supplementary disk at the 
back of this thesis (see Appendix II). This electronic copy requires Varian Saturn software or some 
other compatible software in order to function. The results are shown are shown in section 6.5. 
 
Section 5.8: Solid Phase Extraction of Leuckart impurities from MBDB (8) 
 
The following sections, 5.8.1, 5.8.2, 5.8.3 and 5.8.4, detail the experimental procedures used in order to 
develop an extraction protocol for the extraction of N-formyl BDB (17), ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21) 
from MBDB (8). 
 
Preparation of MBDB (8) 
A batch MBDB•HCl (8) was prepared, by J.J. Keating, in the Department of Pharmaceutical Chemistry 
(for details of the synthesis, vacuum distillation and steam distillation see appendix III). 
 
Preparation of analytical solutions 
Test solutions 24: A 50mg/ml MBDB•HCl solution was prepared in pH 7.0 phosphate buffer.  
Reference solution 25: A composite solution, 0.15 mg/ml in each of N-formyl BDB (17), ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21), 
was prepared in a solution which contained 95% water and 5% methanol.  
Reference solution 26: A 1 mg/ml MBDB (8) solution was prepared by dissolving the appropriate 
amount of MBDB•HCl in H2O. 
 
Solid phase extraction cartridges 
Lida manufactured the solid phase extraction cartridges used. The two phases investigated were 
endcapped Octylsilyl (C8) and endcapped Octadecylsilyl (C18) solid phase extraction cartridges.  Each 
had a sorbent bed volume of 100mg and an average particle size of 50 µm. The average pore size was 
60Å and the silica surface area was 480 m2/g. 
 
Section 5.8.1: Development of a suitable system for the elution of interfering components from a 
matrix containing Leuckart impurities, derived from the synthesis of MBDB (8), from C8 and 
C18 solid phase extraction cartridges. 
 
Column Conditioning 
In the case of each solid phase extraction cartridge (C8 and C18), the cartridges were conditioned with 
300 µl of methanol. The supernatant methanol was drawn off under a slight vacuum (circa. 3ml/min). 
The vacuum was removed in time to avoid drying out the column, the eluate was then discarded. A 300 
µl aliquot of H2O was then added and drawn through the column, taking care not to dry the column 
bed. 
 
MBDB (8) Elution experiment 
Once conditioned a 1 ml aliquot of test solution 24 was then added to the column and drawn through 
under a slight vacuum. As this volume exceeded the bed volume by a factor of ten the excess was 
collected in a glass test tube and labelled appropriately. At this point the elution of MBDB (8) from the 
beds of the respective solid phase extraction cartridges could be tested.  In the case of each system, 1-4, 
2 ml of the relevant solvent (see Table 5.8.1.1) was added, 100 µl at a time. Each 100 µl aliquot was 
collected in a glass vial and labelled appropriately.  
 
System C8 solid phase cartridge C18 solid phase cartridge 
System 1 H2O  H2O  
System 2 pH 4.0 Phosphate Buffer  pH 4.0 Phosphate Buffer  
System 3 H2O : MeOH* (95% : 5%)  H2O : MeOH (95% : 5%)  
System 4 pH 4.0 : ACN (6:1) pH 4.0 : ACN (6:1) 
 
Table 5.8.1.1: Table of various solvents investigated as potential MBDB (8) elution solvents from both C8 and C18 solid phase 
extraction ( * Methanol (MeOH)). 
 
Chromatographic conditions 
The chromatographic conditions are outlined for in Table 5.8.1.2. 
 
Constituents Proportions Column Flow Rate Analytical 
Wavelength  
Injection 
Volume 
pH 3.0 Phosphate 
Buffer : ACN : THF 
66 : 25 : 13 5 ODS  
(4.6 mm × 250 mm) 
1.5 ml/min 289 nm 20 µl 
 
Table 5.8.1.2: Chromatographic conditions used in the development of a solid phase extraction protocol for the elution of MBDB 
(8) from C8 and C18 solid phase extraction cartridges. 
 
Analysis 
Solution 25, which contained, N-formyl BDB (17), 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine 
(20) and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21) was injected (20 µl) into the above 
system for the purpose of system suitability (retention time, peak tailing and column efficiency). Each 
of the 100 µl aliquots collected from the C8 and C18 stationary phases was then subjected to HPLC 
analysis as outlined above. The peak area of the MBDB (8) peak was recorded for each aliquot. The 
results of this experiment are shown in section 6.6. 
 
Section 5.8.2: Assessment of the retention of impurities when subjected to MBDB (8) elution 
protocol. 
 
Impurity retention experiment 
Using H2O, the ability of the C8 and C18 cartridges to retain N-formyl BDB (17), 4-ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21), 
was assessed. In the case of each solid phase extraction cartridge (C8 and C18), the cartridges were 
conditioned as described above (Section 5.8.1). A 100 µl aliquot of reference solution 25 was then 
added to each of the two columns (C8 and C18) and drawn through under a slight vacuum. A volume 
of H2O (2ml) was then passed through each column in 100 µl aliquots. Each 100 µl aliquot was 
collected in a glass vial and labelled appropriately.  
 
Chromatographic conditions 
The chromatographic conditions are outlined for in Table 5.8.2.1. 
 
Constituents Proportions Column Flow Rate Analytical 
Wavelength  
Injection 
Volume 
pH 3.0 Phosphate 
Buffer : ACN : THF 
66 : 25 : 13 5 ODS  
(4.6 mm × 250 mm) 
1.5 ml/min 289 nm 20 µl 
 
Table 5.8.2.1: Chromatographic conditions used in the development of a solid phase extraction protocol for the elution of MBDB 
(8) from C8 and C18 solid phase extraction cartridges. 
 
Analysis 
Reference solution 25, which contained, N-formyl BDB (17), ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21) 
was injected (20 µl) into the above system for the purpose of system suitability. A solution containing 
each of the aliquots was subjected to HPLC analysis as outlined above. The results of this experiment 
are shown in Section 6.6.2. 
 
Section 5.8.3: Development of a suitable system for the elution of Leuckart impurities, derived 
from the synthesis of MBDB (8), from C8 and C18 solid phase extraction cartridges 
 
Impurity Elution Experiment 
The solvents, acetonitrile and tetrahydrofuran, were used in an attempt to elute N-formyl BDB (17), 
ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) 
pyrimidine (21) from the respective solid phase extraction cartridge. Firstly 100 µl of reference 
solution 25 were added to both C8 and C18 cartridges which had been conditioned with methanol (300 
µl) and then H20 (300 µl), as described above (Section 5.8.1). In the case of each solvent, acetonitrile 
and tetrahydrofuran, 1 ml of the relevant solvent was added, 100 µl at a time. Each 100 µl aliquot was 
collected in a glass vial and labelled appropriately. Each of the aliquots was then subjected to HPLC 
analysis as outlined below. The peak area each of the impurity peaks was recorded for each injected 
aliquot. 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 5.8.3.1. 
Constituents Proportions Column Flow Rate Analytical 
Wavelength  
Injection 
Volume 
pH 3.0 Phosphate 
Buffer : ACN : THF 
66 : 25 : 13 5 ODS  
(4.6 mm × 250 mm) 
1.5 ml/min 289 nm 20 µl 
 
Table 5.8.3.1: Chromatographic conditions used in the development of a solid phase extraction protocol for the elution of MBDB  
(8) from C8 and C18 solid phase extraction cartridges. 
 
Analysis 
Reference solution 25, which contained, N-formyl BDB (17), ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21) 
was injected (20 µl) into the above system for the purpose of system suitability. A solution containing 
each of the aliquots was subjected to HPLC analysis as outlined above. The peak area of each of the 
impurity peaks was recorded for each aliquot. The results of this experiment are shown in section 6.6. 
 
Section 5.8.4: Extraction of Leuckart impurities from a sample of MBDB (8) prepared via the 
Leuckart reaction. 
 
Extraction protocol 
The following protocol was adopted for the extraction of compounds 17, 20 and 21 from pure MBDB 
(8). Either a 100 mg C8 or 100 mg C18 (both phases were tested separately) solid phase extraction 
cartridge was conditioned as described above (Section 5.8.1). At this point, 1ml of a test solution 24 
containing 50mg/ml MBDB (8) in pH 7 buffer was added and pulled through the bed at a rate of 
3ml/min. Again the vacuum was removed before drying out the column. An aliquot of 1ml of HPLC 
grade H2O was added at this point and pulled slowly through the column (3ml/min). The vacuum was 
applied at this point to dry the column and remove any traces of H2O. The retained mass was removed 
from the column by applying 100µl of tetrahydrofuran to the column and then collecting the eluent in a 
test tube. This was repeated five times to a final collection volume of 500µl, which was collected in a 
V-vial. The tetrahydrofuran was then removed under a gentle stream of nitrogen. The residue in the V-
vial was reconstituted in 60µl of acetonitrile. 
 
Chromatographic Conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined Table 5.8.4.1. 
 
Constituents Proportions Column Flow Rate Analytical Wavelength  
PH 3.0 Phosphate 
Buffer : ACN  
66 : 30 : 5 5 ODS1  
(4.6 mm × 250 mm) 
2.0 ml/min 289 nm 
 
Table 5.8.4.1: Chromatographic conditions used for the analysis of solid phase extracts of impurities derived from the synthesis 
of MBDB (8) via the Leuckart reaction. 
 
 
The GC-MS conditions used in the analysis are outlined in Table 5.8.3.2. 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm  
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1µl 
Injection Solvent ACN 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 300°C (10minutes) 
Total Run Time 25 minutes 
 
Table 5.8.4.2: Chromatographic conditions used for the analysis of solid phase extracts of impurities derived from the synthesis 
of MBDB (8) via the leuckart-wallach reaction. 
 
Analysis 
Reference solution 25 was injected into both the HPLC-DAD (20µl) and GC-MS (1 µl) system in order 
to assess the system suitability  (retention time, tailing factor and column efficiency). Each of the 
extracts that were collected from the respective solid phase extraction cartridges was subjected to 
HPLC-DAD (20 µl) and GC-MS (1 µl) analysis as described above.  
 
Section 5.9 Development of liquid-liquid extraction for the isolation and 
enrichment of Leuckart-Wallach impurities from MBDB (8) 
 
Preparation of analytical solutions 
Reference Solution 12: A composite standard 0.15 mg/ml in each of the three impurities N-formyl 
MBDB (17), 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-
methylenedioxybenzyl) pyrimidine (21)   was prepared in acetonitrile. 
 
Extraction protocol 
The following procedure was carried out using buffers pH 3, 4, 4.9, 6 and 7. A 50 mg quantity of 
homogeneous powdered MBDB•HCl  (8) was added to 10 ml of buffer and the pH was adjusted back 
to the correct pH with either 0.2M NaOH or 0.2M HCl. The resulting solution was quantitatively 
transferred to a 20 ml clean dry centrifuge tube and sonicated for 20 minutes. The tubes were then 
centrifuged at 3000 rpm for 5 minutes. The supernatant was removed and quantitatively transferred to a 
clean dry separating funnel. The contents of the funnel were then extracted with petroleum ether (10 
ml). The aqueous layer was discarded and then the petroleum ether layer was filtered through 
anhydrous sodium sulphate and evaporated at reduced pressure using a rotary evaporator. The residue 
in the flask was reconstituted with acetonitrile (600 µl ).  The acetonitrile was then transferred to a V-
vial and the acetonitrile was removed at 40°C, under a stream of nitrogen. The V-vials containing the 
residue were stored at -18°C until HPLC and GC-MS analysis. Immediately before analysis the residue 
in each vial was reconstituted in acetonitrile (60 µl). 
 
Chromatographic Conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined Table 5.9.1. 
 
 
 
 
 
Constituents Proportions Column Flow Rate Analytical Wavelength  
pH 3.0 Phosphate 
Buffer : ACN  
66 : 30 : 5 5 ODS  
(4.6 mm × 250 mm) 
2.0 ml/min 289 nm 
 
Table 5.9.1: Chromatographic conditions used for the analysis of solid phase extracts of impurities derived from the synthesis of 
MBDB (8) via the Leuckart reaction. 
 
The GC-MS conditions used in the analysis are outlined in Table 5.9.2. 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm  
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1µl 
Injection Solvent ACN 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 300°C (10minutes) 
Total Run Time 25 minutes 
 
Table 5.9.2: Chromatographic conditions used for the analysis of solid phase extracts of impurities derived from the synthesis of 
MBDB (8) via the leuckart-wallach reaction. 
Analysis  
In each case reference solution 12 was injected (in duplicate) for the purpose of system suitability 
(column efficiency, retention time and peak tailing). The samples, each of which had been extracted at 
different pH values, were then analysed into both GC-MS (1 µl) and HPLC (20 µl) systems. The results 
can be seen in section 6.7. 
 
Section 5.10: Identification of MBDB (8) in illicitly prepared tablets 
 
Preparation of Analytical Solutions 
Reference solution 27: MBDB (8) synthesised in the Department of Pharmaceutical Chemistry (Section 
5.8 ) was used to prepare a solution of 1 mg/ml MBDB (8) in acetonitrile. 
 
Tablets Analysed 
Tablets, #6600, #6840, #A6765, #6660, #6758 and #6758, believed to contain MBDB (8) were 
supplied by Dr. Les King of the Forensic Science Service, Lambeth Road,  London, U.K. These tablets 
were seized in the UK. Tablets 7A and 8A were supplied by the Garda National Drugs Unit and were 
seized in the Republic of Ireland.The tablets analysed, along with their physical description are shown 
in Table 5.10.1. Images of the tablets are shown in Figure 5.10.1. 
 
Tablet Ref. No. Weight of Tablet Weight Extracted Logo  Tablet Colour 
#6600 0.3358g 144.19mg ‘$’ White, mottled 
#6840 0.2733g 143.43mg ‘£’ White, mottled 
#A6765 0.3087g 114.67mg ‘$’ White, mottled  
#8A 0.3256g 128.08mg ‘$’ White, mottled 
#6660 0.3364g 102.74mg ‘Fido Dido’ Off White, mottled 
#7A 0.3159g 117.98mg ‘$’ White , mottled 
#6758 0.3257g 152.58mg ‘£’ White, mottled 
#A6765s* 0.3087g 114.67mg ‘$’ White, mottled 
 
Table 5.10.1:Tablets qualitatively analysed by GC-MS. 
 Figure 5.10.I mages of MBDB (8) tablets: (A) Pound logo, (B), Fido Dido logo and (C) Dollar logo. 
 
 
Preparation of Tablets and standard MBDB (8) for chromatographic analysis 
The tablets were powdered using a mortar and pestle. A small amount of powder, circa 1mg, was added 
to a 10ml test tube. A 1ml volume of water was added and the resulting solution was adjusted to pH 10 
with conc. ammonia. This was then extracted into 1ml of petroleum ether. The petroleum ether was 
evaporated to dryness and reconstituted in a volume of 1ml acetonitrile. A 1 ml aliquot of reference 
solution 27 was extracted in the same way as 1 mg of powdered tablet. 
 
 
 
 
 
 
 
 
 
 
 
Chromatographic conditions 
The chromatographic conditions are outlined in Table 5.10.2. 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 120°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent ACN 
 
Table 5.10.2: GC-MS conditions used for the qualitative analysis of MBDB (8) in illicitly prepared tablets suspected of 
containing MBDB (8). 
 
Analysis 
Extracted reference solution 28, containing MBDB (8), was injected into the chromatographic system. 
The tablet extracts were also injected for analysis. The results of the analysis are shown in 6.9. 
 
 
 
 
Section 5.11: Quantitative analysis of MBDB in illicitly manufactured tablets. 
 
Preparation of analytical solutions 
Reference solution 27: MBDB•HCl (8) synthesised in the Department of Pharmaceutical Chemistry 
was used to prepare standard solutions.  A stock solution of 1 mg/ml MBDB (8) was prepared by 
reconstituting 117 mg of MBDB•HCl in 100 ml of H2O.  
Reference solution 28:  A 0.25 mg/ml MBDB (8) was prepared by diluting the 1.0 mg/ml standard, 
solution 27, with sufficient H2O.. 
Reference solution 29:  A 0.50 mg/ml MBDB (8) was prepared by diluting the 1.0 mg/ml standard, 
solution 27, with sufficient H2O. 
 
Tablets Analysed 
See section 5.10 
 
Preparation of tablets for HPLC analysis 
The weight of each tablet, taken for quantitative analyses are shown in Table 5.11.1 (overleaf).  The 
tablets were powdered in a mortar and pestle and weighed out into a separate plastic weighing boats. 
The contents of the individual weighing boats were quantitatively transferred to separate centrifuge 
tubes with the aid of 5 ml of acetonitrile.  The tubes were then sonicated for twenty minutes before 
being centrifuged at 3000 rpm for 5 minutes. The supernatant for each tube was then quantitatively 
transferred to individual 25 ml volumetric flasks and the contents were made up to volume with 
acetonitrile. 
 
 
 
 
 
 
 
 
Tablet Reference Weight of homogenous powder 
analysed 
Dil # 6660 9.8 mg 
7A 10.1 mg 
Dil # A6765 9.5 mg 
Dil #6758 10.8 mg 
8A 10.8 mg 
Dil # 6840 10.5 mg 
Dil # 6600 10.2 mg 
 
Table 5.11.1: Tablets and amounts of tablet quantitatively analysed for MBDB (8) content using HPLC. 
 
Chromatographic conditions 
The chromatographic conditions used are outlined in Table 5.11.2. 
 
Constituents Proportions Column Flow Rate Analytical Wavelength  
pH 3.0 Phosphate 
Buffer : ACN : TE 
600 : 100 : 1 5 ODS  
(4.6 mm × 250 mm) 
1.5 ml/min 289 nm 
 
Table 5.11.2: Chromatographic conditions for tablets quantitatively analysed for MBDB (8) content using HPLC. 
 
Analysis 
A standard curve was prepared by injecting 0.25 mg/ml, 0.50 mg/ml and 0.10 mg/ml MBDB (8) 
standards (reference solutions 29, 28 and 27 respectively.  The amount of standard and sample analysed 
by HPLC was 20µl. Both standards and samples were analysed in duplicate. The results of the analysis 
can be seen in section 6.10. 
 
 
 
Section 5.12: Attempted extraction of Leuckart impurities from MBDB (8) from 
a spiked sample of an illicitly prepared tablet. 
 
A spiked MBDB (8) tablet was extracted (section 5.12.1). The extract was analysed using HPLC-DAD 
(section 5.12.2) and GC-MS (5.12.3) analysis. 
  
Section 5.12.1 Extraction protocol 
 
Preparation of spiked tablet 
A 1 mg amount of each compound 17, 20 and 21 was added to a 50 mg equivalent of powdered tablet 
#6758 (see Table 5.10.1, Section 5.10) and the resulting powder was homogenised. 
 
Extraction protocol 
An aliquot (10 mg) of homogeneous powdered tablet was weighed accurately. The amount of tablet 
taken in the case of each tablet is shown in Table 2.10.1. The powder was added to 10 ml of pH 4.0 
buffer. The pH was adjusted to pH 4.0 if necessary with 0.2 M sodium hydroxide or 0.2 M hydrochloric 
acid. The resulting solution was quantitatively transferred to a 20ml clean dry centrifuge tube and 
sonicated for 20 after which it was centrifuged at 3000 rpm for 5 minutes. The supernatant was 
removed and quantitatively transferred to a clean dry 100 ml separating funnel. The contents were then 
extracted with 10 ml of petroleum ether. The aqueous layer was discarded and evaporated at reduced 
pressure using a rotary evaporator. The residue in the flask was reconstituted with 600µl acetonitrile.  
The acetonitrile was then transferred to a V-vial and the acetonitrile was removed at 40°C under a 
stream of nitrogen. The V-vials containing the residue were stored at -18°C until analysis. Immediately 
before analysis the residue in each vial was reconstituted in  acetonitrile (50µl).  
 
Preparation of impurity recovery solution 
As well as having prepared the tablet extract, a tablet solution was prepared which would be used to 
determine recovery. A 1 mg amount of each compound 17, 20 and 21 was added to 6 ml of acetonitrile. 
Section 5.12.2 HPLC-DAD analysis of spiked tablet extract and impurity recovery solution. 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15 mg of each in 1 ml of acetonitrile. 
 
Chromatographic conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined Table 5.12.2. 
 
Constituents Proportions Column Flow Rate Analytical Wavelength  
pH 3.0 Phosphate 
Buffer : ACN  
66 : 30 5 ODS  
(4.6 mm × 250 mm) 
2.0 ml/min 289 nm 
 
Table 5.12.2.1: HPLC conditions used for the analysis of MBDB (8) tablet extracts. 
 
Analysis  
An aliquot (20 µl) of reference solution 12 were injected into the HPLC-DAD, for the purpose of 
system suitability (retention time, peak tailing, column efficiency). The spiked tablet extract (20µI) (see 
section 5.12.1) was then analysed by HPLC-DAD. An aliquot (20µI)  of the impurity recovery solution 
was analysed in the same way (see section 5.12.1). The results of this section can be seen in section 
6.11. 
 
Section 5.12.3: GC-MS analysis of spiked tablet extract and impurity recovery solution. 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15mg of each in 1ml of acetonitrile. 
 
 
Chromatographic conditions 
The GC-MS conditions used in the analysis are outlined in Table 5.12.3.1 
 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 210°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent ACN 
 
Table 5.12.3.1: GC-MS conditions used for the analysis of MBDB (8) tablets. 
 
Analysis  
An aliquot (1 µl) of reference solution 12 were injected into the GC-MS, for the purpose of system 
suitability (retention time, peak tailing and column efficiency. The spiked tablet extract (see section 
2.10.1) was then analysed by GC-MS. An aliquot (1µl) of the impurity recovery solution was analysed 
in the same way. The results of this section can be seen in section 6.11. 
 
 
Section 5.13: Attempted extraction of Leuckart impurities from MBDB (8) from 
illicitly manufactured MBDB (8) tablets of an illicitly prepared tablet. 
 
Section 5.13.1: Extraction protocol 
 
Tablets analysed 
The tablets analysed and the respective amounts taken in order that 50 mg of MBDB (8) was taken are 
shown in Table 5.13.1.1. 
Tablet Name Weight equivalent to 50mg 
MBDB (8) 
Tablet Name Weight equivalent to 50mg 
MBDB (8) 
Dil# 6660 102.74mg 8A 129.05mg 
7A 103.98mg Dil# 6840 143.43mg 
Dil#6765 114.45mg Dil# 6600 116.44mg 
Dil# 6758 218.07mg   
 
Table 5.13.1.1: Table containing weights of tablet required to be taken such that 50mg of MBDB (8) could be extracted 
 
Extraction protocol 
An aliquot of homogeneous powdered tablet was weighed accurately in the case of each tablet. The 
amount of tablet taken in the case of each tablet is shown in Table 5.13.1.1. To the powder was added 
to 10 ml of pH 4.0 buffer. The pH was adjusted to pH 4.0 if necessary with 0.2 M sodium hydroxide or 
0.2 M hydrochloric acid. The resulting solution was quantitatively transferred to a 20ml clean dry 
centrifuge tube and sonicated for 20 after which it was centrifuged at 3000 rpm for 5 minutes. The 
supernatant was removed and quantitatively transferred to a clean dry 100 ml separating funnel. The 
contents were then extracted with 10 ml of petroleum ether. The aqueous layer was discarded and 
evaporated at reduced pressure using a rotary evaporator. The residue in the flask was reconstituted 
with 600 µl acetonitrile.  The acetonitrile was then transferred to a V-vial and the acetonitrile was 
removed at 40°C under a stream of nitrogen. The V-vials containing the residue were stored at -18°C 
until analysis. Immediately before analysis the residue in each vial was reconstituted in 60 µl.  
 
Section 5.13.2: HPLC-DAD analysis of tablet extracts 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15 mg of each in 1 ml of acetonitrile. 
 
Chromatographic conditions 
The high pressure liquid chromatographic conditions used in the analysis are outlined Table 5.13.2.1. 
 
Constituents Proportions Column Flow Rate Analytical Wavelength  
pH 3.0 Phosphate 
Buffer : ACN  
66 : 30 5 ODS  
(4.6 mm × 250 mm) 
2.0 ml/min 289 nm 
 
Table 5.13.2.1: HPLC conditions used for the analysis of MBDB (8) tablet extracts. 
 
Analysis  
An aliquot (20 µl) of reference solution 12 were injected into the HPLC-DAD, for the purpose of 
system suitability (retention time, peak tailing, column efficiency). The tablet extracts (see Section 
5.13.1.1) was then analysed by HPLC-DAD. The results of this section can be seen in section 6.12. 
 
Section 5.13.3: GC-MS analysis of tablet extracts 
 
Preparation of analytical solutions 
Reference Solution 12: A combined standard of the three impurities, N-formyl MBDB (17), 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl) pyrimidine 
(21)   was prepared by dissolving 0.15mg of each in 1ml of acetonitrile. 
 
 
Chromatographic conditions 
The GC-MS conditions used in the analysis are outlined in Table 5.13.3.1 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column DB-35 
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.1 µm 
Temperature Program 90°C(1 min) up to 300°C (@ 
15°C/min) hold for 10 minutes 
Ion Trap Temperature 210°C 
Transfer Line Temperature 250°C 
Manifold Temperature 210°C 
Ionisation Mode Electron Ionisation 
Filament Delay 4 minutes 
Injected Volume 1 µl 
Injection Solvent ACN 
 
Table 5.13.3.1: GC-MS conditions used for the analysis of MBDB (8) tablets. 
 
Analysis  
An aliquot (1 µl) of reference solution 12 were injected into the GC-MS, for the purpose of system 
suitability (retention time, peak tailing and column efficiency). The tablet extracts (see section 5.13.1) 
were then analysed by GC-MS. The results of this section can be seen in section 6.12. 
 
Section 5.14: Derivatisation of N-formyl BDB (17) in an attempt to identify peak 
eluting at 10.2 minutes in GC-MS trace of samples. 
 
Preparation of analytical solutions 
Reference solution 30: A 0.10 mg/ml solution of N-formyl BDB (17) was prepared in acetonitrile. 
Derivatising reagent 
Methelut (Sigma –Aldrich Chemicals) was used as the methylating agent. 
 
Derivatising procedure, analysis and chromatographic conditions. 
An aliquot of 50 µl of Methelut reagent was added to a small vial. An aliquot of 200 µl of reference 
solution 30 was added to this vial. This solution was mixed and injected into the GC-MS system 
outlined in Table 5.13.3.1. The remainder of the solution was heated at 80°C for one hour, after which 
time a 20 µl aliquot was injected into the HPLC system outlined in Table 5.13.2.  The results are 
discussed in section 6.13. 
  
 
  
Section 4.1: Impurity profiling 
 
Due to the fact that a large question mark hangs over the 
therapeutic potential of the ‘’Entactogens’’, the recreational 
drug-abuser has not been able to rely on illegally diverted 
pharmaceutically pure forms of these drugs, as may have 
been the case to an extent with amphetamine and 
methamphetamine. Instead, he/she, having chosen to use 
these drugs, will be forced to purchase drugs that have been 
made exclusively in clandestine laboratories.  
 
Impurity profiling is a technique that has for many years, been used as a means of gathering drug 
intelligence to help law enforcement agencies combat clandestine drug manufacture. Illegally produced 
drugs are frequently contaminated as is readily shown via chromatographic analysis (Sinnema, 1981). 
Contaminants in illicitly manufactured drugs can arise from impure starting materials, side and 
subsequent reactions, intermediate products and diluents used as cutting agents in the subsequent 
handling of a drug (Sinnema, 1981). Additives to illicitly prepared tablets may also contain agents 
responsible for bulking, binding, lubricating and colouring used during tablet manufacture. 
 
Two different approaches can be adopted when impurity profiling. There is on the one hand, what is 
known as the ‘’signature method’’ where the chromatographic trace is used as a fingerprint. Usually 
the identity of each peak in the chromatographic trace is not known, but a comparison of two traces 
collected from the same batch should in theory match and the likelihood of getting an identical 
chromatographic trace for a different batch should be low. This method has been used with good effect 
in the profiling of amphetamines (Rashed, 2000; Sten,1998). It has also been used in determining the 
origin of and/or interrelationship of opiate samples (Neumann, 1984; Desage, 1991; Kaa, 1994 and 
Johnston, 1998) and also of cannabis samples (Lehmann, 1995 and de Meijer, 1992). The main 
drawback of this approach is that two separate samples from the same batch stored separately will 
likely be affected by many variables e.g. storage conditions, temperature, humidity, exposure to light 
etc. All of these variables will have a detrimental effect on the integrity of the fingerprint.  
 
The alternative approach takes the fingerprint method a step further by incorporating retention time 
data for known or likely impurities, data that has been generated by running standards of impurities.  
It would be even more desirable if mass spectrometric data 
collected via the Gas Chromatography-Mass Spectrometer 
(GC-MS) was available, as this would enable the 
unequivocal identification of specific impurities. The purity 
of a particular drug provides information on several levels 
(King, 1997). The important aspect from an impurity 
profiling perspective is that certain impurities will only be 
generated when a compound is made via a particular 
synthetic route. Hence, they are classed as route specific 
impurities. The presence of a route specific impurity in a 
sample will indicate the synthetic route used by the 
underground chemist and therefore the reagents required. A 
number of samples, containing these impurities, with very 
similar impurity profiles may be indicative of a link between 
these samples. No information on route specific impurities is 
gathered by using the fingerprint method. 
 
Details of the synthetic routes employed by the underground chemist are easily obtained through the 
Internet, underground literature and indeed the literature of the legitimate scientific community 
(Shulgin, 1991; Shulgin, 1997; Uncle Fester, 1996; Erowid, 2000 and SPDCC, 2000). In general, the 
single step techniques, which require little knowledge of chemistry, are the techniques most likely to be 
used in clandestine laboratory environments. An experienced chemist may be able to devise novel 
syntheses or employ more difficult synthetic routes. However, the easy availability of established 
techniques should ensure their continued dominance in clandestine laboratory applications. In 
particular, the variety of reactions successfully used to synthesise amphetamines, its analogues, 
homologues and derivatives has provided a fertile area for investigation by the clandestine chemist 
(Dal Cason, 1990). A variety of synthetic reactions can be used to synthesise amphetamines, including 
reactions such as reductive amination (Haskelberg, 1948), the Leuckart reaction (Moore, 1949), the 
Ritter reaction (Ritter, 1948), the oxime route (Hey, 1930), the bromopropane route (Anon, 1914) and 
the nitropropene (Anon., 1953) route. Reductive amination, the bromopropane route and the leuckart 
reaction can also be used to synthesise methamphetamine. A very significant amount of research has 
been invested into the impurity profiling of amphetamines and methamphetamine  (Van der Ark, 1977; 
Lambrechts, 1985; Johnson, 1998; Lambrechts, 1984; Lambrects, 1984a; Sinnema, 1981; Van der Ark, 
1978; Verweij, 1989; and Barron, 1974). Impurities, route specific and otherwise, have been identified 
for the synthesis of amphetamine (3) and methamphetamine.  
 
Section 4.2: Impurity profiling MBDB (8) synthesised via the Leuckart-Wallach 
reaction 
 
In the last chapter a method suitable for the analysis of MDA (4), MDMA (5), MDEA (6) and MBDB 
(8) was established. It is noteworthy that on perusal of the GC-MS chromatogram of the MDMA (5) 
containing extract of a Mitsubishi tablets (Figure 3.6.1a) very small peaks are visible in the trace. There 
is no doubt that the MDMA  (5) is of a reasonably high purity, however trace levels of some 
compounds other than MDMA (5) itself are certainly present. Some of these may be impurities or 
adulterants, however if they are impurities they may give some clue as to which route of synthesis was 
used to make the drug, this is investigated further in Chapter III. Due to the fact that the MDA (4), 
MDMA (5), are simply amphetamine (3) and methamphetamine with a methylenedioxy bridge, the 
same reactions mentioned above (Ritter, Leuckart etc.) can be used to synthesise the methylenedioxy 
compounds. The previous work carried out on the impurity profiling of amphetamine (3) and 
methamphetamine is of great help to the analyst profiling MDA (4) and MDMA (5). Indeed a 
significant amount of impurity profiling has been carried out on MDA (4) and MDMA (5) synthesised 
via the aforementioned routes. Routes towards the synthesis of MDA (4) and MDMA (5) which have 
been impurity profiled include the Leuckart route (Lukaszewski, 1978; Verweij, 1992c; Verweij, 
1992a; Renton, 1993 and Bohn, 1993), the nitropropene route (Verweij, 1992a and Verweij, 1992b), 
the reductive amination route (Verweij, 1990; Verweij, 1992a; Noggle, 1991a; Noggle, 1991b and 
Clark, 1994) and the bromopropane route  (Renton, 1993; Clark, 1994; Noggle, 1991a and Verweij, 
1992a). While MBDB (8) & MDEA (6) have not been profiled to the same extent, the routes of 
synthesis used for each are in some cases very similar to those used for MDA (4) and MDMA (5). 
Hence the impurities are assumed, in some cases, to be analogous to those found in MDA (4) and 
MDMA (5). MBDB (8) and MDEA (6) may however also include impurities, which may differ 
significantly to those in MDA (4) and MDMA (5).  
 
The properties and possible risks associated with MBDB (8) were recently extensively reviewed as part 
of a European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) risk assessment (Van 
Aerts, 2000). Although work has been carried out on the metabolism and immunoassay responses for 
MBDB (Maurer, 1996; Kintz, 1997 and Kintz, 1997a) and also on the GC-MS analysis of the MBDB 
(8) and its analogues/structural isomers (Clark, 1995 and Noggle, 1991) no impurity profiling has been 
carried out. 
MBDB (8) can be prepared via several routes (Scheme 4.1 below). The most popular route of synthesis 
for amphetamine (3) and methamphetamine is undoubtedly the Leuckart reaction, which is a 
convenient reaction used for the synthesis of amines from ketones and aldehydes (Lukaszewski, 1978). 
The starting material needed for the synthesis of MBDB (8) via the Leuckart reaction is Piperonyl 
Ethyl ketone (PEK) (16).  
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Scheme 4.1: Routes of synthesis for MBDB (leuckart-wallach route is marked with red arrows). PEK (piperonylethylketone), (16) 
N-formyl MBDB (17) & MBDB (8) are starting material, intermediate and product respectively for the synthesis of MBDB via 
the leuckart-wallach route of synthesis. 
Two routes often used that are often used to synthesise PEK (16) are the nitrostyrene route and the 
glycol route.  The nitrostyrene route involves the reaction of piperonal (11) and nitropropane to form 
the nitrostyrene intermediate, 3,4-methylenedioxyphenyl-3-nitro-but-3-ene (15), which can be reacted 
with Fe to form PEK (16). Alternatively piperonal (16) can be converted to 3,4-methylenedioxybutan-
4-ol (12) via the Grignard reaction. The tertiary alcohol 3,4-methylenedioxybutan-4-ol (12) is then 
dehydrated to 3,4-methylenedioxyphenylbut-3-ene (13) with KHSO4. This methylenedioxyalkene is 
then oxidised using H2O2 to form the 3,4-methylenedioxyphenylbutan-3,4-diol (14). This glycol can 
then be reduced using H2SO4 to form PEK (16). 
 
Using PEK (16) as the starting material, this reaction involves reacting PEK (16) with two molecules of 
formamide to produce the N-formyl derivative (17) of an amine, which can then be hydrolysed with 
HCl to produce BDB (7) or methylated with LiAlH4 to form MBDB (8). MBDB (8) can also be 
synthesised by taking BDB (7) and treating it with formic acid to form the N-formyl derivative and 
treating then with LiAlH4 as before. Alternatively N-methyl formamide can be used to form the N-
methyl, N-formyl derivative (18), this can then be reduced using HCl to form MBDB (8). (see Scheme 
4.1, above). 
 
The Leuckart reaction is notorious for producing impurities (Lambrechts, 1984). Among the most 
common of these impurities in the case of MDA (4) and MDMA (5), are the N-formyl intermediates 
(17) and (18) that are usually found in samples as a result of incomplete hydrolysis of the ketone 
(Lucaszewski, 1978). Other impurities that can arise from the reaction of the ketone (16) formamide 
are usually the result of condensation reactions between the ketone and molecules of formamide (Van 
der Ark, 1977). A second molecule of formamide can condense to the N-formyl-1-
methylendioxyphenyl-2-iminopropane (19) followed by ring closure (see Scheme 4.2) forming a 
pyrimidine.  
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Scheme 4.2 : Proposed condensation of two molecules of formamide and one ketone resulting in the formation of a benzyl 
pyrimidine (B) and a phenyl pyrimidine (A). 
 There is also the possibility of two molecules of ketone condensing with one molecule of formamide 
forming pyridine impurities (see Scheme 4.3). 
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Scheme 4.3 : Proposed condensation of one molecule of formamide and two ketones resulting in the formation of a pyridine. 
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Figure 4.4:Impurities obtained through the Leuckart synthesis of MBDB: (20) 4-ethyl-5-(3,4-methyelendioxyphenyl)pyrimidine, 
(21) 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine, (22) 2,6-diethyl-3,5-di(3,4-methyelendioxyphenyl)pyridine, (23) 2,6-
dimethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine, (24) 4-ethyl-3-methyl-2-(3,4-methylenedioxybenzyl)-5-(3,4-
methylenedioxyphenyl)pyridine, (25) 2-ethyl-5-methyl-3-(3,4-methylenedioxyphenyl)-6-(3,4-methylenedioxybenzyl)pyridine & 
(26) 2,4-diethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine 
 
The synthesis of MBDB (8) via the Leuckart route was investigated in the Department of 
Pharmaceutical Chemistry in the School of Pharmacy, Trinity College, Dublin and a number route 
specific impurities (see Figure 4.2, above) were isolated, purified and then characterised using NMR 
and MS. It is noteworthy that when MBDB (8) is synthesised using PEK (16) and N-methyl formamide 
to produce the N-methyl, N-formyl derivative (18) that no pyrimidine or pyridine impurities are 
produced. 
 
 
 
Section 4.3: Objectives 
 
The aim of the work presented here was to establish a selective and specific HPLC separation using a 
Diode Array Detector (DAD) and a similar GC-MS separation for the analysis of a series of Leuckart 
route specific impurities/intermediates 17, 20 and 21. Using that data generated from the HPLC-DAD 
and GC-MS spectral libraries for the relevant compounds would be constructed. By developing a 
suitable solid phase extraction protocol or liquid-liquid extraction, it was hoped that the Leuckart 
specific impurities/intermediates could be extracted from MBDB•HCl that had been prepared via the 
Leuckart route in the School of Pharmacy. The best extraction method would be selected on the basis 
of chromatographic data that would be obtained using the HPLC-DAD and GC-MS methods 
established. The most suitable extraction method would then be applied to the extraction of illicitly 
prepared tablets known to contain MBDB (8) on the basis of GC-MS and HPLC-DAD analysis. The 
extracts would be subjected to GC-MS and HPLC-DAD analysis in order to determine whether or not 
the tablets had been made via the Leuckart reaction investigated. 
Section 6.1: Liquid chromatographic separation of seven Leuckart impurities 
derived from the synthesis of MBDB (8) 
 
As discussed in the introduction the drug, MBDB (8), 
referred to as ecstasy, can be synthesised via several routes. 
One of the routes that can be used is the Leuckart route (see 
Scheme 6.1.1, below). This route involves the reaction 
between PEK (16) via the N-formyl BDB (17) intermediate 
generated from the reaction between one molecule of PEK 
(16) and one molecule of formamide (Moore, 1949) via a N-
formyl BDB (17) intermediate. This reaction also has the 
potential to generate a number of pyrimidine impurities by 
the reaction of a second molecule of formamide via an N-
formyl-1-methylenedioxyphenyl-2-iminopropane 
intermediate (Van der Ark, 1977). There is also the 
possibility of two molecules of ketone condensing with one 
molecule of formamide, forming pyridine impurities. 
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Scheme 6.1.1: The synthesis of MBDB (8) via the Leuckart reaction. 
 
 
A number of these impurities have been isolated from the 
reaction mixture in the Department of pharmaceutical 
chemistry in school of pharmacy, Trinity College Dublin, 
and were subsequently characterised using NMR and MS 
(Keating, 2001) (see Figure 6.1.1). 
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Figure 6.1.1:Impurities obtained through the Leuckart synthesis of MBDB: (20) 4-ethyl-5-(3,4-
methyelendioxyphenyl)pyrimidine, (21) 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine, (22) 2,6-diethyl-3,5-di(3,4-
methyelendioxyphenyl)pyridine, (23) 2,6-dimethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine, (24) 4-ethyl-3-methyl-2-(3,4-
methylenedioxybenzyl)-5-(3,4-methylenedioxyphenyl)pyridine, (25) 2-ethyl-5-methyl-3-(3,4-methylenedioxyphenyl)-6-(3,4-
methylenedioxybenzyl)pyridine & (26) 2,4-diethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine 
 
The N-formyl BDB (17) and any of the pyridine or 
pyrimidine impurities found in an illicitly prepared tablet 
would indicate that the tablet was made via the Leuckart 
reaction as these impurities are route specific. This 
information would useful in combating clandestine drug 
manufacture at the law enforcement level. 
 In order to detect these compounds in an illicitly prepared 
tablet a suitable means of detecting them is required. The 
main techniques used for doing this are HPLC and GC-MS. 
The following section details the result of an attempt to 
develop a HPLC method to be used to detect one 
intermediate, N-formyl BDB (17), 2 pyrimidines 20, 21 and 3 
pyridine impurities, 22, 23, 25 and 26. Compound 24, 4-
ethyl-3-methyl-(3,4-methylenedioxybenzyl)-5-(3,4-
methylenedioxyphenyl)pyrimidine was excluded as it was 
isolated at the trace level from the reaction. 
 
Of the mobile phase systems investigated (see Section 5.3) 
system 3 was deemed to be the best as it gave the most 
desirable chromatography in the shortest runtime System 3 
consisted of pH 3.0 phosphate buffer: ACN:THF (66:25:13) 
at a flow rate of 1.5ml/min . A chromatographic trace 
recorded for the system outlined in section 5.3 involving the 
separation of seven leuckart-wallach impurities (17, 20, 21, 
22, 23, 24 and 26) is shown below (Figure 6.1.2).  
 
Figure 6.1.2.HPLC trace (289nm) recorded for the separation of seven leuckart-wallach impurities, 17, 20, 21, 22, 23, 25 and 
26 derived from the synthesis of MBDB (8) via the leuckart-wallach reaction. For chromatographic conditions see section 5.3. 
 
Chromatographic parameters such as capacity factors, resolution, peak tailing, column efficiency and 
wavelength maxima were calculated using the CLASS-VP software and are tabulated below (Table 
6.1.1). For details of the formulae used see appendix I. 
 
 
 
 
 
 
 
 
 
Peak Peak 
Identity 
tR (mins) Width 
(mins) 
Capacity 
Factor 
Resolution Asymmetry Theoretical 
Plates 
λ Max >190/ 
>260 
1 17 4.7 1.0 3.7 0.00 1.04 6059 206/285 
2 21 5.7 1.23 4.7 4.26 1.2 9850 207/287 
3 20 7.1 1.1 6.1 5.51 1.25 11181 205/293 
4 23 8.3 1.0 7.27 3.65 1.93 7096 206/284 
5 24 10.9 1.03 9.9 6.09 1.66 8457 206/281 
6 26 11.8 1.33 10.8 1.85 1.59 8815 205/263 
7 22 13.3 1.87 12.27 2.76 1.63 8878 205/271 
 
Table 6.1.1. Table of chromatographic parameters calculated from the chromatographic trace recorded for the separation of seven 
leuckart-wallach impurities, 17, 20, 21, 22, 23, 25 and 26 derived from the synthesis of MBDB (8) via the leuckart-wallach 
reaction 
 
The peaks in the mixture, reference solution 8, were identified by comparison with the retention times 
of the peaks in reference solutions 1-7 which contained compounds 17, 20, 21, 22, 23, 25 and 26 
respectively. The first peak to elute from the mixture was the most polar compound N-formyl BDB 
(17) at circa 4.7minutes. This was followed then by the less polar pyrimidines, 5-methyl-4-(3,4-
methylenedioxybenzyl)pyrimidine (21) and 4-ethyl-5-(3,4-methyloenedioxy) pyrimidine (20) at 
5.7minutes and 7.1 minutes respectively. The most polar impurities, the pyridines, 2,6-diethyl-3,5-
di(3,4-methylenedioxyphenyl)pyridine (22), 2,6-dimethyl-3,5-di(3,4-methylenedioxyphenyl)pyridine 
(23), 2-ethyl-5-ethyl-3-(3,4-methylenedioxybenzyl)pyridine (25), and 2,4-diethyl-3,5-di(3,4-
methylenedioxyphenyl)pyridine (26)  eluted at 8.3 minutes, 10.9 minutes, 11.8 minutes and 13.3 
minutes respectively. Ideally, in a liquid chromatographic separation one strives for a capacity factor 
value between 2-10, however values between 1-20 are acceptable (Dolan, 2000). The capacity factors 
for the seven compounds were between 3.7 and 12.27, which is good. Baseline resolution was achieved 
in all cases, the lowest resolution value estimated was 1.85, between the sixth (26) and the seventh (22) 
peaks.  The peak symmetry was found to be within acceptable limits for the first three peaks, however 
it deteriorated for the latter four peaks 1.93 (23), 1.66 (25), 1.59 (26) and 1.63 (22). Ideally, one would 
accept values of less than 1.2 (Snyder, 1997).  
 
 
On the basis that the N-formyl BDB (17) and the pyrimidines (20 & 21) were generated in much  
higher quantities than the pyridines and it was probable that they would be most likely to appear in 
illicit samples it was decided that the development of an impurity profiling procedure would focus on 
the route-specific N-formyl BDB intermediate (17) and the two route specific pyrimidines (20 & 21). 
The pyridines would be excluded, hence their poor peak shape was not a concern. The diode array 
detector allowed for the estimation of the wavelength which gave the highest absorbance. Although the 
actual wavelength maxima for the compounds differed slightly, it was felt that 289nm was a suitable 
wavelength for detecting the N-formyl BDB (17) and the pyrimidines (20 & 21). Calculating the 
average wavelength for each of these three compounds provided this value.  
 
Section 6.2 HPLC-DAD separation of three Leuckart impurities derived from 
the synthesis of MBDB (8) 
 
Section 6.2.1 Development of HPLC-DAD separation of three Leuckart impurities derived from 
the synthesis of MBDB (8) 
 
The twelve HPLC systems described in section 5.4.1 were investigated to determine whether they were 
suitable for the separation of the N-formyl BDB (17) and the two route-specific pyrimidines (20 & 21) 
(See Table 5.4.1.1). Various combinations of mobile phases were investigated (see Section 5.4.1) and 
based on criteria such as run time, peak tailing and resolution, it was decided that system 12 was the 
most suitable for the separation of the compounds.  The other systems, (1-11) were rejected on visual 
inspection of the chromatograms as they gave poor peak shape or they did not adequately separate the 
compounds of interest. System 12 involved a pH 3.0 phosphate buffer, acetonitrile and tetrahydrofuran 
(66:30:5). A typical chromatogram of test solution 8 (containing compounds 17, 20 and 21) is shown 
below (Figure 6.2.1.1). The identity, retention time, width, capacity factor, resolution, peak tailing and 
column efficiency for each of the peaks was estimated (see Table 6.2.1.1). The formulae used to 
calculate these parameters are included in appendix I. 
 
Figure 6.2.1.1 HPLC trace (289nm) recorded for the separation of three leuckart-wallach impurities, 17, 21 and 20 derived from 
the synthesis of MBDB (8) via the leuckart-wallach reaction, using system 12. 
 
 
The wavelength maximum for each of the compounds 17, 20 
and 21 were 285nm, 287nm and 293nm. The most suitable 
wavelength for analysis of all three compounds was found 
289nm. Calculating the average wavelength for all three 
arrived at this value. 
 
Peak Peak 
Identity 
tR (mins) Width 
(mins) 
Capacity 
Factor 
Resolution Peak 
Tailing 
Theoretical 
Plates 
λ Max >190/ 
>260 
1 17 5.3 0.63 4.33 0.00 1.20 7781.34 204/285 
2 21 7.6 0.93 6.63 4.85 1.14 9288.54 203/287 
3 20 9..9 0.97 8.90 6.48 1.18 10616.11 203/293 
 
Table 6.2.1.1 Table of chromatographic parameters calculated from the HPLC trace recorded for the separation of three  Leuckart 
impurities, 17, 21 and 20 derived from the synthesis of MBDB (8) (for chromatographic conditions see section 5.4.1). 
 
The order of elution was, as observed for the chromatographic system described in section 6.1. The N-
formyl BDB (17) and the less polar pyrmidines, 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine 
(21) and 4-ethyl-5-(3,4-methyloenedioxy) pyrimidine (20)  eluted at 5.3 minutes, 7.6 minutes and 9.9 
minutes respectively. The three peaks were found to be symmetrical with values of 1.2, 1.14 and 1.18 
calculated for the peaks of compounds 17, 20 and 21 respectively. The capacity factors were also 
within the desired range for the standards, 2-10 (Dolan, 2000), for all three peaks.  
 
 
Section 6.2.2: Assessment of precision of HPLC-DAD separation of three Leuckart impurities derived 
from the synthesis of MBDB (8) 
 
The precision of system twelve was assessed by analysing six replicate injection of reference solution 
12. Chromatographic parameters such as retention time and peak area were estimated using the 
formulae in appendix I. The relative standard deviations, R.S.D. (Appendix I) was calculated for the 
retention times and peak areas of each of the three peaks in the six chromatograms.  The results of 
these calculations are shown in Table 6.4.2.1 below. 
 
Parameter Peak 1 (17) Peak 2 (21) Peak (20) 
tR R.S.D 0.23 % 0 % 0 % 
Area R.S.D. 1.76 % 1.39 % 1.57 % 
 
Table 6.4.2.1: Relative standard deviation in retention time and peak area for the three compounds 17, 20 and 21. 
 
As can be see there was very little variation between 
injection based on the R.S.D. values returned, values of less 
than 2 % are considered to be very good (Riley, 1996). 
 
Section 6.2.3: Assessment of selectivity of HPLC-DAD separation of three Leuckart impurities 
derived from the synthesis of MBDB (8) 
 
The selectivity of the separation achieved with system 12 was tested by analysing a series of potentially 
interefering compounds under the chromatographic conditions described in system 12. The compounds, 
which were tested were; MBDB (8), BDB (7), MDA (4), MDMA (5), MDEA (6), amphetamine (3), 
ketamine (27), 4-methylthioamphetamine (9), caffeine (28), paracetamol (29) and piperonyl ethyl 
ketone (16). None of these compounds were found to interfere with the three compounds of interest 
(17, 20 and 21) under the conditions of system 12. Most of the compounds eluted within 2.6 minutes. 
Piperonyl ethyl ketone (17), the starting material for the synthesis for MBDB (8), was an exception as 
it eluted much later.  An overlaid chromatogram of the three compounds of interest  (17, 20 and 21) 
and a chromatogram of an injection of reference solution 23, (containing a standard solution of 
piperonyl ethyl ketone (16)) (Figure 6.2.3.1), shows that the separation is selective. The resolution 
between the two closely eluting peaks at circa five minutes was calculated and found  to be, 1.57, 
which is acceptable. It is notable that the chromatogram of reference solution 23 containing PEK (16), 
had more than one peak. This would infer that PEK (16) is not a very stable compound and these extra 
peaks are breakdown products.  
M inutes
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Figure 6.2.3.1.Overlaid chromatogram obtained with the compounds 17 , 20 and 21 (uppermost chromatogram) and a 
chromatogram obtained with  piperonyl ethyl ketone (16) (lower chromatogram). 
 
The liquid chromatographic separation established was considered applicable to the detection of the 
possible presence of the N-formyl BDB (17), and the two pyrimidines (20 and 21) in illicit tablets, 
provided that an appropriate sample preparation procedure was established. 
 
Section 6.3: Construction of UV-Vis spectral library of Leuckart impurities, 
derived from the synthesis of MBDB (8), and related compounds. 
 
The zero order UV-Vis spectra (zero order spectra are plots of wavelength versus absorbance) collected 
for the impurities 17, 20 and 21 were entered into the custom UV-Vis spectral library. Unlike NMR 
and IR, which are well known for giving highly featured, zero-order,  spectra in the liquid phase, UV-
Vis spectroscopy does not.  Therefore often derivative spectra are calculated as they can be more 
featured and therefore be more useful from an identification point of view. The CLASS-VP software 
offers the option to enter derivative spectra into spectral libraries. The 1st and 2nd derivatives of the zero 
order spectra were also entered into the library. Examples of the zero order, 1st and 2nd derivative 
spectra for compounds 17, 20 and 21 are shown below in Figures 6.3.1, 6.3.2 and 6.3.3 respectively. 
These spectra were collected from a standard injection of reference solution 12 (containing compound 
17, 20 and 21).  
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Figure 6.3.1 (1a) UV spectrum of N-formyl BDB (17), (1b) 1nd derivative spectrum of N-formyl BDB (17) and (1c) 2nd derivative 
spectrum of N-formyl BDB (17). 
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Spectrum at time 7.53 min.
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Figure 6.3.2 (2a) zero order UV spectrum of 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21), (2b) 1st derivative 
spectrum of 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21),  and (2c) 2nd derivative spectrum of 5-methyl-4-(3,4-
methylenedioxybenzyl)pyrimidine (21). 
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Spectrum at time 9.83 min.
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Spectrum at time 9.83 min.
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Figure 6.3.3 (1a) zero order UV spectrum of 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20),  (1b) 1nd derivative spectrum 
of 4-ethyl-5-(3,4-methylenedioxyphenyl)pyrimidine (20), and (1c) 2nd derivative spectrum of 4-ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20. 
 
As can be seen the zero order spectra for the three 
compounds (17, 20 and 21) showed some similarity to one 
and other  (See Figures 6.3.1a, 6.3.2a and 6.3.3a). The N-
formyl BDB (17) had a spectrum with three maxima at 
204nm, 233nm and 285nm respectively (Figure 6.3.1a). The 
signal at 204nm was highest but as it was close to the solvent 
cut-off, it was decided that one of the other two maxima 
would be most useful for analytical work.  The 5-methyl-4-
(3,4-methylenedioxybenzyl)pyrimidine (21) gave a similar 
spectrum to the N-formyl BDB (17) (See Figure 6.3.2.a) 
where the three absorbance maxima which were observed 
were at 204nm, 251nm and 287nm. Again the third 
maximum (287nm ) was deemed to be most suitable for 
analytical work. The zero order spectrum for the 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20) was found to be 
different from the other two as the second maximum was not 
quite as well resolved  and hence the only two significant 
maxima that were observed were at 203nm and 293nm (see 
Figure 6.3.3a). It was decided that the third maxmum was 
most suitatble for analytical work as it was again sufficiently 
far from the solvent cut-off. As mentioned in section 6.2 the 
analytical wavelength, which would be used for future work, 
would be 289nm as this was the best compromise wavelegth 
for all three compounds (17, 20 and 21).  
 
One of the drawbacks of diode array detection is that UV 
spectra for a similar compounds may not differ sufficiently  
to enable them to be used in unequivocal identification. 
However  in this instance  it is fortunate that all three of the 
target compounds differ sufficiently to enable definite 
distinction between the compounds of interest spectrally. All 
of the spectra which were entered into the library were later 
used in the attempted identification of route specific 
impurities derived from the synthesis of MBDB (8) via the 
Leuckart reaction. Derivative spectra are included here 
(Figures 6.3.1b, 6.3.1c, 6.3.2b, 6.3.2c, 6.3.3b, 6.3.3c). 
Derivative spectra are generally more structured than zero 
order spectra, enabling very tiny differences between the 
original spectra to be amplified. The second and other even 
numbered derivative spectra are generally considered to be 
more useful than first order spectra (Gorog, 1995). In this 
instance the derivative spectra are not that different, 
probably due to the high spectral bandwidth of the 
instrument which yields poorly structured 2nd order 
derivative spectra. The zero order spectra were to be used as 
the main spectra when searching for the target compounds 
in chromatograms. The representative UV-Vis spectra of the 
standards, MBDB (8), BDB (7), MDA (4), MDMA (5), 
MDEA (6), amphetamine (3), ketamine (27), 4-
methylthioamphetamine (9), caffeine (28), paracetamol (29) 
and piperonyl ethyl ketone (16), were also entered into the 
library. Spectra were taken over the whole peak so as to 
allow for concentration differences when searching. An 
electronic copy of the library is included in appendix II. A 
copy of the Shimadzu CLASS-VP software is required to use 
this library (Shimadzu, 1999) . 
Section 6.4: GC-MS separation of three Leuckart impurities derived from the 
synthesis of MBDB (8). 
 
Section 6.4.1 Development of GC-MS separation of three Leuckart impurities derived from the 
synthesis of MBDB (8) 
 
Although a HPLC-DAD method had been established for the analysis of the Leuckart route specific 
compounds 17, 20 and 21, it was considered worthwhile to attempt to develop a GC-MS separation. It 
was intended that this method be applicable to the analysis of these impurities in illicitly produced 
tablets. Using a standard mixture of the three impurities 17, 20 and 21, seven temperature programmes 
were investigated (see Table 5.6.1.2).  Of the seven programmes investigated, system 1 was found to be 
the most suitable. The conditions are described in detail in Section 5.6.1. The temperature programme 
involved an initial temperature of 90°C (held for 1minute), ramping up to 300°C at a rate of 15°C/min. 
The oven was held at the final temperature of 300°C for 10 minutes. Compounds 17, 20 and 21 were 
separated and gave clear mass spectral fragmentation patterns. A typical reconstructed ion 
chromatogram (RIC) obtained with a standard containing compounds 17, 20 and 21 is shown below 
(Figure 6.4.1.1). A RIC is a plot of the intensity of the ions in the ion trap versus time. 
 
 
 
 
 
 
 
 
 
 
Figure 6.4.1.1 Reconstructed ion chromatogram trace recorded for the separation of three impurities, 17, 21 and 20 derived from 
the synthesis of MBDB (8) via the leuckart-wallach reaction, using GC-MS system 1. 
 
Chromatographic parameters such as retention time, peak width, resolution, tailing factor, column 
efficiency, for the above chromatogram are shown below (see Table 6.4.1.1, for formulae see Appendix 
I). The primary ions observed from the mass spectra recorded for each peak are also tabulated. All 
three compounds 17, 20 and 21 were well separated. The order of elution was determined by 
comparing the retention time of individual standards containing compounds 17, 20 and 21 respectively 
with the chromatographed mixture. The first compound to elute from the column was the 4-ethyl-5-
(3,4-methylenedioxyphenyl)pyrimidine (20) at 9.5 minutes. This was followed at 10.0 minutes and 
10.2 minutes by the N-formyl BDB (17) and the 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine 
(21) respectively. The peaks were, as expected in capillary GC, extremely symmetrical, with all peaks 
Comment [RM1]:  Need 
chromatogram here. 
showing tailing factor values of 1.0.  The resolution between the N-formyl BDB (17) and the 4-ethyl-5-
(3,4-methylenediocyphenyl)pyrimidine (20) was found to be 3.88, and the resolution between the N-
formyl BDB (17) and the 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21) was 1.68. As 
resolution values greater than 1.7 are ideal (Dolan, 2000) this separation was considered acceptable. 
The efficiency of the column for each of the peaks was good for a 30 metre column. Typically, one 
would expect values of ca. 90,000 plates (Baugh, 1993). The efficiency of the N-formyl BDB (17) peak 
was low, but not so low that the method was not considered useful. 
 
Peak Peak 
Identity 
tR (minutes) Width 
(minutes) 
Resolution Tailing  
Factor 
Column 
Efficiency 
Primary Ions in mu (abundance) 
1 20 9.5 0.12 ---- 1.0 102,400 229mu* (100%),  228 (38%), 
168mu (9%) and 115mu (6%) 
2 17 10.0 0.16 3.88 1.0 63,756 176mu (100%), 222mu (31%), 
135mu (32%), 58mu (34%) 
3 21 10.2 0.12 1.68 1.0 168,428 228mu (100%), 229 (73%), 
135mu (30%), 169mu (28%) 
 
Table 6.4.1.1: Table of chromatographic parameters calculated from the reconstructed ion chromatogram recorded for the 
separation of three impurities, 17, 21 and 20, derived from the Leuckart synthesis of MBDB (8) using GC-MS system 1 (for 
chromatographic conditions see section 5.6.1). *mu refers to mass units 
 
 
Section 6.4.2: Assessment of precision of GC-MS separation of three Leuckart impurities derived 
from the synthesis of MBDB (8) 
 
A series of five replicate injections were chromatographed 
using the conditions outlined in system 1 (see section 5.6.1). 
The R.S.D. of the retention times of the compound (17, 20 & 
21) were less than 0.01% in all cases. The R.S.D. of the peak 
areas was less than 3% in all cases. The precision of the 
method was considered acceptable. Mass spectral data was 
recorded for each peak and is discussed in section 6.5.  
 
Section 6.4.3: Assessment of selectivity of GC-MS separation of three Leuckart impurities 
derived from the synthesis of MBDB (8) 
 
The selectivity of the separation achieved with system 1 was tested by analysing a series of potentially 
interefering compounds under the chromatographic conditions described in programme one (see 
Section 5.6.1). The compounds, which were tested, were MBDB (8), BDB (7), MDA (4), MDMA (5), 
MDEA (6), amphetamine (3), ketamine (27), 4-methylthioamphetamine (9), caffeine (28), paracetamol 
(29) and piperonyl ethyl ketone (16). None of these compounds were found to interfere with the three 
compounds of interest (17, 20 and 21) under the conditions of system 1. The PEK (16) appeared to 
breakdown over time as mentioned above (see Section 3.2.3) but was not found to interfere with the 
compounds of interest. 
 
The method provided a basis for the analysis of route-
specific target compounds 17, 20 and 21 in MBDB (8) 
tablets, where the MBDB (8) had been synthesised via the 
Leuckart reaction. 
 
 
 
 
 
 Section 6.5: Construction of Mass spectral library of Leuckart impurities, 
derived from the synthesis of MBDB (8), and related compounds. 
 
The mass spectra collected for the impurities 17, 20 and 21, and potentially interfering compounds 
were entered into the custom mass spectral library. Mass spectra for compounds 17, 20 and 21 are 
shown below in Figure 6.5.1. 
(a) 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
Figure 6.5.1 Mass spectra for compounds 17 (a) and 20 (b). 
 
 
 
 
 
 
 
 
 
  
 
 
 
( C)  
Figure 6.5.1(cont’d): Mass spectra for compound 21 (c). 
 
The last compound to elute was the 5-methyl-5-(3,4-
methylenedioxybenzyl)pyrimidine (21). It is clear from the 
electron ionisation mass spectral fragmentation pattern (see 
Figure 6.5.1.c) that the molecule does not undergo 
significant fragmentation. Given that the molecular mass of 
the compound was calculated to be 228 mass units (mu), the 
molecular ion was at this mass in the spectrum, as expected. 
The molecular ion was the base peak in the mass spectrum 
compound 21. There was a large M+1 peak (73%), which is 
likely due to proton addition. Proton addition to the 
molecular ion in electron ionisation is not that common, but 
can occur and seems to have occurred in this instance (Todd, 
1995). There was also a significant ion at 169mu, which is 
difficult to interpret, but would seem to be derived from 
fragmentation of both the pyrimidine and the 
methylenedioxy ring. Although there are other fragment 
peaks, they are all generally less than 10% of the abundance 
of the base peak. For confirmational analysis in GC-MS one 
strives for a fragmented spectra, as it is not impossible that 
many compounds of the mass 228mu would have poor mass 
spectral fragmentation patterns. The possibility of 
derivatisation in order to obtain a more fragmented and 
therefore unique spectrum was considered. However, it was 
felt that as none of the potentially interfering compounds 
eluted at similar retention times, hence this spectrum would 
suffice for the analysis of the target compounds. 
Derivatisation also adds an additional analytical step, which 
can lead to errors. In addition, in the case of the pyrimidines 
there is no suitable functionality that could be easily 
exploited in order to form a derivative. A proposed 
fragmentation pattern for 5-methyl-5-(3,4-
methylenedioxybenzyl)pyrimidine (21) is shown below 
(Figure 6.5.2).  
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Figure .5.2: Proposed fragmentation pattern for 5-methyl-5-(3,4-methylenedioxybenzyl)pyrimidine (21). 
 
The other pyrimidine, 4-ethyl-5-(3,4-methylendioxybenzyl) 
(20) eluted  first and unlike compound 21 it gave a poor 
fragmentation pattern (see Figure 6.5.2.b), when compared 
to compound 21.Again, the large M+1 peak was observed, 
but this time it was the base peak, indicating significant 
proton addition.  The fragments previously observed with 
compound 21 at 115mu and 169mu were again observed in 
the mass spectrum of compound 20, but were at a very low 
abundance. It is proposed that these were due to the 
fragmentation of the pyrimidine and the methylenedioxy 
ring.   
 
The N-formyl BDB (17) gave a good fragmentation pattern. 
The main ions observed were the molecular ion at 222mu, 
and further ion fragments at 176mu, 161mu, 135mu and 
58mu. The proposed pathway of fragmentation is shown 
below (see Figure 6.5.2). 
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Figure 6.5.2 proposed fragmentation pattern for N-formyl BDB (17). 
 
The mass spectra of compounds 17, 20 and 21 were entered 
in to the custom library once suitable representative mass 
spectra had been found. Spectra which were considered to 
be representative of the compounds were entered into the 
mass spectral library. The representative Mass spectra of 
the standards, MBDB (8), BDB (7), MDA (4), MDMA (5), 
MDEA (6), ketamine (27), 4-methylthioamphetamine (9), 
caffeine (28), paracetamol (29) and piperonyl ethyl ketone 
(16), were also entered into the library. Amphetamine (3) 
was excluded as it seemed to be eluting during the 4 minute 
filament delay at the start of the chromatographic run. An 
electronic copy of this library is included in Appendix II. 
The Varian sotware is required when using this library 
(Varian, 1989-1998).  
 
It was decided that instead of using the reconstructed ion 
chromatogram (RIC) mode, which plots all the ion 
intensities recorded while a compound elutes from the 
column into the mass spectrometer, Selected Ion 
Monitoring,  SIM, would be used. SIM is a technique 
employed in mass spectrometry that allows the selection of a 
selected ions for recording. The ions are usually the base 
peak or some other ion that gives a high abundance in the 
compounds being analysed. This SIM technique reduces the 
background signal and allows for much better selectivity. 
The SIM mode was used for all subsequent analyses and the 
ions that were chosen for the compounds 17, 20 and 21 were 
176mu, 229mu and 228mu respectively. These ions were 
chosen as they were the most intense (see Figure 6.5.1 (a), (b) 
and (c)) ions observed for the mass spectra of the respective 
analytes.  
 
Section 6.6: Solid Phase Extraction of Leuckart impurities 
from MBDB (8) 
 
In attempting to develop a method for the extraction of the 
target compounds 17, 20 and 21 from MBDB (8) synthesised 
via the Leuckart reaction the starting point was a method 
described by Lambrechts et al. (Lambrechts, 1985). They 
employed bonded phase silica sorbents in an attempt to 
develop a rapid sampling protocol for HPLC analysis of 
impurities in illicit amphetamine (3).  A method was 
developed which allowed the detection of N-
formylamphetamine, 4-methyl-5-phenylpyrimidine and N,N-
di(β-phenylisopropyl)formamide in a seizure of illicit 
amphetamine by using a protocol involving a 100mg C8 
bond elut® solid phase extraction cartridge and the 
following protocol. 
Two column volumes HPLC grade MeOH 
↓ 
Two column volumes of HPLC grade H2O 
↓ 
1 ml of 50mg/ml amphetamine in pH7.0 buffer 
↓ 
Two column volumes of HPLC grade H2O 
↓ 
Column was dried under vacuum 
↓ 
Analytes eluted with 3×100µl of HPLC grade Acetonitrile 
where each Acetonitrile aliquot was allowed to remain on 
the phase for 2 minutes. 
↓ 
The  resulting solution was then analysed by HPLC 
 
 
The compounds of most significance in the resultant 
chromatogram were collected at the waste tube of the 
detector and submitted for GC-MS analysis, which allowed 
for identification of the aforementioned analytes.  
 The approach adopted in the present study differed in that 
the HPLC and GC-MS analyses had been established and 
validated for the qualitative analysis of three target 
compounds (sections 6.2-6.5). Then, using 100mg C8 and 
C18 solid phase extraction cartridges and the Varian 
Sorbent Extraction Technology Handbook (Blevins, 1993) a 
suitable procedure was developed for extraction of the target 
compounds from MBDB (8) synthesised via the Leuckart 
reaction.  
 
Section 6.6.1: Development of a suitable system for the elution of interfering components from a 
matrix containing Leuckart impurities, derived from the synthesis of MBDB (8), from C8 and 
C18 solid phase extraction cartridges. 
 
Using the HPLC chromatographic system outlined in section 
5.8.1 an attempt was made to determine the most suitable 
elution solvent.  The best elution solvent is the one, which 
elutes the interfering compounds, but allows retention of the 
target compounds (Blevins, 1993). Complete elution of 
MBDB (8) itself and interfering compounds from both C8 
and C18 phases was the aim of the experiment, with 
retention of compounds 17, 20 or 21. The ability of the 
elution systems investigated (systems 1-4 table 5.8.1.1) was 
assessed based on the peak area returned for MBDB (8) on 
injection into the HPLC system at 289nm. Peak areas were 
graphed for both C8 and C18 solid phase extraction 
cartridges and are shown below (Figure 6.6.1.1). 
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Figure 6.6.1.1: Graph of elution profiles of MBDB (8), from a 100mg C18 solid phase extraction cartridge, using different 
elution solvents. 
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Figure 6.6.2: Graph of elution profiles of MBDB (8),  from 100mg C8 solid phase extraction cartridge, using different elution 
solvents. 
 
In the case of the C18 cartridge 3 solvent systems namely, H2O, pH 3 phosphate:ACN (6:1) and 
H2O:MeOH (95:5) performed similarly, but since further work indicated the organic modifier might 
have the effect of disturbing the target analytes, H2O was chosen as the elution solvent. In the case of 
the C8 cartridge both H2O and H2O:MeOH (95:5) performed best. H2O was again chosen as the most 
suitable solvent for the elution of MBDB (8) for C8. The MBDB•HCl would appear to be water-
soluble and to have no affinity for the non-polar stationary phase of the extraction cartridges in the 
presence of H2O. The target compounds 20 and 21 are not as water soluble, however the N-formyl 
BDB (17) is slightly more water-soluble (Keating, 1999). 
 
Section 6.6.2: Assessment of the retention of impurities when subjected to MBDB (8) elution 
protocol. 
 
Using H2O, the ability of the C8 and C18 cartridges to retain N-formyl BDB (17), 4-ethyl-5-(3,4-
methylenedioxyphenyl)pyrimidine (20)  and 5-methyl-4-(3,4-methylenedioxybenzyl)pyrimidine (21), 
was assessed. By chromatographically analysing the eluate from the experiment described in section 
5.8.2 it was evident, that the MBDB (8) elution protocol that involved H2O, discussed above did not 
appear to be eluting the target compounds 17, 20 and 21. Featureless chromatograms were observed for 
these extracts. 
 
Section 6.6.3: Development of a suitable system for the elution of Leuckart impurities, derived 
from the synthesis of MBDB (8), from C8 and C18 solid phase extraction cartridges 
 
The next step involved the selection of the most suitable 
solvent, for the elution of the designated impurities from the 
two stationary phases. The best solvent is the one, which 
completely elutes the previously retained analytes in the 
smallest volume (Blevins, 1993). Acetonitrile and 
tetrahydrofuran were tested as potential, impurity elution 
solvents. Several fractions of each were collected from C8 
and C18, SPE cartridges and chromatographed. The peak 
areas from the chromatograms for all three compounds 
versus microlitres of respective solvent (THF and ACN). The 
plots of how each compound eluted from its respective phase 
in either THF or ACN are shown below (see Figure 6.6.3.1, 
6.6.3.2, 6.6.3.3 and 6.6.3.4). 
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Figure 6.6.3.1: Graph of elution profiles of compounds 17, 20 and 21, from 100mg C18 solid phase extraction cartridge using 
ACN. Where  peak 1 is compound 17, peak 2 is compound 21 and peak 3 is compound 20. 
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Figure 6.6.3.2: Graph of elution profiles of compounds 17, 20 and 21, from 100mg C8 solid phase extraction cartridge using 
ACN. Where peak 1 is compound 17, peak 2 is compound 21 and peak 3 is compound 20. 
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Figure 6.6.3.3: Graph of elution profiles of compounds 17, 20 and 21, from 100mg C18 solid phase extraction cartridge using 
THF. Where peak 1 is compound 17, peak 2 is compound 21 and peak 3 is compound 20. 
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Figure 6.6.3.4: Graph of elution profiles of compounds 17, 20 and 21, from 100mg C8 solid phase extraction cartridge using 
THF. Where peak 1 is compound 17, peak 2 is compound 21 and peak 3 is compound 20. 
 
Based on the results above graphs it was evident that ACN was not the best solvent as it was still 
giving peak signals after 500 µl of solvent had been passed through the cartridge. The THF had 
eluted all three compounds successfully after 500 µl as can be seen form the above graphs and 
hence THF was chosen as the most suitable elution solvent for both the C8 and C18 solid phase 
extraction cartridges. As the main objective of the procedure was to enrich the impurities as 
much as possible, an added advantage of using THF is that it was easily evaporated at room 
temperature, under a stream of nitrogen gas. Once evaporated the residue could be reconstituted 
in the desired amount of HPLC grade ACN. It was felt that 60 µl of ACN was a suitable volume 
as it could then be used for two HPLC injections and two GC-MS injections. One could use a 
lower volume if the levels of impurity were extremely low.  
 
The protocol that was employed on the basis of the above results for extracting compounds 17, 20 
and 21, synthesised via the Leuckart reaction, is outlined in section 5.8, the results of which 
follow. 
 
Section 6.6.4: Extraction of Leuckart impurities from a sample of MBDB (8) prepared via the 
Leuckart reaction. 
 
Using water to elute MBDB (8) and THF to then elute the target compounds 17, 20 and 21 the 
solid phase extraction, protocol was applied to MBDB (8) synthesised by the Leuckart reaction, 
in the Department of Pharmaceutical Chemistry, T.C.D. The extracts were subjected to HPLC 
analysis and GC-MS analysis as described in Section 5.8.4, in an attempt to confirm the Leuckart 
route as the route of synthesis. Typical HPLC chromatograms for extraction of 50mg of MBDB 
(8), extracted using 100mg C8 and C18 are shown below (Figure 6.6.4.1 and 6.6.4.2 respectively).  
 
Figure 6.6.4.1 HPLC  (289nm) of 50mg MBDB•HCl solid phase extracted with a C18 cartridge using H2O to elute MBDB (8) 
and THF to elute analytes. 
 
Figure 6.6.4.2 HPLC (289nm) of 50mg MBDB•HCl solid phase extracted with a  C8 cartridge using H2O to elute MBDB (8)  
and THF to elute analytes. 
 
Using the UV-Vis library previously described  in section 6.3, the above chromatograms were 
compared to the UV-Vis spectra in the custom UV-Vis spectral library. Compounds 17, 21 and 20 
were found to be eluting at at 5.3 minutes, 7.6 minutes and 9.9minutes respectively. The spectra 
of the components in each of the traces eluting at 5.3 minutes, 7.6 minutes and 9.9 minutes, in 
each chromatogram were found to  match those of the N-formyl BDB (17) , 5-methyl-(3,4-
MDbenzyl)pyrimidine (21) and 4-ethyl-5-(3,4-MDP)pyrimidine (20) respectively. 
 
The CLASS-VP software for the HPLC enables background correction. This is simply carried 
out by first setting a background spectrum, which is generally selected at some point in the 
chromatogram where there is no peak eluting or at the base of the peak of interest. Once the 
background spectrum is set it can be subtracted from the analyte spectrum. This process 
improves the quality of the analyte spectrum and should allow for more accurate identification. 
The signal was low in the case of all three components, however background correction of the 
spectra yielded reasonable spectra. The match quality value was calculated by the software and 
are tabulated below for both chromatograms (see Table 6.6.4.1). A value as close to 1.0 as 
possible is considered to be very good (Shimadzu, 1997) and a value greater than 0.99 was 
returned each case, however it is worth noting that there is a high background especially around 
the N-formyl BDB (17), hence the possibility of isomeric/structurally similar compounds in the 
mixture could not be ruled out.  
 
Compound Spectral Match Quality 
17 0.995 
20 0.998 
21 0.992 
 
Table 6.6.4.1: Spectral match quality for compounds 17, 21 and 20. 
 
GC-MS chromatograms were also obtained for the impurities from the MBDB (8) and are shown 
below (see Figure 6.6.4.3 for C18 and Figure 6.6.4.4 for C8). Both pyrimidines were present in the 
C8 and C18 extracts when compared to the spectra in the library esablished in section 6.5. The 4-
ethyl-5-(3,4-MDP)pyrimidine (20) eluted at 9.5minutes and 5-methyl-4-(3,4-
MDbenzyl)pyrimidine (21) at 10.2 minutes. The library was searched for these compounds and 
gave poor results. The chromatograms were visually inspected and it was confirmed that the 
compounds aforementioned were indeed present. There was no evidence of the N-formyl BDB 
(17) however there was a peak eluting at 10.3 minutes which would appear to be N-formyl MBDB 
(18). The identity of this was confirmed using the technique (described in section 5.14) of 
methylating a sample of N-formyl BDB (17) to form N-formyl MBDB (18), the results of which 
can be found in section 6.13. The occurrence of the N-formyl MBDB (18) may be due to an 
impurity in the formamide used in the synthesis (i.e. an N-methlyformamide impurity). The N-
formyl MBDB (18) may have been too water soluble to be retained on either phase hence the 
absence from the trace. The N-formyl MBDB (18), being slightly more polar than the desmethyl 
analogue (17) may have been retained hence, the N-formyl MBDB (18) may have been the large 
peak eluting at 6.1 minutes the HPLC chromatograms (Figures 6.6.4.2 & 6.6.4.2), this is 
investigated further in section 6.3.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6.4.3 GC-MS chromatogram of 50mg MBDB•HCl solid phase extracted with a  C18 cartridge using H2O to elute 
MBDB (8) and THF to elute analytes. The trace shows the extracted ions 228mu, 229mu and 176mu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 6.6.4.4 GC-MS chromatogram  of 50mg MBDB•HCl solid phase extracted with a  C8 cartridge using H2O to elute 
MBDB (8) and THF to elute analytes. The trace shows the extracted ions 228mu, 229mu and 176mu. 
 The result of the above experiment lead to the conclusion that it was possible to detect Leuckart 
specific impurities generated via the synthesis of MBDB (8) using the solid phase extraction 
protocols developed using both C8 and C18 cartridges. The procedure developed was done so by 
extracting the impurities from pure MBDB•HCl, which had been synthesised to a very high 
standard and rigourously purified in the Department of Pharmaceutical Chemistry in the School 
of Pharmacy (see Appendix III). The next step was to carry out an extraction of the impurities 
using liquid-liquid extraction at different of pH values to see if any improvement on the solid 
phase extraction protocol could be established.  
 
Section 6.7: Development of liquid-liquid extraction for the isolation and enrichment 
of Leuckart impurities from MBDB (8) 
 
Although a solid phase extraction protocol, capable of confirming that a batch of MBDB (8) was 
synthesised via the Leuckart route was established, it was considered worthwhile to investigate 
the possibility of using liquid-liquid extraction as an alternative method. The optimum liquid-
liquid extraction pH was chosen, by extracting samples of MBDB•HCl at different values of pH 
(3, 4, 4.9, 6 and 7) into petroleum ether. The chromatographic systems used to monitor the 
success of the various extractions were the GC-MS and HPLC systems outlined in section 5.9. 
The most suitable pH was chosen on the basis that it gave a higher recovery of impurities from 
the same batch of MBDB (8). It was considered that pH 4 was the most suitable. Typical 
chromatograms  (HPLC and GC-MS) obtained after MBDB•HCl was extracted at pH 4 
extractions, are shown below (Figure 6.7.1 and Figure 6.7.2 respectively).  
 
 
 
Figure 6.7.1 HPLC chromatogram (289nm) of 50mg MBDB•HCl (8) liquid-liquid extracted at pH 4 with petroleum ether. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7.2 SIM GC-MS  chromatogram of 50mg MBDB•HCl (8) liquid-liquid extracted at pH 4 with Petroleum Ether. 
Trace was constructed using ions 228, 229 and 176. 
 
The peak areas for each of the compounds  (17, 20 and 21) were calculated and plotted against 
extraction pH for the GC-MS and for the HPLC. These plots are shown below (Figure 6.7.3 and 
Figure 6.7.4 respectively). As can be seen from the Figure 6.7.4  (GC-MS) the best pH for the 
extraction of all three compounds was pH 4. Although pH 5 appeared to be better than pH 4 for 
extracting the N-formyl MBDB (18), it was obvious from chromatograms that there is a lot of 
compounds being extracted at this higher pH. It may have been possible that the pKa of MBDB 
(8) was being approached and less of the MBDB (8) was ionised, such that the unionised amine 
was partitioning into the organic phase. However the pKa was determined experimentally for 
MBDB (8) (see appendix IV) and was found to be 10.25, hence it is unlikely that MBDB (8) is 
what is being carried over between pH 5 and pH 7.  It is more plausible that neutral impurities 
were interfering at this stage. These impurities were not of interest at this stage as there are no 
reports in the literature about route specific neutral impurities, hence they were considered as an 
interference. The HPLC data also indicated that pH 4 was the optimum (see Figure 6.7.3.), 
however the N-formyl BDB (17) peak appeared not to match the library spectrum sufficiently 
well. It appeared that there was an interfering compound eluting. Because of this the N-formyl 
BDB (17) was excluded from figure 6.7.3. This observation undermined the selectivity of the 
HPLC assay. This was not a problem with respect to the GC-MS assay, which serves to highlight 
the desirability of different methodologies. It is however, worth noting that it was possible to 
identify the pyrimidine peaks for compounds 20 and 21 easily from the UV spectra acquired 
using the HPLC-DAD method developed in section 6.2. 
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Figure 6.7.3 Graph of HPLC (289nm) trace peak areas for compounds 17, 20 and 21 versus extraction pH for 50 mg of 
MBDB•HCl into petroleum ether. Compound 20 in marked in pink and compound 21 is plotted in navy. 
Plot of peak areas of compounds 20, 21 and 18 (generated 
from the merging of the 227, 228, 229, 176 and 236 ions) 
versus extraction pH.
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Figure 6.7.4 Graph of GC-MS trace peak areas (for ion 228mu, 229mu and 176mu) for compounds 17, 20 and 21 versus 
extraction pH for 50 mg of MBDB•HCl into petroleum ether. Compound 18 is plotted in yellow (suspected N-formyl MBDB 
(17)), compound 20 is plotted in navy and compound 21 is plotted in pink 
 
Section 6.8: Comparison of Solid Phase Extraction and Liquid-Liquid Extraction. 
 
Having investigated both solid phase extraction and the pH extraction method, the best 
extraction protocol based on the peak areas obtained via GC-MS analysis for extractions of the 
same sample of MBDB (8), was the pH 4 extraction procedure. Although the N-formyl MBDB 
(18) was not initially a target compound it was felt that, it was so significant that it could not be 
excluded. This procedure would be adopted for the analysis of the tablets. A bar chart 
constructed from the GC-MS peak areas of the pyrimidines 20 and 21 was constructed for the 
above liquid –liquid extractions and the solid phase extractions and is shown below (Figure 
6.7.5). This chart demonstrates quite clearly that the method of choice is the pH 4 extraction, 
when the pyrimidines are concerned. This pH is also suitable for the extraction of the N-formyl 
MBDB (18) as shown in Figure 6.8.1 
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Figure 6.8.1:Bar chart constructed from the GC-MS peak areas of the pyrimidines 20 and 21 versus the extraction technique 
employed.  
 
Section 6.9: Qualitative analysis of illicitly prepared MBDB (8) 
 
Although the HPLC-DAD analysis (see Section 6.10) had 
been performed on the tablets, it was felt that it would be 
worthwhile to get mass spectral data for the tablets, given 
the interference with the N-formyl MBDB (18) noted earlier. 
Using the GC-MS procedure outlined in section 5.10 the 
identity of the main active ingredient in the illicitly prepared 
tablets was checked against standard MBDB (8). All of the 
tablets were found to contain MBDB (8) as the most 
significant peak eluting at the same as the standard, 7.4 
minutes, where the mass spectra were comparable to the 
mass spectrum of MBDB (8).  The fit algorithm in the GC-
MS Saturn software returned values in excess of 970 which 
is considered acceptable when presented along with 
retention time data (Varian, 1989-1998). The results are 
tabulated below (Table 6.9.1). 
 
 
  
 
 
 
Tablets Analysed Retention Time Ions (in order of intensity) 
Standard MBDB 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
Dil #6660 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
7A 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
Dil #A6765 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
Dil #6758 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
8A 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
Dil #6840 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
Dil #6600 7.4 minutes 208mu, 72 mu, 135 mu, 177 mu.  
                    
 Table 6.9.1: Retention time and primary ion data for the qualitative analysis of MBDB (8) in illicitly prepared tablets and 
standard MBDB (8). 
 
 
 
Section 6.10: Quantitative analysis of MBDB (8) in illicitly 
manufactured tablets 
In order treat each tablet similarly, the concentration of 
MBDB (8) in each of the tablets had to be determined, such 
that a 50mg MBDB (8) equivalent of each tablet could be 
subjected to extraction into petroleum ether at pH 4. All of 
the tablets were analysed using the HPLC method outlined 
in section 5.11. MBDB (8) was found to elute at 12.3 minutes 
in the above system.  
 
Each of the tablets was treated as detailed in Section 5.11 
before injection into the HPLC system. All of the tablets 
contained MBDB (8) as the only significant peak in the 
chromatogram. The UV-Vis spectra for MBDB (8) in the 
library were compared with the suspected MBDB (8) peak, 
eluting at 12.30 minutes in each of the samples. Each of the 
tablets main peaks eluted at the same time as MBDB (8) and 
matched the MBDB (8) library entry. The fit was always 
greater 0.99, which is considered good. The areas of the 
peaks for the MBDB (8) standards (see Section 5.11) were 
calculated and a standard curve was constructed (Figure 
6.10.1). The R2 value was 0.999 and the equation of the line 
was y=10572x+63672 as calculated with the aid of Microsoft 
Excel (Microsoft®, 1997). 
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Figure 6.10.1: MBDB (8) Standard Curve 
 
The peak areas were calculated and the concentration values 
were interpolated from the standard curve for each of the 
samples analysed. The amount of MBDB (8) per tablet was 
calculated using the following equation: 
 
The results are tabulated below (Table 6.10.1). 
 
Tablet 
Reference 
Weight of 
homogenous powder 
analysed 
Tablet 
Weight 
Peak Area Interpolated 
Concentration 
Concentration of 
MBDB (8) 
Dil # 6660 9.8 mg 336.4 mg 5130192 0.48 mg/ml 163.72 mg 
7A 10.1 mg 278.41 mg 4592539 0.43 mg/ml 133.88 mg 
Dil # A6765 9.5 mg 308.70 mg 4446056 0.41 mg/ml 134.84 mg 
Dil #6758 10.8 mg 465.49 mg 3803090 0.35 mg/ml 106.73 mg 
8A 10.8 mg 328.07 mg 4520714 0.42 mg/ml 127.11 mg 
Dil # 6840 10.5 mg 273.30 mg 3936944 0.40 mg/ml 95.27 mg 
Dil # 6600 10.2 mg 335.8 mg 4708358 0.44 mg/ml 144.19 mg 
 
Table 6.10.1: Quantitative data for the determination of MBDB (8) in illicitly prepared tablets. 
 
As can be seen from table 6.10.1 there was a significant 
difference in the concentration of MBDB (8) in the tablets 
analysed. The concentration of MBDB (8) ranged from 
95.27mg 163.72mg. The average MBDB (8) content was 
129.39mg, with a standard deviation of 21.15mg. Doses 
ranging from 150-210mg seem to be normal for MBDB (8) 
(Shulgin, 1991), but significant variation has been recorded. 
Rothe and co-workers claim that on average MBDB (8) 
tablets contained 97mg (Rothe, 1997). The risk assessment 
published by the EMCDDA (Van Aerts, 2000) noted that the 
mean amount of MBDB (8) in tablets was 100mg, whereas 
Kintz reports that the concentrations are in the region of 76-
228mg (Kintz, 1997). The amount of each tablet (equivalent 
to 50mg) required for each of the tablets was calculated 
(Table 6.10.2). 
 
Tablet Name Weight equivalent to 
50mg MBDB 
Tablet Name Weight equivalent to 
50mg MBDB 
Dil# 6660 102.74mg 8A 129.05mg 
7A 103.98mg Dil# 6840 143.43mg 
Dil#6765 114.45mg Dil# 6600 116.44mg 
Dil# 6758 218.07mg   
 
Table 6.10.2: Table containing weights of tablet required to be taken such that 50mg of MBDB (8) could be extracted 
 
 
Section 6.11: Attempted extraction of Leuckart impurities from MBDB (8) from 
a spiked sample of an illicitly prepared tablet. 
 
A 50mg equivalent of MBDB (8) from typical tablet, A6765, 
was spiked with approximately 2% each of compounds 17, 
20 and 21. The tablet was extracted as outlined in Section 
(5.12.1). The resultant HPLC chromatogram for this 
experiment is shown below (Figure 6.11.1). As can be seen, 
compounds 20 and 21 were well extracted but the recovery 
of compound 17 was poor. The SIM GC-MS trace of the 
sample is also shown (Figure 6.11.2). Compounds 20 and 21 
are clearly extracted, however compound 17, N-formyl BDB, 
is not extracted with the same efficiency as the other two 
compounds.  So the limitation of the method was that it was 
not effective at extracting N-formyl BDB (17). 
 
 
Figure 6.11.1 HPLC trace (289nm) for spiked sample A6765s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 6.11.2 SIM GC-MS trace of ions 176mu, 228mu and 229mu for spiked sample A6765. 
Although it had been previously established that the pH 4 liquid –liquid extraction method was the best 
of the methods investigated (see Section 6.8) the actual recovery was not calculated.  The recovery was 
assessed by comparing the peak areas returned for GC-MS and HPLC-DAD for the standard peaks 
fund in the spiked tablet after extraction to the peak areas of the impurity recovery solution analysed in 
section 5.13. The impurity recovery solution was prepared such that, if the impurities in the spiked 
tablet were exhaustively extracted then the solution to the following equation should be 100%; 
 
 
Table 16.11.1 shows the respective peak area values observed for the tablet extract solution and the 
impurity recovery solution as well as the solutions to the above equation for the respective method 
(HPLC-DAD and GC-MS). 
 
Compound Number Impurity Recovery Solution 
Peak Area (Arb. Units) 
Spiked Tablet Extract Solution 
Peak Area (Arb. Units) 
Recovery 
17 (HPLC-DAD) 908 197836 0.4% 
17 (GC-MS) 7532 1425941 0.5% 
20 (HPLC-DAD) 143489 213488 67% 
20 (GC-MS) 825169 1304528 63% 
21 (HPLC-DAD) 183255 200561 91% 
21 (GC-MS) 1378970 1565740 88% 
 
Table 16.11.1: Respective peak area values observed for the tablet extract solution and the impurity recovery solution as well as 
the solutions to the above equation for the respective method (HPLC-DAD and GC-MS). 
 
As already mentioned the recovery of the N-formyl BDB was very poor, the recovery of pyrimidines 
was much better (see Table 6.11.1). The recovery of compound 21 was particularly good. There was 
little difference between the recovery estimates between the two method of analysis (GC-MS and 
HPLC-DAD (see Table 6.11.1).  
 
Section 6.12: Attempted extraction of Leuckart impurities from MBDB (8) from 
illicitly manufactured MBDB (8) tablets. 
 
All of the tablets were extracted as described in section 5.12 and from the chromatograms, none were 
found to contain any of compounds 17, 20 or 21, which would infer that the MBDB (8) was not 
synthesised via the route investigated. Samples, #6840, #8A and 7A did however appear to contain 
compound 18, N-formyl MBDB, eluting at circa 10.2 minutes, on the GC-MS evidence, at a low level. 
N-formyl MDA and N-formyl MDMA have been detected in samples of MDA (4) and MDMA  (5) as 
specific intermediate products of the Leuckart synthesis (Verweij, 1992c). It follows therefore that 
detection of N-formyl BDB (17) and N-formyl MBDB (18) in a sample of MBDB (8) would be also be 
proof that the Leuckart synthesis was involved. A variation of the Leuckart route that could be 
exploited in the synthesis of MBDB (8) is via the N-formyl MBDB (18) (see Scheme 6.12.1, below).  
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Scheme 6.12.1: Leuckart routes from PEK (16) to MBDB (8). 
 It is noteworthy that this latter route does not yield pyridine or pyrimidine impurities (Keating 1999). 
The results would appear to indicate that none of the tablets were prepared via the Leuckart route of 
synthesis investigated here, inferring that they were likely to be synthesised via another route. However 
the presence of what may be N-formyl MBDB (18) (see section 6.13) could indicate that the tablets 
may have been prepared by the Leuckart route, via the N-formyl MBDB (18) intermediate. 
Alternatively, the MBDB (8) may have been synthesised via the other Leuckart route where N-methyl 
formamide is present as an impurity in the formamide used as a reagent (intermediate via compound 
17, scheme 6.12.1). It is likely that this is where compound 18 arose from in the MBDB (8) prepared in 
the School of Pharmacy (see section 6.6 and 6.7). The spiking experiment rules out the possibility that 
this compound is formed during sample preparation and/or GC-MS analysis. The N-formyl MBDB 
(18) was not present in spiked street tablet sample (#A6765s) which had been spiked with compounds 
17, 20 and 21. If compound 17 were the source of compound 18 one would have expected it to arise 
during this experiment, but this was not the case.  
 
Section 6.13 Derivatisation of N-formyl BDB (18) in an attempt to identify peak 
eluting at 10.2 minutes in GC-MS trace of samples.  
 
The compound eluting at circa 10.3 minutes was positively 
identified as N-formyl MBDB (18). A sample of N-formyl 
(17), which had been prepared in the Department of 
Pharmaceutical Chemistry, was derivatised to form the N-
formyl MBDB (18). The GC-MS trace for the Methelut-
derivatised N-formyl BDB (17) is shown below (Figure 
6.13.1) and the corresponding mass spectrum for the peak is 
also shown (Figure 6.13.2). This mass spectrum is identical 
to the mass spectrum of the unknown compound found to be 
eluting at 10.2 minutes in section 6.6.4. 
 
 
 
 
 
 
 
 
 
 
Figure 6.13.1: GC-MS trace for N-methylated derivative of N-formyl BDB (17). 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 6.13.2 Mass spectrum for compound eluting at 10.2 minutes from GC-MS system employed in section 5.14. 
 
A dilution of the solution containing the reagents, starting material and reaction products was injected 
into the HPLC system outlined in section 2.2, system 12. Figure 6.13.3 shows the chromatogram 
obtained. The peak eluting at 5.3 minutes was compound 17, hence the peak eluting at 6.1 minutes 
must be that of the N-formyl MBDB (18).  
 
Figure 6.13.3: HPLC trace (289nm) of derivatised N-formyl BDB (17). 
 
On the basis of this HPLC data, the large peak eluting at 
circa 6.1 minutes in the HPLC chromatograms of the C8 
and C18 extracts in section 6.6.4 is most likely N-formyl 
MBDB (18). The spectrum of the standard N-formyl MBDB 
(18) was compared to the spectra of the large peaks in 
Figures 6.6.4.1 and 6.6.4.2 and it was discovered that the 
spectra of the standard and sample were a good match 
(>0.90). It is noteworthy that the GC-MS procedure is 
preferred as the unequivocal identification of N-formyl 
MBDB (18) was achieved. 
 
Section 6.14:Conclusion 
 
HPLC-DAD and GC-MS procedures were established for 
the identification of Leuckart route specific impurities. An 
extraction protocol was then established and applied to a 
series of samples. The results indicated that it was likely that 
four of the tablets analysed were synthesised via the 
Leuckart route as the intermediate N-formyl MBDB (18) 
was detected. This compound was also detected in the 
MBDB (8) synthesised in the School of Pharmacy, which had 
been used synthesised via the Leuckart Route and may have 
arisen due to impure starting materials via the reaction 
used. 
 
 
 
 

Section 7: Introduction  
 
As mentioned before there are many routes available for the synthesis of phenylalkylamine (ecstasy) 
type compounds. The main routes used in the synthesis of MDA (4), MDMA (5), MDEA (6), MBDB 
(8) and 4-MTA (9) are outlined below. 
 
Section 7.1: Synthesis of Propanamines, MDA (4), MDMA (5) and MDEA (6).  
 
The synthesis of MDA (4), MDMA (5) and MDEA (6) among others has been excellently reviewed by 
Dal Cason et al.  (1990). The most important aspects of that particular paper with respect to the work 
presented here are outlined below. 
 
Synthesis of PMK 
 
Two of the main starting materials for the synthesis of MDA (4) are Piperonal (11) and 
Piperonalmethylketone (PMK, 33).  PMK can be prepared by converting Isosafrole (34) into Isosafrole 
glycol (32) and then by oxidising the alcohols to form the ketone (See scheme 7.1). Alternatively it can 
be synthesised via the nitropropene route (see below). Isosafrole (34) can be synthesised from safrole 
(40), which can be acquired from Sassafras oil by distillation (French, 1995). 
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Scheme 7.1: Reaction scheme for the synthesis of PMK (33) from Isosafrole (34). 
 
 Nitropropene Route 
This method involves the condensation reaction between piperonal (11) and nitroethane to form the 
intermediate piperonyl nitropropene (35), which can be treated with LiAlH4 or H2/Pd to form MDA (4), 
(Scheme 7.2). The nitropropene can be used to synthesise PMK (33) using Iron as a catalyst. Then 
using any one of a variety of reactions, which are discussed below, the appropriate 
methylenedioxyphenyl ring-substituted amphetamine can be manufactured.  
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Scheme 7.2:Reaction scheme for the synthesis of PMK (33) and MDA (4) via the nitropropene route (35). 
 
The Leuckart-Wallach Reaction  
Using PMK (33) as the starting material this reaction involves the reaction between PMK (33) and two 
molecules of formamide to produce the N-formyl derivative (36) of the amine, which can then be 
hydrolysed with HCl to produce MDA (4) or methylated with LiAlH4. MDMA (5) can also be 
synthesised by taking MDA (4) and treating it with formic acid to form the N-formyl derivative (36) 
and treating then with LiAlH4 as before. Alternatively N-methyl formamide can be used to form the N-
methyl, N-formyl derivative (37), this can then be reduced using HCl to form MDMA (5). (see Scheme 
7.3). MDEA (6) can also be synthesised in this manner by treating MDA (4) with acetic anhydride to 
form the N-acetyl derivative of MDA (38). This N-acetyl intermediate (38) is then treated with LiAlH4 
to form MDEA (6) (Scheme 7.3a) 
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Scheme 7.3:Reaction scheme of the synthesis of MDA (4) and MDMA (5) via the Leuckart route. 
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Scheme 7.3a:Reaction scheme for the synthesis of MDEA (6) via the Leuckart route. 
 
Reductive Amination 
Reductive amination involves the reaction between PMK (33) and methylamine at reduced pressure 
and slightly elevated temperatures (ca. 80°C). The ketone (33) reacts with the amine to form the 
intermediate imine as the intermediate product, which is then subsequently reduced to the 
corresponding amine. MDMA (5) can also be manufactured in this way using methylamine and either 
NaCNBH3 or AlHgCl2. MDEA (6) can also be synthesised by this particular route. MDEA (6) can also 
be synthesised in this way but instead of using methylamine as is the case with MDMA (5) one would 
use ethylamine. (See Scheme 7.4). 
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Scheme 7.4:Synthesis of MDA (4), MDMA (5) and MDEA (6) via the reductive amination route. 
 
 
The Oxime route 
This reaction involves the formation of the oxime from the reaction between PMK (33) and a 
hydroxylamine molecule, which yields MDA (4) on hydrogenation with LiAlH4 (see scheme 7.5). 
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Scheme 7.5:Reaction scheme for the synthesis of MDA (4) via the oxime route. 
 
Bromopropane Route 
MDMA (5) can be synthesised directly from safrole via the bromopropane route (Merck, 1914). This 
involves the bromination of safrole (40) using HBr. The methylenedioxyphenyl-2-bromopropane 
intermediate can then be treated with methylamine to form MDMA (5) (see Scheme 7.6). 
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Scheme 7.6:Reaction scheme for the synthesis of MDA (4) via the bromopropane route. 
 
Alkylation using Alkyl Iodides 
MDMA (5)  (Braun, 1980) or MDEA (6) can be formed by reacting MDA (4) with methyl or ethyl 
iodide reagent (see scheme 7.7). 
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Scheme 7.7:Reaction scheme for the synthesis of MDEA (6) and MDMA (5) from MDA (4) via Alkylation 
 
 
Section 7.2: Synthesis of Butanamines, BDB (7) & MBDB (8). 
 
There is very little information available on the synthesis of MBDB (8) in the literature, however the 
EMCDDA report on the risk assessment of MBDB (8) (EMCDDA, 1999) suggests that reductive 
amination and nitropropene routes of synthesis may be popular in clandestine laboratories. However it 
is important to note that BDB (7) and MBDB (8) differ from MDA (4) and MDMA (5) by only one 
extra carbon atom on the alkyl side chains respectively, while the amine function remains at the two 
position in all cases. Hence it follows that the reactions for the synthesis of MDA (4) and MDMA (5) 
would directly apply to the synthesis of BDB (7) and MBDB (8). Butane type precursors are therefore 
required for BDB (7) and MBDB (8) instead of the propane type precursors needed for MDA (4) and 
MDMA (5). The possible reactions for the synthesis of BDB (7) and MBDB (8) are outlined below. 
Synthesis of PEK (16) 
As with MDA (4) and MDMA (5) one of the main starting precursors for BDB (7) and MBDB (8) the 
ketone possessing an extra carbon in the side-chain. This is called piperonyl ethyl ketone or PEK (16). 
This can be synthesised in much the same way as PMK (33) starting with piperonal. The nitrobutene 
derivative can also be formed from piperonal (11) which again under Iron catalytic conditions can be 
converted to PEK (16) (see scheme 7.8). 
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Scheme 7.8:Reaction scheme for the preparation of PEK (16). 
 
Once PEK (16) is prepared one can easily synthesise MBDB (8) via the Leuckart or Reductive 
Amination routes (see below). 
 
Nitrobutene Route to MBDB (8) 
 
Using nitropropane and piperonal one can synthesise the nitrobutene derivative (15), which under 
reducing conditions forms the methylenedioxyphenyl-2-butylamine or (BDB) (7) which can be 
alkylated using methyl Iodide (see scheme 7.9). 
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Scheme 7.9:Reaction scheme for the synthesis of MBDB (8) from Nitrobutene followed by Alkylation. 
 
Reductive Amination to MBDB (8) 
 
This is straightforward as with the propanamines where methylamine and NaCNBH3 or AlHgCl2 are 
used to aminate PEK (16), forming BDB (7) or MBDB (8). 
 
Leuckart-Wallach Reaction to MBDB (8) 
 
Using BDB (7) from the nitrobutene route or PEK (16) one can form the N-formyl derivative (17) and 
then reduce to MBDB (8) with LiAlH4. One can also form the N-methyl, N-formyl-derivative (18) and 
then use a less aggressive reducing reagent (HCl) to form MBDB  (8) (see scheme 7.10). 
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Scheme 7.10:Reaction scheme for the synthesis of MBDB (8) via the Leuckart-Wallach Route 
The Oxime route 
This reaction involves the formation of the oxime (43) from the reaction between the PEK (16) and a 
hydroxylamine molecule, which yields BDB (7) on hydrogenation with LiAlH4 (see scheme 7.11). 
BDB (7) can be converted to MBDB  (8) via alkylation with CH3I. 
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Scheme 7.11:Oxime Route 
 
Section 7.3: Synthesis of 4-MTA (9). 
 
As with the butanamines there is very little information available on the reactions that could be used in 
the synthesis of 4-MTA (9). The nitropropene route is the only route discussed in the literature 
(Holland, 1963; Poortman, 1998 & 1999), however 4-MTA (9) could be made by any of the reactions 
used to synthesise MDA (4). The only difference this time is that the precursors used will not be 3,4-
methylenedioxylated, but instead will be methylthioylated at the 4 position of the benzene ring. 
 
Synthesis of 4-Methylthiophenylpropan-2-one 
 
One of the main starting materials for the synthesis of 4-MTA (9) would be 4-methylthiophenylpropan-
2-one (MPP) (44).  MPP (44) can be prepared by converting 4-methylthiophenylacetic acid (45) to the 
ketone (44) (See scheme 7.12). MPP (44) can also be synthesised via the nitropropene route starting 
with 4-methylthiobenzaldehyde (46) via a 4-methylthiophenylnitrpropene (47) intermediate (see 
Scheme 7.12). 
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Scheme 7.12: Reaction scheme for the synthesis of MPP (44) from 4-methylthiophenylacetic acid (45) and also via the 
nitropropene route 
 
 
 
 Nitropropene Route 
The nitropropene intermediate (47) mentioned above can be reduced directly to form 4-MTA (9) (see 
Scheme 7.13).  
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Scheme 7.13: Reaction scheme for the synthesis of 4-MTA (9) via the Nitropropene route. 
 
The Leuckart-Wallach Reaction  
This involves the reaction between MPP  (44) and two molecules of formamide to produce the N-
formyl 4-MTA (48), which can then be hydrolysed with HCl to produce 4-MTA (9) (see Scheme 7.14).  
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 Scheme 7.14:Reaction scheme for the synthesis of 4-MTA (9) via the Leuckart-Wallach route 
 
Reductive Amination 
This involves the reaction between MPP (44) and NaCNBH3 and ammonium acetate (see Scheme 
7.15), to form 4-MTA (9) in one step. 
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Scheme 7.15:Reaction scheme for the synthesis of 4-MTA (9) via the reductive amination route 
 
The Oxime route 
This reaction involves the formation of the oxime from the reaction between the MPP (44) and a 
hydroxylamine molecule forming an oxime intermediate (49), which yields 4-MTA (9) on 
hydrogenation with LiAlH4 (see scheme 7.16). 
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Scheme 7.16: Reaction scheme for the synthesis of 4-MTA via the oxime route 
 
7.4: Objectives 
Chapter II showed the benefits of using mass spectrometry as a means of determining the route of 
synthesis. Identification of the route was simplified by using standard reference material isolated from 
MBDB (8) derived from the Leuckart reaction. If a mass spectral library of compounds known to be 
route specific impurities or intermediates were established for MDA (4), MDEA (5), MDMA (6) 
MBDB (8) and 4-MTA (9) it may be possible to use it to identify the routes of synthesis of these 
compounds in a forensic setting.  The reactions outlined above have been studied in the Department of 
Pharmaceutical Chemistry, School of Pharmacy, Trinity College Dublin. Stable impurities, 
intermediates and products (e.g. MDA (4), MDMA (5) etc.), were isolated in the Dept. of 
Pharmaceutical Chemistry. These compounds were made available to the Dept. of Pharmacognosy for 
the purpose of establishing a mass spectral library that could be used in the determination of the type of 
reactions used to synthesise ecstasy-type drugs. 
Section 8.1: Instrumentation & Solvents 
 
GC-MS 
The GC-MS system consisted of a Hewlett Packard 5973 MSD coupled to a 6890 GC system. Samples 
were introduced into the system with the aid of  6890 Injector Autosampler. A Hewlett Packard HP-
5MS column (30m x 0.25mm x 0.25µm film thickness) was used throughout the experiments detailed 
below. 
 
Miscellaneous Instruments 
A fisons bench-top whirlimixer was used to agitate samples. 
 
Solvents 
All solvents used were HPLC grade unless otherwise stated. 
 
Section 8.2: GC-MS analysis of standard impurities, intermediates and products 
derived from the synthesis of Ecstasy.   
 
Origin of impurities, intermediates & products. 
All of the compounds chosen for inclusion in the mass spectral database were either synthesised or 
isolated from intermediates or products by JJ Keating, in the Department of Pharmaceutical Chemistry 
at the School of Pharmacy, Trinity College Dublin. The exact structures were elucidated with the aid of 
H1 and C13 NMR. The details of synthesis, isolation and structural elucidation can be found in the 
Ph.D. Thesis of JJ Keating (2001). 
 
Preparation of analytical solutions of impurities, intermediates and products. 
All solutions were prepared by dissolving approximately 0.01mg, of material to analysed, in 100µl of 
acetonitrile. The solutions were vortex mixed in a small vials before injection into the chromatographic 
system. 
 
Reference solution 1: Piperonal (11) 
Reference solution 2: Isosafrole (34) 
Reference solution 3: 3,4-MDP-butane-1,2-diol (14) 
Reference solution 4: Piperonyl methyl ketone (33)  
Reference solution 5: N-formyl MDA (36) 
Reference solution 6: 1-(3,4-MDP)-2-nitro-1-propene (35) 
Reference solution 7: 1-(3,4-methylenedioxyphenyl)-propan-2-oxime (39)  
Reference solution 8: 2-methyl-3-(3,4-MDP)-aziridine (50) 
Reference solution 9: MDA (4) 
Reference solution 10: 2-(3,4-methylenedioxybenzyl)-aziridine (51) 
Reference solution 11: 4-methyl-5-(3,4-MDP)-pyrimidine (52)  
Reference solution 12: 4-(3,4-Mdbenzyl)-pyrimidine (53) 
Reference solution 13: 2,6-dimethyl-3,5-di(3,4-MDP)-pyridine (23) 
Reference solution 14: 2,4-dimethyl-3,5-di(3,4-MDP)-pyridine (54) 
Reference solution 15: 6-methyl-5-(3,4-MDP)-2-(3,4-MDbenzyl)-pyridine (55)  
Reference solution 16: 2,4-dimethyl-3-(3,4-MDP)-6-(3,4-Mdbenzyl)-pyridine (56)  
Reference solution 17: 4-methyl-5-(3,4-MDP)-2-(3,4-Mdbenzyl)-pyridine (57) 
Reference solution 18: Safrole (40) 
Reference solution 19: 3,4-MDP-butane-1,2-diol (14)  
Reference solution 20: 3,4-MDP-2-bromopropane (41)  
Reference solution 21: N-formyl, N-methyl MDA (37) 
Reference solution 22: MDMA (5) 
Reference solution 23: N-acetyl MDA (38) 
Reference solution 24: MDEA (6) 
Reference solution 25: 3,4-MDP-(2-nitro-but-1-ene) (15) 
Reference solution 26: Piperonyl ethyl ketone (16) 
Reference solution 27: 3,4-methylenedioxyphenyl-(butan-2-one oxime) (43) 
Reference solution 28: N-formyl BDB (17) 
Reference solution 29: N-formyl, N-methyl BDB (18)  
Reference solution 30: 4-ethyl-5-(3,4-MDP)-pyrimidine (20)  
Reference solution 31: 2,6-diethyl-3,5-di-(3,4-MDP)-pyridine (22)  
Reference solution 32: 5-methyl-4-(3,4-MDbenzyl)-pyrimidine (21) 
Reference solution 33: 2,6-dimethyl-3,5-di-(3,4-MDP)-pyridine (23) 
Reference solution 34: 4-ethyl-3-methyl-2-(3,4-Mdbenzyl))-5-(3,4-MDP)-pyridine (24) 
Reference solution 35: 2-ethyl-5-methyl-3-(3,4-MDP)-6-(3,4-Mdbenzyl)-pyridine (25) 
Reference solution 36: 2,4-diethyl-3,4-di-(3,4-MDP)-pyridine (26) 
Reference solution 37: 3,4-MDP-3-ethyl aziridine (58)  
Reference solution 38: BDB (7) 
Reference solution 39: MBDB (8) 
Reference solution 40: 4-methylthio-benzaldehyde (46) 
Reference solution 41: 1-methylthio-4-(2-nitro-propenyl)-benzene (47) 
Reference solution 42: 1-(4-methylthio-phenyl)-propan-2-one (44)  
Reference solution 43 N-formyl 4-MTA (48) 
Reference solution 44 1-(4-methylthio-phenyl)-propan-2-oxime (49) 
Reference solution 45 2-ethyl-3-(4-methylthio-phenyl)-aziridine (59) 
Reference solution 46 4-(4-methylthio-benzyl)-5-(4-methylthio-phenyl)-pyrimdine (60)  
Reference solution 47 2-(4-methylthio-benzyl)-3-(3-methylthio-phenyl)-aziridine (61) 
Reference solution 48 4-methyl-5-(4-methylthio-phenyl)-pyrimidine (62) 
Reference solution 49: 4-(4-methylthio-benzyl)-pyrimidine (63) 
Reference solution 50: 2,6-dimethyl-3,5-bis-(4-methylthio-phenyl)-pyridine (64)  
Reference solution 51: 2,4-dimethyl-3,5-bis-(4-methylthio-phenyl)-pyridine (65) 
Reference solution 52: 2-methyl-6-(4-methylthiobenzyl)-3-(4-methylthio-phenyl)-pyridine (66)  
Reference solution 53: 2,4-dimethyl-6-(4-methylthio-benzyl)-3-(4-methylthio-phenyl)-pyridine (67)  
Reference solution 54: 4-methyl-2-(4-methylthio-benzyl)-5-(4-methylthio-phenyl)-pyridine (68) 
Reference solution 55: 1-methyl-4-methyl thio-benzene (69) 
Reference solution 56: N,N-bis-[1-methyl-2-(4-methylthio-phenyl)-ethyl]-formamide (70) 
Reference solution 57: 4-MTA (9) 
Reference solution 58: 3,4-MDP-propane-1,2-diol (71) 
 
Chromatographic Conditions 
The GC-MS conditions used in the analysis are outlined in Table 8.2.1 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column HP-5MS  
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.25 µm  
Transfer Line Temperature 280°C 
Ionisation Mode Electron Ionisation 
Injection Mode Splitless 
Initial Temperature (Hold Time) 90°C (1 minute) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 280°C (6 minutes) 
Total Run Time 19.7 minutes 
Detected  Mass Range  40 – 600 m/z 
 
Table 8.2.1: Chromatographic conditions used for the analysis of impurities, intermediates and products derived from the 
synthesis of ecstasy.  
 
Analysis 
Each of the reference solution extracts were chromatographed (in duplicate) using the above 
chromatographic system. The results of this section are discussed in section 9. 
 
 
 
 
8.3: Construction of Mass Spectral Library. 
 
The Hewlett-Packard Chemstation  software (Hewlett Packard, 1986-1996) that controlled the mass 
spectral detector allowed for the construction of mass spectral libraries. Compounds were entered into 
the custom spectral library from chromatographic data generated in section 8.1. Library creation using 
Chemstation is fully explained in the software help tool. The help tool in the HP software was used in 
order to create and modify the library entitled Mslib.l. An electronic copy of this library, called Mslib.l, 
can be found on the supplementary disk at the back of this thesis (see Appendix II). This electronic 
copy requires Chemstation software or some other compatible software in order to function. The results 
of this section are shown in section 9.1. 
 
Section 8.4: GC-MS analysis of ecstasy of licit origin 
 
Origin of Ecstasy  
Samples of MDMA (5), MDA (4), 4-MTA (9), BDB (7) and MDEA (6) were prepared in the 
Department of Pharmaceutical Chemistry by JJ Keating. The route used in the synthesis of each is 
shown in Table 8.4.1. 
Compound Route of Synthesis 
MDMA.HCl Leuckart Route 
4-MTA.HCl Reductive Amination Route 
BDB.HCl Oxime Route 
MDEA.HCl Reductive Amination Route 
MDA .HCl Leuckart Route 
MDA.HCl Oxime Route 
MDA (crude reaction product) Oxime route 
 
Table 8.4.1: Licitly produced ecstasy analysed by GC-MS. 
 
Preparation of ecstasy prior to GC-MS analysis 
An aliquot of the powder  (10mg) was added to water (5ml) that had been made alkaline by the 
addition of conc. ammonia (0.5 ml). This solution was extracted with 5ml of petroleum ether. The ether 
layer was transferred to a clean dry test tube, where it was evaporated under a stream of nitrogen at 
40°C. The residue was reconstituted in 10ml of acetonitrile. The resulting solution was injected into the 
chromatographic system.  
 
Chromatographic Conditions 
The GC-MS conditions used in the analysis are outlined in Table 8.4.2. 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column HP-5MS  
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.25 µm  
Transfer Line Temperature 280°C 
Ionisation Mode Electron Ionisation 
Injected Volume 1µl 
Injection Mode Splitless 
Initial Temperature (Hold Time) 90°C (1 minute) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 280°C (6 minutes) 
Total Run Time 19.7 minutes 
Detected  Mass Range  40 – 600 m/z 
 
Table 8.4.2: Chromatographic conditions used for the analysis of licitly produced ecstasy.  
Analysis 
Each of the extracts were chromatographed (in duplicate) using the above chromatographic system. 
The results of this section are discussed in section 9.2. 
 
 
 
 
 
Section 8.5: GC-MS analysis of ecstasy of illicit origin 
 
Origin of Ecstasy  
Samples of ecstasy tablets were supplied by the Garda National Drugs unit. Physical descriptions of the 
tablets are included below in Table 8.5.1. 
Tablet 
Number 
Appearance No. in Batch Average 
Weight 
1 Yellow, Round, Bi-convex 6 0.2532g 
2 White, Round, Bi-convex 6 0.2974g 
3 White, Round, Flat, Half scored on one 
side, other side bearing bird logo 
6 0.3321g 
4 White, Round, Flat, Half scored on one 
side, other side bearing bird logo 
6 0.2987g 
5 Salmon, Round, Bi-convex, Half-scored 
on one side, other side bearing a 
Mitsubishi logo.  
100 0.3050g 
 
Table 8.5.1: Illicitly produced tablets analysed by GC-MS. 
 Preparation of Tablets prior to GC-MS analysis 
Tablet were powdered and homogenised in a mortar and pestle. An aliquot of the powder  (30mg) was 
added to water (5ml) that had been made alkaline by the addition of conc. ammonia (0.5 ml). This 
solution was extracted with 5ml of petroleum ether. The ether layer was transferred to a clean dry test 
tube, where it was evaporated under a stream of nitrogen at 40°C. The residue was reconstituted in 3ml 
of acetonitrile. A portion (1µl) resulting solution was injected into the chromatographic system.  
 
 
 
 
 
 
 
 
Chromatographic Conditions 
The GC-MS conditions used in the analysis are outlined in Table 8.5.2. 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column HP-5MS  
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.25 µm  
Transfer Line Temperature 280°C 
Ionisation Mode Electron Ionisation 
Injected Volume 1µl 
Injection Mode Splitless 
Initial Temperature (Hold Time) 90°C (1 minute) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 280°C (6 minutes) 
Total Run Time 19.7 minutes 
Detected  Mass Range  40 – 600 m/z 
 
Table 8.5.2: Chromatographic conditions used for the analysis of illicitly produced ecstasy tablets.  
 
Analysis 
Each of the extracts were chromatographed (in duplicate) using the above chromatographic system. 
The results of this section are discussed in section 9.3. 
 
Section 9.1: GC-MS analysis of standard impurities, 
intermediates and products derived from the synthesis of 
Ecstasy.   
 
The reactions outlined in the introduction were studied in the Department of Pharmaceutical 
Chemistry, School of Pharmacy, Trinity College Dublin for synthesis of MDA (4), MDMA (5), MDEA 
(6), MBDB (8) and 4-MTA (9). Stable impurities and intermediates and products, which were isolated 
in the Dept. Pharmaceutical Chemistry, were made available to the Department of Pharmacognosy for 
the purpose of establishing a mass spectral library. 
 
By analysing selected compounds by GC-MS a sample mass spectrum from the chromatogram could 
be stored in a specially constructed library. This library could then be used when trying to identify 
compounds in illicitly prepared ecstasy tablets or reaction mixtures from clandestine labs etc. The type 
of information that it was hoped would be gleaned would be the identification of the route of synthesis 
by the identification of certain route specific impurities/intermediates. This kind of information would 
be of use to law enforcement authorities.  
 
The idea of establishing a mass spectral database is not a new one in the case of the propanamines 
(especially MDA (4) and MDMA (5)) (Bohn, 1993; Verweij, 1992a). However there has been no 
attempt made to establish such a library in the case of MDEA (6), MBDB (8) and 4-MTA (9). 
 
The structure and name for the impurities and/or intermediates included in the library for MDA (4), 
MDMA (5), MDEA (6), MBDB (8) and 4-MTA (9) are shown in Tables 9.1.1, 9.1.2, 9.1.3, 9.4 and 
9.1.5 respectively. The route from which the impurity/intermediate was obtained from and whether that 
impurity is route specific or not is also indicated in the following tables. 
 
 
 
  
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
Piperonal [5.85 
minutes], (11) 
O
O
CHO
 
Precursor for Piperonal 
methyl ketone (PMK) (33) 
and for 1-(3,4-MDP)-2-
nitro-1-propene (35). 
149 (100), 150 (95), 
63 (35), 121 (32), 65 
(21), 91 (12). 
Isosafrole [6.27 
minutes], (34) 
O
O  
Precursor for PMK (33). 162 (100), 104 (44), 
103 (41), 131 (40), 
77 (31), 51 (24). 
3,4-MDP-propane-
2,3-diol [7.12 
minutes], (71) 
O
O
OH
OH
 
Intermediate between 
Isosafrole (34) and PMK 
(33). 
65 (42), 93 (74), 123 
(21), 151 (100), 196 
(24). 
Piperonyl methyl 
ketone [7.08 
minutes], (33) 
O
O
O  
Intermediate between 1-
(3,4-MDP)-2-nitro-1-
propene (35) and MDA (4) 
(nitropropene route). 
Precursor to N-formyl 
MDA (36) (Leuckart 
route). Starting material for 
MDA (4) via one step 
reductive amination route. 
Precursor to oxime route.  
135 (100), 77 (27), 
178 (25), 51 (21). 
N-formyl MDA 
[10.34 minutes], 
(36) 
HN
O
O CHO  
Leuckart route specific 
intermediate between PMK 
(33) and MDA (4). 
162 (100), 135 (75), 
77 (40), 72 (40). 207 
(12). 
1-(3,4-MDP)-2-
nitro-1-propene 
[9.91 minutes], (35) 
NO2
O
O  
Intermediate between 
piperonal and MDA (4). 
Also precursor to PMK 
(33). 
103 (100), 77 (62), 
160 (73), 175 (15), 
207 (7), 149 (17), 63 
(28), 150 (18), 131 
(16) 
1-(3,4-
methylen
edioxyph
enyl)-
propan-2- 
oxime 
[8.60 
minutes], 
(39) 
O
O
N
OH 
Oxime route specific 
intermediate between PMK 
(33) and MDA (4). 
42 (34), 51 (44), 77 
(45), 105 (16), 118 
(115), 135 (100), 136 
(43), 146 (23), 160 
(30), 177 (19), 193 
(49). 
2-methyl-3-(3,4-
MDP)-aziridine 
[7.65 minutes], (50) 
O
O
N
H  
Oxime route specific 
impurity. 
42 (84), 51 (30), 77 
(31), 78 (37), 106 
(32), 135 (92), 136 
(100), 177 (49). 
MDA [7.11 
minutes], (4) 
O
O
NH2
 
Product amine sold as 
ecstasy. Can easily be 
converted to MDMA (5). 
44 (100), 77 (8), 135 
(8), 136 (19). 
 
Table 9.1.1: Names, structures, synthetic route information and mass spectral data for selected 
intermediates, impurities and product for the synthesis of MDA (4) (continued overleaf). 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
2-(3,4-
methylenedioxybe
nzyl)-aziridine 
[8.14 minutes], (51) 
O
O
N
H  
Oxime route specific 
impurity. 
51 (14), 7 (16), 89 
(12), 121 (14), 135 
(100), 147 (28), 148 
(22), 177 (50). 
4-methyl-5-(3,4-
MDP)-pyrimidine 
[10.09 minutes], 
(52) 
O
O
N
N
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
51 (24), 77 (30), 135 
(6), 155 (31), 156 
(19), 185 (10), 213 
(59), 214 (100), 215 
(26). 
4-(3,4-Mdbenzyl)-
pyrimidine [9.86 
minutes], (53) 
N
N
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
62 (16), 76 (10), 88 
(13), 102 (14), 145 
(12), 146 (13), 155 
(21), 156 (13), 183 
(7), 213 (50), 214 
(100), 215 (25). 
2,6-dimethyl-3,5-
di(3,4-MDP)-
pyridine [18.24 
minutes], (23) 
O
O
N
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
288 (11), 346 (27), 
347 (100), 348 (26). 
2,4-dimethyl-3,5-
di(3,4-MDP)- 
pyridine [18.72 
minutes], (54) 
O
O
N
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
288 (10), 346 (14), 
347 (100), 348 (26). 
6-methyl-5-(3,4-
MDP)-2-(3,4-
MDbenzyl)-
pyridine [17.94 
minutes], (55) 
O
O
N O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
77 (13), 135 (10), 15 
(8), 288 (10), 318 
(13), 346 (52), 347 
(100), 348 (24). 
2,4-dimethyl-3-
(3,4-MDP)-6-(3,4-
Mdbenzyl)-
pyridine [18.03 
minutes], (56) 
O
O
N O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
77 (11), 135 (8), 165 
(36), 302 (9), 332 
(15), 346 (19), 347 
(11), 360 (65), 361 
(100), 362 (27). 
 
4-methyl-5-(3,4-
MDP)-2-(3,4-
Mdbenzyl)-
pyridine [19.04 
minutes], (57) 
O
O
N O
O
 
Leuckart route specific 
impurity derived from 
reaction between PMK 
(33) and N-formyl MDA 
(36). 
77 (13), 158 (158), 
288 (17), 318 (10), 
346 (13), 347 (100), 
348 (23). 
 
 
Table 9.1.1 (continued): Names, structures, synthetic route information and mass spectral data for 
selected intermediates, impurities and product for the synthesis of MDA (4). 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
Piperonal [5.85 
minutes], (11) 
O
O
CHO
 
Precursor for Piperonal 
methyl ketone (PMK)  (33) 
and for 1-(3,4-MDP)-2-
nitro-1-propene (35) 
149 (100), 150 (95), 
63 (35), 121 (32), 65 
(21), 91 (12). 
 
 
Safrole [5.42 
minutes], (40) 
O
O  
Precurser for 3,4-
methylenedioxy-bromo-2-
propane (41). 
50 (15), 51 (40), 63 
(16), 77 (43), 103 
(41), 104 (54), 105 
(14), 131 (45), 132 
(16), 135 (34), 161 
(29), 162 (100), 161 
(13). 
Isosafrole [6.27 
minutes], (34) 
O
O  
Precursor for PMK (33) 162 (100), 104 (44), 
103 (41), 131 (40), 
77 (31), 51 (24). 
1-(3,4-MDP)-2-
nitro-1-propene 
NO2
O
O  
Intermediate between 
piperonal (11) and MDA 
103 (100), 77 (62), 
160 (73), 175 (15), 
[9.91 minutes], (35) (4). Also precursor to PMK 
(33). 
207 (7), 149 (17), 63 
(28), 150 (18), 131 
(16) 
3,4-MDP-propane-
2,3-diol [7.12 
minutes], (71) 
O
O
OH
OH
 
Intermediate between 
Isosafrole (11) and PMK 
(33). 
65 (42), 93 (74), 123 
(21), 151 (100), 196 
(24). 
Piperonyl methyl 
ketone [7.08 
minutes], (33) 
O
O
O  
Intermediate between 1-
(3,4-MDP)-2-nitro-1-
propene (35) and MDA (4) 
(nitropropene route). 
Precursor to N-formyl 
MDA (36). Starting 
material for MDMA (5) 
via one step reductive 
amination route. Precursor 
to oxime route.  
135 (100), 77 (27), 
178 (25), 51 (21). 
 
 
 
 
 
 
 
3,4-MDP-2-
bromopropane 
[8.09 minutes],  
(41) 
O
O
Br
 
Intermediate between 
Safrole (40) and MDMA 
(5) in the bromopropane 
route. 
51 (16), 77 (21), 105 
(15), 135 (100), 163 
(19), 242 (19), 244 
(21) 
N-formyl MDA 
[10.34 minutes], 
(36) 
HN
O
O CHO  
Leuckart route specific 
intermediate between PMK 
(33) and MDA (4). 
162 (100), 135 (75), 
77 (40), 72 (40). 207 
(12). 
 
Table 9.1.2: Names, structures, synthetic route information and mass spectral data for selected 
intermediates, impurities and product for the synthesis of MDMA (5) (continued overleaf). 
 
Name 
[Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
1-(3,4-
methylenedioxyph
enyl)-propan-2- 
oxime [8.60 
minutes], (39) 
O
O
N
OH 
Oxime route specific 
intermediate between PMK 
(33) and MDA (4). 
42 (34), 51 (44), 77 
(45), 105 (16), 118 
(115), 135 (100), 136 
(43), 146 (23), 160 
(30), 177 (19), 193 
(49). 
2-methyl-3-(3,4-
MDP)-aziridine 
[7.65 minutes], (50) 
O
O
N
H  
Oxime route specific 
impurity. 
42 (84), 51 (30), 77 
(31), 78 (37), 106 
(32), 135 (92), 136 
(100), 177 (49). 
2-(3,4-
methylenedioxybe
nzyl)-aziridine 
[8.14 minutes], (51) 
O
O
N
H  
Oxime route specific 
impurity. 
51 (14), 7 (16), 89 
(12), 121 (14), 135 
(100), 147 (28), 148 
(22), 177 (50). 
N-formyl, N-
methyl MDA 
[10.52 minutes] 
(37) 
N
O
O CHOH3C  
Leuckart route specific 
intermediate between PMK 
(33) and MDMA (5). 
51 (33), 72 (41), 77 
(41), 105 (11), 135 
(75), 136 (20), 162 
(100), 207 (9). 
MDA [7.11 
minutes], (4) 
O
O
NH2
 
Product amine sold as 
ecstasy, which can easily 
be reduced to form 
MDMA (5). 
44 (100), 77 (8), 135 
(8), 136 (19). 
MDMA [7.53 
minutes], (5) 
O
O
HN
CH3  
Product amine sold as 
ecstasy. 
51 (5), 58 (100), 77 
(6), 135 (5). 
 
Table 9.1.2 (continued): Names, structures, synthetic route information and mass spectral data for 
selected intermediates, impurities and product for the synthesis of MDMA (5). 
 
 
 
 
 
 
 
 
 
 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
Piperonal [5.85 
minutes], (11) 
O
O
CHO
 
Precursor for Piperonal 
methyl ketone (PMK) (33) 
and for 1-(3,4-MDP)-2-
nitro-1-propene (35). 
149 (100), 150 (95), 
63 (35), 121 (32), 65 
(21), 91 (12). 
 
 
Isosafrole [6.27 
minutes], (34) 
O
O  
Precursor for PMK (33). 162 (100), 104 (44), 
103 (41), 131 (40), 
77 (31), 51 (24). 
3,4-MDP-propane-
2,3-diol [7.12 
minutes], (71) 
O
O
OH
OH
 
Intermediate between 
Isosafrole (34) and PMK 
(33). 
65 (42), 93 (74), 123 
(21), 151 (100), 196 
(24). 
1-(3,4-MDP)-2-
nitro-1-propene 
[9.91 minutes], (35) 
NO2
O
O  
Intermediate between 
piperonal (11) and PMK 
(33). 
103 (100), 77 (62), 
160 (73), 175 (15), 
207 (7), 149 (17), 63 
(28), 150 (18), 131 
(16). 
 
Piperonyl methyl 
ketone [7.08 
minutes], (33) 
O
O
O  
Intermediate between 1-
(3,4-MDP)-2-nitro-1-
propene (35) and MDA (4) 
(nitropropene route).  
135 (100), 77 (27), 
178 (25), 51 (21). 
 
 
N-acetyl MDA 
[10.10 minutes], 
(38) 
O
O
HN CH3
O  
Intermediate between 
MDA (4) and MDEA (6). 
51 (21), 77 (26), 86 
(17), 135 (33), 162 
(100), 16 (14), 221 
(6). 
MDA [7.11 
minutes], (4) 
 
O
O
NH2  
 
Intermediate between 
PMK (33) and N-acetyl 
MDA (38) 
44 (100), 77 (8), 135 
(8), 136 (19). 
MDEA [7.94 
minutes], (6) 
O
O
HN
 
Product amine sold as 
ecstasy 
51 (10), 72 (100), 77 
(13), 105 (4), 135 
(12). 
 
Table 9.1.3: Names, structures, synthetic route information and mass spectral data for selected 
intermediates, impurities and product for the synthesis of MDEA (6). 
 
 
 
 
 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
Piperonal [5.85 
minutes], (11) 
O
O
CHO
 
Precursor for Piperonal 
ethyl ketone (PMK) (16) 
149 (100), 150 (95), 
63 (35), 121 (32), 65 
and for 1-(3,4-MDP)-2-
nitro-1-butene (15) 
(21), 91 (12). 
 
 
3,4-MDP-(2-nitro-
but-1-ene) [10.21 
minutes], (15) 
O
O
NO2
 
Intermediate between 
piperonal (11) and BDB 
(7) or between piperonal 
(11) and PEK (16). 
51 (27), 63 (35), 91 
(43), 102 (32 ), 115 
(100), 116 (51), 117 
(65),145 (32), 150 
(16), 159 (25), 174 
(54), 221 (52). 
Piperonyl ethyl 
ketone [7.95 
minutes], (16) 
O
O
O
 
Precursor for N-formyl 
BDB (17) and N-formyl, 
N-methyl BDB (18) via the 
Leuckart reaction. 
Precursor for MBDB (8) 
via reductive amination 
route.  Precursor for oxime 
route to BDB (7). 
51 (21), 57 (21), 77 
(25), 105 (6), 135 
(100), 192 (22). 
3,4-methylene 
dioxyphenyl-  
(butan-2-one 
oxime) [9.66 
minutes], (43) 
O
O
N
OH  
Intermediate between PEK 
(16) and BDB (7). 
51 (36), 63 (39), 77 
(30), 91 (55), 102 
(32), 115 (100), 116 
(47), 117 (66), 135 
(17), 145 (29), 159 
(13), 174 (72), 221 
(50). 
N-formyl BDB 
[10.67 minutes], 
(17) 
O
O
HN
CHO  
Intermediate between PEK 
(16) and MBDB (8). 
58 (60), 86 (65), 135 
(62), 161 (12), 176 
(100), 221 (9). 
N-formyl, N-
methyl BDB [10.99 
minutes], (18) 
O
O
N
CHO  
Intermediate between PEK 
(16) and MBDB (8). 
72 (67), 77 (18), 88 
(11), 100 (100), 135 
(20), 176 (60), 235 
(2) 
4-ethyl-5-(3,4-
MDP)-pyrimidine 
[10.30 minutes], 
(20) 
N
N
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK (16) 
and N-formyl BDB (17). 
62 (26), 84 (17), 115 
(30), 145 (17), 169 
(35), 197 (17), 212 
(11), 227 (99), 228 
(100), 229 (27). 
2,6-diethyl-3,5-di-
(3,4-MDP)-
pyridine [18.18 
minutes], (22) 
N
O
O O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK (16) 
and N-formyl BDB (17). 
135 (8), 346 (10), 
374 (100), 375 (57). 
 
Table 9.1.3: Names, structures, synthetic route information and mass spectral data for selected 
intermediates, impurities and product for the synthesis of MBDB (8) (continued overleaf). 
Name 
[Retention 
Time, 
minutes] 
Structure Route Mass Spectral 
fragmentation 
m/z               
(% abundance) 
5-methyl-4-(3,4-
MDbenzyl)-
pyrimidine 
[10.89 minutes], 
(21) 
N
N
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK 
(16) and N-formyl BDB 
(17). 
51 (24), 77 (27), 
135 (47), 169 (28), 
227 (83), 228 
(100), 229 (21). 
2,6-dimethyl-3,5-
di-(3,4-MDP)-
pyridine [18.72 
minutes], (23) 
N O
OO
O  
Leuckart route specific 
impurity derived from 
reaction between PEK 
(16) and N-formyl BDB 
(17). 
77 (20), 135 (15), 
207 (13), 360 (11), 
374 (54), 375 
(100), 376 (27). 
4-ethyl-3-
methyl-2-(3,4-
Mdbenzyl))-5-
(3,4-MDP)-
pyridine [20.90 
minutes], (24) 
N
O
O
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK 
(16) and N-formyl BDB 
(17). 
44 (28), 73 (26), 
135 (14), 207 (38), 
253 (12), 281 (15), 
374 (100), 375 
(46). 
2-ethyl-5-
methyl-3-(3,4-
MDP)-6-(3,4-
Mdbenzyl)-
pyridine [19.78 
minutes], (25) 
N
O
O
O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK 
(16) and N-formyl BDB 
(17). 
77 (12), 135 (12), 
172 (9), 252 (15), 
316 (8), 346 (14), 
360 (15), 374 (92), 
375 (100), 376 
(32). 
2,4-diethyl-3,5-
di-(3,4-MDP)-
pyridine [18.37 
minutes], (26) 
N
O
O O
O
 
Leuckart route specific 
impurity derived from 
reaction between PEK 
(16) and N-formyl BDB 
(17). 
135 (8), 346 (10), 
374 (100), 375 
(58), 376 (13). 
3,4-MDP-3-ethyl 
aziridine  [8.30 
minutes], (58) 
O
O
N
H  
Aziridine impurity 
derived from the the 
synthesis of BDB (7) 
from 3,4-methylene 
dioxy phenyl-(butan-2- 
one oxime) (43) 
54 (27), 65 (20), 
77 (29), 91 (32), 
119 (45), 135 (47), 
149 (42), 162 (13), 
176 (100), 190 
(58), 191 (70). 
BDB [8.00 
minutes], (7) 
O
O
NH2  
BDB (7) ( product amine 
which can be easily 
converted to MBDB (8) 
58 (100), 72 (11), 
135 (12), 136 (20). 
MBDB [8.23 
minutes], (8) 
O
O
HN
 
MBDB (8) product 
amine sold as ecstasy. 
51 (19), 72 (100), 
77 (23), 135 (19). 
 
Table 9.1.3 (continued): Names, structures, synthetic route information and mass spectral data for 
selected intermediates, impurities and product for the synthesis of MBDB (8). 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z (% 
abundance) 
4-methylthio-
benzaldehyde [7.15 
minutes], (46) 
CHO
H3CS  
Precursor for the formation of 
the1-methylthio-4-(2-nitro-
propenyl)-benzene (47). 
50 (18), 51 (18), 54 
(11), 69 (16), 77 (13), 
108 (14), 109 (16), 123 
(14), 151 (88), 152 
(100), 153 (15). 
1-methylthio-4-(2-
nitro-propenyl)-
benzene [10.86 
minutes], (47) 
H3CS
NO2
 
Intermediate between 4-
methylthio-benzaldehyde (46) 
and 1-(4-methylthio-phenyl)-
propan-2-one (44). 
63  (15), 77 (15), 89 
(19), 103 (10), 115 
(100), 116 (64), 147 
(32), 162 (69), 209 
(43). 
1-(4-methylthio-
phenyl)-propan-2-
one [8.16 minutes], 
(44) 
H3CS
O
 
Precursor to 4-MTA (9) via 
reductive amination. Precursor 
for N-formyl 4-MTA  (48) 
(Leuckart route). Also precursor 
for 1-(4-methylthio-phenyl)-
propan-2-oxime (49) (Oxime 
route). 
63 (12), 78 (15), 89 
(11), 121 (25), 122 
(33), 137 (100), 180 
(24). 
N-formyl 4-MTA 
[10.64 minutes], 
(48) H3CS
HN
CHO  
Intermediate between 1-(4-
methylthio-phenyl)-propan-2-one 
(44) and 4-MTA (9). Leuckart 
route specific impurity. 
444 (56), 72 (46), 91 
(11), 122 (20), 137 
(55), 164 (100), 209 
(10). 
1-(4-methylthio-
phenyl)-propan-2-
oxime [9.57 
minutes], (49) 
H3CS
N
OH 
Intermediate between 1-(4-
methylthio-phenyl)-propan-2-one 
(44) and 4-MTA (9). Route 
specific impurity of the oxime 
route. 
63 (18), 78 (21), 89 
(21), 121 (39), 12 
2(51), 131 (37), 137 
(100), 162 (23), 195 
(46). 
2-ethyl-3-(4-
methylthio-
phenyl)-aziridine 
[9.40 minutes], (59) 
H3CS
N
H  
Route specific aziridine impurity 
derived from the oxime route 
51 (17), 63 (19), 69 
(14), 77 (23), 91 (23), 
104 (20), 109 (15), 117 
(29), 122 (12), 130 
(20), 135 (32), 136 
(39), 137 (41), 146 
(16), 150 (41), 151 
(53), 164 (8), 178 
(100), 192 (37), 193 
(52) 
 
Table 9.1.4: Names, structures, synthetic route information and mass spectral data for selected 
intermediates, impurities and product for the synthesis of 4-MTA (9) (continued overleaf). 
  
 
 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
4-(4-methylthio-
benzyl)-5-(4-
methylthio-
phenyl)-pyrimdine 
[19.19 minutes], 
(60) 
N
N
SCH3
SCH3  
Leuckart route specific 
impurity in the synthesis 
of 4-MTA (9) via N-
formyl 4-MTA (48). 
121 (13), 122 (19), 
137 (32), 244 (9), 
290 (14), 323 (13), 
337 (55), 338 (100). 
2-(4-methylthio-
benzyl)-3-(3-
methylthio-
phenyl)-aziridine 
[16.90 minutes], 
(61) 
N
H
SCH3
H3CS  
Route specific aziridine 
impurity derived from 
the oxime route 
55 (18), 137 (23), 89 
(24), 91 (25), 121 
(35), 122 (76), 123 
(22), 137 (100), 148 
(16), 164 (9), 207 
(3), 281 (66), 301 
(17). 
4-methyl-5-(4-
methylthio-
phenyl)-
pyrimidine [10.55 
minutes], (62) 
N
N
SCH3
 
Leuckart route specific 
impurity in the synthesis 
of 4-MTA (9) via N-
formyl 4-MTA (48). 
121 (16), 122 (24), 
137 (47), 168 (56), 
169 (28), 201 (40), 
215 (39), 216 (100), 
217 (31), 218 (12). 
4-(4-methylthio-
benzyl)-pyrimidine 
[10.66 minutes], 
(63) 
N
N
SCH3
 
Leuckart route specific 
impurity in the synthesis 
of 4-MTA (9) via N-
formyl 4-MTA (48). 
122 (18), 137 (29), 
244 (30), , 290 (14), 
323 (12), 337 (55), 
338 (100), 339 (30), 
340 (12). 
2,6-dimethyl-3,5-
bis-(4-methylthio-
phenyl)-pyridine 
[20.35 minutes], 
(64) N
SCH3H3CS
 
Leuckart route specific 
impurity in the synthesis 
of 4-MTA (9) via N-
formyl 4-MTA (48). 
175 (10), 288 (7) 303 
(7), 336 (9), 351 
(100), 352 (30), 353 
(13). 
2,4-dimethyl-3,5-
bis-(4-methylthio-
phenyl)-pyridine 
[20.38 minutes], 
(65) N
SCH3H3CS
 
Leuckart route specific 
impurity in the synthesis 
of 4-MTA (9) via N-
formyl 4-MTA (48). 
175 (9), 257 (6), 288 
(7), 289 (8), 303 (6), 
336 (8), 351 (100), 
352 (31), 353 (15). 
 
Table 9.1.4 (continued): Names, structures, synthetic route information and mass spectral data for 
selected intermediates, impurities and product for the synthesis of 4-MTA (9) (continued overleaf). 
 
 
 
 
Name [Retention 
Time, minutes] 
Structure Route Mass Spectral 
fragmentation m/z 
(% abundance) 
2-methyl-6-(4-
methylthiobenzyl)-
3-(4-methylthio-
phenyl)-pyridine 
[20.54 minutes] 
(66) 
N
H3CS
SCH3
 
Leuckart route 
specific impurity in 
the synthesis of 4-
MTA (9) via N-
formyl 4-MTA (48). 
122 (9), 137 (11), 
152 (10), 254 (6), 
289 (9), 303 (13), 
321 (7), 336 (44), 
350 (58), 351 (100), 
352 (31), 364 (24), 
365 (37). 
2,4-dimethyl-6-(4-
methylthio-
benzyl)-3-(4-
methylthio-
phenyl)-pyridine 
[2.47], (67) 
N
SCH3
H3CS
 
Leuckart route 
specific impurity in 
the synthesis of 4-
MTA (9) via N-
formyl 4-MTA (48). 
137 (10), 159 (18), 
303 (17), 317 (7), 
335 (12), 350 (59), 
364 (65), 365 (100), 
366 (31), 367 (13). 
4-methyl-2-(4-
methylthio-
benzyl)-5-(4-
methylthio-
phenyl)-pyridine 
[21.46 minutes], 
(68) 
N
SCH3
H3CS
 
Leuckart route 
specific impurity in 
the synthesis of 4-
MTA (9) via N-
formyl 4-MTA (48). 
127 (9), 152 (15),  
289 (11), 303 (10), 
321 (7), 336 (31), 
350 (100), 351 (92), 
352 (31), 353 (11), 
354 (2). 
N,N-bis-[1-methyl-
2-(4-methylthio-
phenyl)-ethyl]-
formamide [21.01 
minutes], (70) 
N
H3CS SCH3
CHO
 
Leuckart route 
specific impurity in 
the synthesis of 4-
MTA (9) via N-
formyl 4-MTA (48). 
70 (11), 91 (7), 117 
(25), 137 (32), 164 
(100), 165 (91), 166 
(19), 236 (38), 373 
(1). 
1-methyl-4-
methylthio-
benzene [4.46 
minutes], (69) 
H3CS  
Leuckart route 
specific impurity in 
the synthesis of 4-
MTA (9) via N-
formyl 4-MTA (48). 
45 (17), 91 (58), 123 
(29), 138 (100). 
4-MTA [7.78 
minutes], (9) 
H3CS
NH2
 
Product amine sold 
as ecstasy. 
44 (100), 78 (12), 91 
(15), 122 (21), 137 
(21), 138 (65). 
 
Table 9.1.4 (continued): Names, structures, synthetic route information and mass spectral data for 
selected intermediates, impurities and product for the synthesis of 4-MTA. 
 
 
Section 9.2: GC-MS analysis of ecstasy of licit origin 
 
A total of seven samples of various ecstasy type drugs which had been prepared in the School of 
Pharmacy via known routes were analysed for the presence for any of the impurities entered into the 
mass spectral library. 
The first sample to be analysed was a sample of MDMA (5) that had been prepared via the Leuckart 
route of synthesis. MDA (4) and MDEA (6) were detected as impurities. There is also a spectrum that 
on visual inspection shows similarities to N-formyl, N-methyl MDA (37) at 10.5 minutes (the same 
retention time as the N-formyl, N-methyl MDA (37) standard. The presence of this component 
indicates that the MDMA (5) was indeed synthesised via the Leuckart route. 
 
The second sample to be analysed was 4-MTA (9). This had been prepared via the reductive amination 
route and as expected there were no impurities observed 
 
The third sample analysed was BDB (7), which had been prepared via the Leuckart route. This extract 
was found to contain the 3,4-methylenedioxyphenyl-(butan-2-one oxime) (43) eluting at 9.3 minutes 
(Quality 93%) which may have been due to the synthesis of PEK (16) and also the N-formyl BDB (17), 
eluting at 10.7 minutes which was due to the Leuckart reaction (see Figure 9.2.1). Both the retention 
time and the mass spectrum for the unknown matched those of the standard well (mass spectral match 
quality, 93 %). See Figure 9.2.2 for the selected ion monitoring of the 176 ion which is the base peak of 
the mass spectrum of N-formyl BDB (17). 
 
 
Figure 9.2.1: Selected Ion Monitoring Chromatogram of the 135 ion for the analysis of BDB made via 
the Leuckart route. The 3,4-methylenedioxyphenyl-(butan-2-one oxime) (43) is annotated above its 
peak.. 
 
The oxime is most likely an intermediate resulting from the synthesis of PEK (16) via the oxime route, 
while the N-formyl BDB (17) impurity is the intermediate between PEK (16) and MBDB (8) for the 
Leuckart reaction. 
 
 Figure 9.2.2: Selected Ion Monitoring Chromatogram of the 176 ion for the analysis of BDB made via 
the Leuckart route. The compound N-formyl BDB (17) is annotated above its peak. 
 
 
The next sample analysed was MDEA (6) synthesised via the reductive amination route. There were no 
obvious impurities present other than, low levels of MDA (4) and MDMA (5) (less than 0.2% based on 
peak area measurements), which was as expected for the reductive amination route. 
 
The fifth sample analysed was MDA (4) which had been prepared via the Leuckart reaction, MDMA 
(5) and MDEA (6) were present as minor impurities, however the presence of N-formyl MDA (36) 
noted at 10.0 minutes indicating that the sample had been prepared via the Leuckart reaction (see 
Figure 9.2.3). The mass spectrum of the unknown and the standard N-formyl MDA (36) had a match 
quality of 81%, which was considered good. Hence, the MDA (4) was proven to have been 
manufactured via the Leuckart route. 
 
 
Figure 9.2.3: Selected Ion Monitoring Chromatogram of the 162 ion for the analysis of MDA (4) made via the Leuckart route. 
The compound N-formyl MDA (36) is annotated above its peak. 
 
The sixth sample analysed was MDA (4) prepared via the oxime route. Although containing MDA (4), 
there were no impurities observed. This may have been due to the fact that the procedure used to clean 
up the product was particularly rigorous (vacuum distillation, flash column chromatography) and 
leaving the level of impurity at an undetectable level. One would expect to have detected the route 
specific aziridine impurities (50) and (51), however these compounds were not detected.  
 
The final sample, which was analysed, was a sample of MDA (4), which had been prepared via the 
oxime route. The sample analysed in this case was the crude reaction product prior to clean up. 
Although the chromatogram contains many peaks (see Figure 9.2.4), the aziridine impurities (50) and 
(51) which are route specific for the oxime route to MDA (4) were easily identified with the aid of the 
mass spectral library. The retention times matched those of the standard (7.6 minutes and 8.1 minutes 
for compounds (50) and (51) respectively) and the mass spectral match quality in both cases was 
greater than 95%. This highlights the effect that sample clean-up has on the impurity profile of drugs. 
 
 Figure 9.2.4: Selected Ion Monitoring Chromatogram of the 177 ion for the analysis of crude MDA (4) 
made via the Oxime route. The aziridines (50) and (51) are annotated above their respective weeks. 
 
Section 9.3: GC-MS analysis of Ecstasy of illicit origin 
 
The tablets discussed in section 8.5 were extracted and analysed under the conditions described. The 
GC-MS chromatograms obtained were searched for the presence of any compounds that had been 
entered into the mass spectral library, Mslib.l. It was found that some of the tablets did indeed contain 
impurities that indicated the route of synthesis. 
 
The first tablet analysed was the yellow bi-convex tablet. The main peak in the chromatogram was 
found to be MDMA (5) eluting at 7.58 minutes under the conditions described (See Figure 9.3.1). 
There was also small peak eluting at 7.11 minutes which was identified as MDA (4) with the aid of the 
library. This was not considered unusual as this type of impurity may be as a result of any number of 
reasons, e.g. adulteration, poor laboratory hygiene between batches etc. The most likely source of 
MDA (4) would be incomplete reaction in the synthesis of MDMA (5) or side reaction due to low level 
impurities in the starting materials resulting in the formation of MDA (4). 
 Figure 9.3.1:Reconstructed Ion Chromatogram for the extract of Tablet 1. MDA (4) and MDMA (5) 
are annotated on their respective peaks. 
 
Of more interest was the presence of compound eluting at 10.5 minutes (the same retention time as the 
standard N-formyl, N-methyl MDA (37)), (see Figure 9.3.2). The peak area was found to be 0.2 % of 
the peak area of the main MDMA (5) peak. When the library was used to search for the identity of this 
compound it was found that the quality of the match between this unknown compound and N-formyl, 
N-methyl MDA (37) was 97 %, which is excellent. The compound was therefore considered most 
likely to be N-formyl, N-methyl MDA (37).  
 
The consequence of this discovery is apparent if one peruses Table 9.1.2, where it is stated that N-
formyl, N-methyl MDA (37) is the intermediate route specific product between PMK (33) and MDMA 
(5) in the synthesis of MDMA (5) via the Leuckart reaction. Hence it is plausible to state that this 
particular tablet was most likely synthesised using the Leuckart reaction via the N-formyl, N-methyl-
MDA (37), intermediate. 
 
 
 
Figure 9.3.2: Selected ion monitering chromtaogram for ions 86, 58, 153 and 162  for the extract of 
Tablet 1. 
 
The second tablet analysed contained mainly MDA (4) (see Figure 9.3.3). There was also a small 
MDMA  (5) peak noticeable at 7.6 minutes. The only other peak that could be identified with the aid of 
the mass spectral library was a small peak eluting at 10.0 minutes (the same retention time as N-formyl 
MDA (36)) (see Figure 9.3.4). The mass spectrum of the unknown compound was compared against 
the spectra in the library and was found to match the library spectrum for N-formyl MDA (36) to a 
quality level of 91%, which was considered very good.  The information presented in Table 9.1.1 states 
that the presence of this particular impurity indicates that the MDA (4) was synthesised using the 
Leuckart reaction. Hence this illicit preparation contained MDA (4) manufactured using the Leuckart 
reaction. 
 
Figure 9.3.3:Reconstructed Ion Chromatogram for the extract of Tablet 3. MDA (4) and MDMA (5) 
are annotated at their respective peaks. 
 
Figure 9.3.4: Selected ion monitering chromatogram for ion162 (specific for N-formyl MDA)  for the extract of Tablet 3. (N-
formyl MDA (36) is annotated. 
 
Tablet 3 was a white tablet bearing a bird logo (see Figure 9.3.5). Analysis of the extract of tablet 3 
revealed a similar pattern to that described for the extract of tablet 1. MDMA (5) was the main 
component eluting at 7.5 minutes and there was small pea eluting at 7.11 minutes (less than 2% the 
area of the main peak), which was identified as MDA (4). There was an MDEA (6) peak found  eluting 
at 8.00 minutes, which compares well with the retention time for standard MDEA (6). There was also 
the presence of the peak at 10.5 minutes which was successfully identified as N-formyl, N-methyl 
MDA (37). It was hard to identify as it was co-eluting with some other compound, however a match for 
the N-formyl, N-methyl MDA (37) library entry of 59 % was recorded, which is considered acceptable 
when the retention times for standard and unknown were compared (10.5 minutes versus 10.5 minutes, 
respectively) (Kavanagh, 2001).  The area of the peak was particularly small; less than 0.2% the area of 
the primary peak. This MDMA (5) also seemed to be made via the Leuckart route, but could not be 
linked to the previous batch as it contained additional components (e.g. MDEA (6)), which were not 
evident in tablet 1. 
 
 
Figure 9.3.5: Image of tablet 3 and 4. 
 
The fourth tablet was the same as tablet 3 in as much as that the tablets were both white, of the same 
dimensions and bearing a similar bird logo. The main peak was MDMA (5), there was a trace of both 
MDEA (6) and MDA (4) and the presence, at a low level, of N-formyl, N-methyl MDA (37) could be 
confirmed with the aid of the library (spectral match quality 70%, retention time 10.5 minutes). The 
two tablets were certainly supplied to the School of Pharmacy as part of the same seizure so it is 
plausible that the two tablets were part of the same manufactured batch. On visual inspection the 
chromatograms had very similar chromatographic profiles, however the peak areas of the compounds 
MDA (4), MDEA (6) and N-formyl, N-methyl MDA (37) were estimated with the aid of the software’s 
integration tool and divided by the area of the MDMA (5) peak. In the case of both tablets, the values 
estimated were plotted on a chart (see Figure 9.3.6). As can be seen from the chart the impurities seem 
to occur at the same level, with a similar ratio to each other, adding credence to the theory that they 
may be from the same batch. It is worth noting however, that it would be desirable to have more peaks 
to compare to each other or a software tool such as Spectrogram (Doolin, 2000) which would allow a 
qualitative mathematical comparison of the two separate chromatograms. This product was designed 
and manufactured by VG Gas Analysis Systems (Cheshire, U.K) but is not available for purchase at the 
time of writing. 
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Figure 9.3.6: Chart showing peak area ratios for impurities in tablet 3 and 4 compared to the area of 
MDMA (5) the main constituent. 
 
The fifth and final tablet to be analysed was a tablet bearing a Mitsubishi logo (see Figure 9.3.7). This 
tablet contained mainly MDMA (5) but it also contained a peak eluting at the same time as PMK (33) 
standard, 7.0 minutes (see Figure 9.3.8). Figure 9.3.8 shows the SIM chromatogram for the 135 ion, 
which is a common ion, found in compounds sharing the methylenedioxyphenyl moiety. The spectral 
match quality between the standard and the unknown was 74 %, which was considered good. The 
absence of Leuckart route impurities may indicate that the tablet was not made via this route. The 
presence of PMK (33) would rule out the Bromopropane route, as PMK (33) is not an intermediate of 
this route. The same applies to alkylation, which proceeds via a nitropropene intermediate (35) to MDA 
(4) and then alkylation to MDMA (5), without the need for  PMK (33). The other possibility is a one 
step route from PMK to MDMA (5), via the reductive amination route. This route is known to be a 
favoured route of synthesis for the manufacture of MDMA (5) (King, 1999). This route is not known to 
yield any route specific impurities at a detectable level (Keating, 2001). Therefore it is possible that the 
route of synthesis used was the reductive amination route, but this cannot be proven as this conjecture 
is based predominantly on the absence of certain impurities as opposed to the presence of known route 
specific impurities. 
 
Figure 9.3.7:Image of Mitsubishis tablets analysed. 
 
Figure 9.3.8: Selected ion monitering for ion135  for the extract of Tablet 5. The compounds MDMA 
(5) and PMK (33) are annotated at their respective peaks. 
 
Section 9.4: Conclusion 
The mass spectral library was easily set up once the relevant compounds were available. The library 
proved a useful tool in the analysis of ecstasy of illicit and licit origin, in terms of its ability to aid the 
determination of route of synthesis. In some cases, especially when the drug was licitly prepared 
identification proved difficult e.g. MDA (4) via the oxime route. This is primarily due to the likelihood 
that the samples were rigorously cleaned. Such clean up is less likely to be employed in the case of the 
illicit samples, but not out of the question. It is also noteworthy that the intermediates were easier to 
detect than most of the impurities, which had been isolated and included in the library e.g. The pyridine 
and pyrimidine impurities of the Leuckart routes. It may be that, by taking and extracting larger 
quantities of drug, detection of these impurities would be achievable.  
10.1: Introduction 
 
The metabolism of MDA (4), MDMA (5), MDEA (6), BDB (7), MBDB (8) and 4-MTA (9) is of 
interest on several levels as the presence/absence indicates whether a drug has been abused or not. 
In the emergency medicine setting it is important to be able to determine the type of compound 
that an admission may have ingested in order to administer suitable treatment. In accidental deaths 
associated with drug abuse it is important for coroners to be able to ascertain the types of drugs 
that the victim had ingested, which may or may not have lead to the patients death. Workplace 
drug testing has also become a common feature in society and therefore samples of blood and 
urine are often analysed for drug content prior to a hiring decision being made. Metabolism studies 
are also used in an attempt to determine the toxicity of certain drugs, as the parent drug itself may 
not be dangerous in its initial form, however it may be rendered so on metabolism. Since 
metabolites are claimed to be responsible for the hypothermic, the neurotoxic and/or hepatotoxic 
effects  (Hiramatsu, 1990 & Carvalho, 1996), of amphetamine type drugs, detailed knowledge of 
the metabolism is necessary. 
 
In general urine and blood are analysed for parent drugs and metabolites, with immunoassay being 
used as a screening procedure. Commercial amphetamine immunoassays e.g. radioimmunoassay 
(Cody, 1990; Kintz, 1997a), enzyme immunoassays (Kunsman, 1990; Kintz, 1997a & Howard-
Taylor, 1999) or fluorescence polarisation immunoassays (Kunsman, 1990; Kintz, 1997a & 
Hensslin, 1996) have been used for screening methylenedioxyamphetamines. The poor selectivity 
of immunoassay techniques has been associated with false positive results where compounds 
similar to amphetamine such as phentermine, the appetite suppressant, and ephedrine, the 
bronchodilator and decongestant, have been found to yield erroneously positive amphetamine 
results (Howard-Taylor, 1999). It is noteworthy that five enzyme immunoassay systems, recently 
tested for accuracy all gave spurious results, however the manufacturers of all five systems stated 
that any positive results should be confirmed by GC-MS (Howard-Taylor, 1999). Confirmation 
and quantification methods using GC-MS, HPLC, CE and TLC in detection of amphetamine type 
designer drugs in urine and blood were recently reviewed (Kraemer, 1998). The determination of 
‘Ecstasy’ components in alternative biological specimens (saliva, sweat and hair) has also been 
reviewed (Kintz, 1999).  
 
In recent years there has been a significant amount of research carried out on the metabolism of 
Ecstasy-type compounds (Maurer, 2000; Garret, 1991; Helmlin, 1996; Kintz, 1999; Kintz, 1997; 
Sadeghipour, 1998 and Maurer, 1996). .  Maurer et al. carried out an extensive study on the 
metabolism of racemic MDA (4), MDMA (5), MDEA (6), MBDB (8) and BDB (7), where the 
metabolites were identified in urine by GC-MS after enzyme hydrolysis, acetylation and 
methylation (Maurer, 1996). In phase I metabolism, the drugs were found to undergo O-
dealkylation of the methylenedioxy group to form a dihydroxy derivative and N-dealkylation of 
the amine function to form the desmethyl analogue of the parent molecule (see Figure 11.2). 
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Figure 11.2: The O-dealkylation and N-dealkylation of the methylenedioxy compounds (R=CH3 for propanamines, 
R=CH2CH3 for butanamines), (R’=CH3 for MDMA (5) and MBDB (8), R’=CH2CH3 for MDEA (6)) 
 
Of course the primary amines MDA (4) and BDB (7) cannot undergo the latter pathway, as they 
have no N-alkyl group to be dealkylated. The consequence of this is that the primary amine MDA 
(4) will be present as a dealkylated metabolite in urine after ingestion of MDMA (5) and MDEA 
(6). Similarly BDB (7) will be present as the de-alkylated metabolite of MBDB (8). Hence the 
presence of the primary amine may not necessarily prove it was the ingested compound, as it may 
only be present as a result of metabolism.  The phase II metabolism involves the formation of 
glucuronic acid and sulphate conjugates (Maurer, 1996). 
 
The major metabolite in the case of MDMA (5) (Helmlin, 1996) and 4-MTA (9) (Kavanagh, 1999) 
in urine is the parent molecule. MDA (4) was detected in biological fluids using GLC (Midha, 
1976). Lim et al. detected MDA (4) and MDMA (5) in bio-fluids using GC-MS (Lim,  1988 & 
Lim, 1989). MDMA (5) and MDA (4) were detected in bio-fluids by HPLC in the work of Garret 
et al. and in blood using HPLC with electrochemical detection by Michel et al. (Garret, 1991 & 
Michel, 1993).  The detection of parent drug in the case MDMA (5), MDEA (6) and MBDB (8) 
was possible in samples of urine, and was used to differentiate the type of drug in the various 
samples (Maurer, 1996) using GC-MS. Kronstrand et al. detected MBDB in urine using GC-MS 
(Kronstrand, 1996).  Kintz analysed for the parent drug and the desmethylated metabolite in an 
experiment used to follow the excretion of MBDB  (8) and BDB (7) in urine, saliva and sweat 
(Kintz, 1997) with GC-MS incorporating heptafluorobutyric acid derivatisation. On the basis of 
these results it should be possible to determine whether methylenedioxypropanamines (MDA (4), 
MDMA (5) or MDEA (6)), methylenedioxybutanamines (BDB (7) or MBDB (8)) or 
thioamphetamines (4-MTA (9)) are being abused by analysing urine samples from individuals 
using these types of drugs, using GC-MS. Also as difficulty has been expressed in the past 
concerning the ability to distinguish the underivatised spectra of MDMA (5) and BDB (7) a 
derivatisation step, which might allow better spectral differentiation, may be desirable (Noggle, 
1991). 
  
The main objective of this study was to determine the types of amphetamines being abused by a 
group of recovering heroin addicts attending a drug rehabilitation programme in Dublin. It is widely 
accepted that many heroin users are polydrug abusers and a precondition of the methadone 
programme is the abstention from opiate drug abuse. However other drugs, such as amphetamines 
and benzodiazapines are being abused (Best, 2000; Schifano, 1998 & Browne, 1998). Urine 
samples were taken from methadone clinic clients, all from the same locality. One hundred samples 
which tested positive for amphetamine/ring-substituted amphetamine abuse by EMIT (enzyme 
multiplied immunoassay technique) immunoassay screen were further analysed. A GC-MS 
procedure, which incorporated a chemical derivatisation step, for the analysis of a series of 
amphetamine type compounds was established. The 100 samples, which had tested positive on 
screening, were liquid-liquid extracted and chemically derivatised and analysed using the GC-MS 
procedure already established. It was hoped from the results it would be possible to see whether 
methylenedioxypropanamines (MDA (4), MDMA (5) & MDEA (6)), methylenedioxybutanamines 
(BDB (7) & MBDB (8)) or thioamphetamines (4-MTA (9)) were being abused by the cohort of 
clients. 
 
 
 
 
 Section 11.1: Instrumentation  
 
GC-MS 
The system consisted of a Hewlett Packard 5973 MSD quadrupole mass spectral detector coupled to a 
6890 GC system and a 6890 Injector Autosampler. The column used was a HP5-MS (5%-phenyl-95%-
dimethylsiloxane-copolymer, 30M × 0.25mm × 0.25µm film thickness). The system was computer 
controlled with the aid of Hewlett-Packard Chemstation software.  
 
Immunoassay Analyser 
All urine samples were tested by instrumental immunoassay on an Olympus AU 600 Analyser. 
 
Miscellaneous Instruments 
All weighing was carried out using a Sartorius BP110 S analytical weighing balance. 
 
Section 11.2: Solvents & Blank Urine 
 
Solvents 
All solvents used were HPLC grade and 0.22 µm filtered. 
 
Drug free urine 
Drug free urine was collected from a drug free candidate outside of the drug treatment programme 
and stored at -18°C until required 
 
Section 11.3: EMIT test procedure  
 
Urine samples were taken, under strict supervision, from clients over a period of two months (July-
August 1999), in a Drug Treatment Centre in Dublin. Urine samples were tested by instrumental 
immunoassay on a Olympus AU 600 analyser, according to manufacturers instructions, using the 
EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine (Syva) kit. The staff of the Drug 
Treatment Centre conducted this procedure. EMIT positive samples were refrigerated (-18°C) until 
extraction (see Section 11.5). 
 
Section 11.4:GC-MS procedure for the analysis of a series of derivatised amphetamine 
analogues  
 
Preparation of analytical solutions 
All reference solutions 1-7 were prepared by dissolving 2.0 mg/ml aliquots of the relevant 
compound(s) in 1 ml of drug free urine unless otherwise stated (see overleaf). 
 
Reference Solution 1: Amphetamine (3) 
Reference Solution 2: Methamphetamine (30) 
Reference Solution 3: BDB (7) 
Reference Solution 4: MBDB (8) 
Reference Solution 5: MDA (4) 
Reference Solution 6: MDMA (5) 
Reference Solution 7: MDEA (6) 
Reference Solution 8: 4-MTA (9) 
 
Derivatisation procedure 
Chemical derivatives of the reference standards (1-7) were prepared as follows. Each solution (2 ml) 
was made alkaline by the addition of conc. aqueous ammonia (0.5 ml) and extracted with 2 ml of 
petroleum ether. The supernatant petroleum ether was quantitatively transferred to a V-vial. The 
ether was then evaporated to dryness under a stream of nitrogen at room temperature. The residue 
was reconstituted in toluene (80 µl). N-methyl-bis(trifuoracetamide) (MBTFA) (20µl) was then 
added to the vial immediately before injection into the chromatographic system (see below). 
  
 
 
 
Chromatographic conditions 
The GC-MS conditions used in the analysis are outlined in Table 11.4.1. 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column HP-5MS  
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.25 µm  
Transfer Line Temperature 280°C 
Ionisation Mode Electron Ionisation 
Injected Volume 1µl 
Injection Mode Splitless 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 280°C (6 minutes) 
Total Run Time 19.7 minutes 
Detected  Mass Range  40 – 600 m/z 
 
Table 11.4.1: Chromatographic conditions used for the development of a GC-MS procedure for the analysis of a series of 
derivatised amphetamine analogues.  
 
Analysis 
Each of the reference solution extracts were chromatographed (in duplicate) using the above 
chromatographic system. The results of this section are discussed in section 12. 
 Section 11.5: Construction of mass spectral library. 
Mass spectra of compounds analysed in section 11.4 were entered into the custom spectral library 
from chromatographic data generated in section 11.4. Library creation using Chemstation (Hewlett-
Packard, 1986-1996) is fully explained in the software help tool. The help tool in the HP software 
was used in order to create and modify the library entitled Metab.l. An electronic copy of this 
library is included in Appendix II. This electronic copy requires Chemstation software or some 
other compatible software in order to function.  The results of this section are shown in 13. 
 
Section 11.6: Extraction and GC-MS analysis of EMIT positive urine 
 
Section 11.6.1: Extraction of EMIT positive urine samples in preparation for GC-MS analysis 
 
Sample collection and storage 
Urine samples were collected as part of normal drugs of abuse screening at the Drug Treatment 
Centre, Trinity Court, Pearse Street, Dublin 2, during July and August 1999. 100 samples which had 
tested positive for Amphetamines by EMIT immunoassay in the treatment center were stored at -
18°C until GC-MS analysis (see Section 11.3). 
 
Derivatisation procedure 
An aliquot of each urine sample (2ml) was made alkaline by the addition of conc. aqueous 
ammonia (0.5ml) and extracted with 2ml of petroleum ether. The supernatant petroleum ether was 
quantitatively transferred to a V-vial. The ether was then evaporated to dryness under a stream of 
nitrogen at room temperature. The residue was reconstituted in toluene (80 µl). MBTFA (20µl) was 
then added to the vial immediately before injection into a chromatographic system. The 
chromatographic system employed is described in Section 11.6.2. 
 
Section 11.6.2: GC-MS analysis of EMIT positive urine sample extracts 
 
Samples Analysed 
The 100 EMIT positive urine samples that had been prepared in Section 11.3 were submitted for GC-
MS analysis. 
 
 
 
 
 
 
 
Chromatographic conditions 
The GC-MS conditions used in the analysis are outlined in Table 11.6.1 
GC-MS Parameter GC-MS Condition 
Carrier Gas Helium 
Carrier Gas Flow Rate 1 ml/min 
Column HP-5MS  
Column Internal Diameter 0.25 mm 
Column Length 30 M 
Column Film Thickness 0.25 µm  
Transfer Line Temperature 280°C 
Ionisation Mode Electron Ionisation 
Injection Mode Splitless 
Initial Temperature (Hold Time) 90°C (1minutes) 
Ramp Rate 15°C/min 
Final Temperature (Hold Time) 280°C (6 minutes) 
Total Run Time 19.7 minutes 
Detected  Mass Range  40 – 600 m/z 
 
Table 11.6.1: Chromatographic conditions used for the development of a GC-MS procedure for the analysis of a series of 
derivatised amphetamine analogues.  
 Analysis 
Each extract was chromatographed (in duplicate) under the GC-MS conditions described above. The 
results are discussed in Section 12.3. 
 
 
 
Section 12.1: EMIT test procedure 
 
The Drug Treatment Centre Board is responsible for the 
administration of much of the methadone treatment 
programme in Dublin. The programme is run through 
several drug clinics situated all over the city.  Clients 
normally attend these clinics on a daily basis, where a 
Pharmacist dispenses a controlled amount of methadone. A 
pre-requisite of the programme is that clients do not 
continue to abuse drugs once they are accepted onto the 
programme, and instead rely only on methadone prescribed 
by the Clinicians of the Drug Treatment Centre Board. As 
the clients do not always adhere to this condition, screening 
programmes are necessary in order to detect non-
compliance. EMIT immunoassay is a common screening 
procedure which is used by the Drug Treatment Centre to 
assess compliance with the conditions of the programme. If a 
client is in breach of the agreement then they are given a 
period of time to clear their system of the drug 
(benzodiazepine, amphetamine etc.) before receiving further 
methadone maintenance. 
 
Of the numerous urine samples taken over the course of July-August 1999 in one Dublin drug 
treatment centre 100 urine samples tested positive for amphetamine by EMIT II immunoassay. It was 
not discernible whether or not these samples actually contained amphetamine itself or some analogues 
of amphetamine. The reason for this uncertainity was the poor selectivity and cross reactivity exhibited 
by the immunoassay kits (Price, 1997). A positive immunoassay result could mean that one or more of 
a number of possible amphetamine type drugs are being abused. The d-amphetamine cut-off for the kit 
used is comparatively high, 1000 ng/ml (Syva®, 1998), when compared to other systems (e.g. FPIA-
Amphetamine/Methamphetamine II, Abbott 300 ng/ml). Coupled with this is the fact that the detection 
period for MDA and MDMA is ca. 2 days (de la Torre, 1997). Hence, it is possible that many of the 
clients could have been using these drugs but evaded detection due to the fact that the concentration of 
abused drug was below the limit of detection of the screening system employed. The short half-life of 
the drugs in question may also have contributed to negative results on screening.  As aforementioned 
the manufacturers of many of these systems advocate that any positive results be confirmed by GC-MS 
(see Section 10). Hence the objective of this study was to confirm that amphetamines (ring-substituted 
or otherwise) were being abused and more specifically to see whether methylenedioxypropanamines 
(MDA (4), MDMA (5) and MDEA (6), methylenedioxybutamines (MBDB (8)), thioamphetamines (4-
MTA (9)) or non-ring substituted amphetamines (amphetamine (3) and methamphetamine (30)) were 
being abused.  
 
Section 12.2: GC-MS procedure for the analysis of a series of derivatised amphetamine 
analogues.  
 
In order to confirm the presence of amphetamine type compounds and more specifically the family of 
compounds (methylenedioxypropanamine/butanamines etc.), an analytical protocol was required that 
would allow for this type of determination. GC-MS seemed like the most logical option as it has the 
ability to unequivocally identify chemical compounds.  
 The target analytes chosen were considered the most likely amphetamine type compounds being 
abused in the Republic of Ireland, based on reference information (An Garda Siochana, 1997; An 
Garda Siochana, 1998). The compounds chosen were amphetamine (3), MDA (4), MDMA (5), MDEA 
(6), and MBDB (8). The compounds 4-MTA (9) and BDB (7) were included in this study along with 
the previously mentioned compounds. It was expected, based on the metabolism studies referred to in 
the introduction, that the parent drug would be excreted in the case of all of the aforementioned drugs 
and as such would be the target analyte. It is worth mentioning once more that it is not possible to 
identify whether the primary amines MDA (4) and BDB (7), if detected would be present as the N-
alkyl metabolites of MDMA (5), MDEA (6), or MBDB (8) or whether the drug abuser additionally 
took them. Once the target analytes had been selected a GC-MS system capable of analysing them was 
required.  
 
A GC-MS system that had been in use for some time in the Department of Pharmacology and 
Therapeutics, T.C.D. that involved chromatographic conditions that are applicable to most basic drugs 
was exploited.  The system involved a HP-5 column (length: 30 M, i.d.: 0.25 mm, film thickness: 0.25 
µm). The temperature programme used had an initial temperature at 90°C, which was held for 1 
minute, before being ramped up to 280°C at a rate of 15°C/min. The temperature was then held at 
280°C for 6 minutes (see Section 11.4 for full details). The method also employed a chemical 
derivatisation step using MBTFA.  
 
A chemical derivatisation step was chosen based for two reasons. 
 
1. Amines (the functional group common to all of the selected target compounds) do not give very 
featured (well fragmented) mass spectral fragmentation patterns and as such are not very good for 
confirmational analysis. It is much better if highly featured mass spectra can be obtained (Mc 
Lafferty, 1993)  
 
2. Some of the analytes e.g. MDMA (5) and BDB (7) are isomers and concern was expressed in the 
past about the spectra of these compounds being too similar for the purposes of differentiation 
(Noggle, 1991). 
 
The derivatisation in the case of the amines usually provides more featured fragmentation patterns 
when subjected to mass spectral analysis (Mc Lafferty, 1993).  
 
Using the GC-MS system outlined (see Section 11.4) all of the compounds analysed, amphetamine (3), methamphetamine (30), 
MDA (4), MDMA (5), MDEA (6), BDB (7), MBDB (8) and 4-MTA (9) were sufficiently separated (based on visual inspection) 
(see Figure 12.1, overleaf). The retention times were determined for each of the standards which had been extracted from drug 
free urine (Table 12.2.1 below). The peaks were identified by comparison of the retention times of the standards containing the 
individual standards (reference solutions 1-7) with the retention time of the standards in the mixture (reference solution 9).  
Figure 12.1 was prepared by plotting the extracted ion abundance (most intense mass spectral ion for each of the analytes) versus 
time (minutes) from reference solution 9. The most intense ions (140 m/z, 154 m/z, 265 m/z, 135 m/z, 137 m/z and 168 m/z) 
were individually plotted and superimposed using the HP Chemstation software resulting in the merged chromatogram (see 
Figure 12.2.1, overleaf). 
 
 
 
 
Analyte (TFA Derivative) Retention Time (minutes) 
Amphetamine (3) 5.83 
Methamphetamine (30) 6.75 
MDA (4) 8.50 
BDB (7) 9.08 
4-MTA (9) 9.16 
MDMA (5) 9.41 
MDEA (6) 9.75 
MBDB (8) 9.83 
 
Table 12.2.1: Retention times) for amphetamines analysed. 
 
 Figure 12.2.1: Extracted ions abundance (x-axis) plotted against Time (minutes). The most intense ions (140 /z, 154 m/z, 265 
m/z, 135 m/z, 137 m/z and 168 m/z) were individually plotted and merged using the HP Chemstation software resulting in the 
merged chromatogram above. Peaks are annotated with compound reference number. Note all compounds are TFA derivatised 
 
 
The mass spectra of each of the analytes consisted of well fragmented mass spectra at high mass for the MBTFA derivatives (see 
Table 12.2.2).  
 
 
 
 
Analyte (TFA Derivative) Main Mass Spectral Peaks m/z  (relative abundance %) 
Amphetamine (3) 140 (100), 118 (92), 91 (66 ), 69 (31) 
Methamphetamine (30) 154 (100), 118 (36), 110 (36), 91 (32), 69 (20) 
MDA (4) 135 (100), 162 (57), 77 (31), 275 (18) 
BDB (7) 135 (100), 176 (50), 289 (15), 77 (17) 
4-MTA (9) 137 (100), 164 (88), 69 (49), 277 (44), 122 (39) 
MDMA (5) 154 (100), 168 (100), 135 (73), 110 (44), 97 (34), 280 (14) 
MDEA (6) 168 (100), 162 (63), 140 (38), 138 (42), 77 (19), 303 (7) 
MBDB (8) 168 (100), 176 (85), 135 (59), 303 (11) 
 
Table 12.2.2: Most significant ions in the mass spectra acquired for the respective chromatographic 
peaks. Note: the subscript of the mass ion refers to the mass spectral peak abundance 
 
The proposed fragmentation patterns for amphetamine (3), methamphetamine (30), MDA (4), 
MDMA (5), MDEA (6), BDB (7), MBDB (8) and 4-MTA (9) are shown in Figures 12.2.2, 12.2.3, 
12.2.4, 12.2.5, 12.2.6, 12.2.7, and 12.2.8 respectively. Typically what happens is an alpha cleavage 
to form a benzyl moiety (ring substituted or otherwise) yielding two significant ions, the benzyl and 
he amine fragment. The formation of styrene type molecule (ring substituted or otherwise) also 
yields a significant fragment in the mass spectra of these compounds. 
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Figure 12.2.2: Proposed fragmentation pattern of the amphetamine-TFA derivative. 
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Figure 12.2.3: Proposed fragmentation pattern of the methamphetamine-TFA derivative. 
 
 
  
O
O
HN CF3
O
O
O
O
O
m/z = 275
m/z = 135 m/z = 162  
Figure 12.2.4: Proposed fragmentation pattern of the MDA-TFA derivative. 
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Figure 12.2.5: Proposed fragmentation pattern of the MDMA-TFA derivative. 
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Figure 12.2.6: Proposed fragmentation pattern of the MDEA-TFA derivative. 
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Figure 12.2.7: Proposed fragmentation pattern of the BDB-TFA derivative. 
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Figure 12.2.8: Proposed fragmentation pattern of the MBDB-TFA derivative. 
H3CS
HN CF3
O
H3CS H3CS
- CH3
m/z = 122
m/z = 137 m/z = 164
m/z = 277
 
Figure 12.2.9: Proposed fragmentation pattern of the 4-MTA-TFA derivative. 
 
Now that a suitable chromatographic system had been established, which was capable of identifying 
the target molecules in urine, it could be applied to the analysis of the EMIT amphetamine positive 
urine samples acquired from the Drug Treatment Centre. The mass spectra of the compounds were 
entered into a specially constructed mass spectral library, which would be used when analysing 
future samples. The title of this library is metab.l and an electronic copy of it is available in 
Appendix II. 
 
Section 12.3 GC-MS analysis of EMIT positive urine sample extracts 
 
Using the GC-MS system described in section 12.2 the EMIT positive urine samples were extracted 
and analysed by GC-MS, as described in Section 11.4. The MBTFA derivatives of the target 
analytes, amphetamine (3), methamphetamine (30), MDA (4), MDMA (5), MDEA (6), BDB (7), 
MBDB (8) and 4-MTA (9), were searched for manually using the HP Chemstation interface in the 
10 EMIT positive samples. Peaks were positively identified if the retention time and the mass 
spectrum (at that retention time) both matched. 
 
In  21 out of 100 samples analysed, amphetamine (3) was the only drug detected. The amphetamine  
(3) peak was observed eluting at 5.83 minutes and the mass spectrum matched that of the amphetamine 
(3) peak on visual inspection. An example is shown below for sample 20 with the major selected ions 
extracted (140 m/z, 154 m/z, 265 m/z, 135 m/z, 137 m/z and 168 m/z) and superimposed (see Figure 
12..3.1). 
 
 
Figure 12.3.1: GC-MS chromatograms of selected ions (140 m/z, 154 m/z, 265 m/z, 135 m/z, 137 m/z 
and 168 m/z) used for monitoring EMIT positive sample 20. The amphetamine (3) peak is annotated 
above the relevant peak. 
 
The spectrum for the compound eluting at 5.83 minutes was subjected to a search of the specially 
constructed library and the result is shown below (see Figure 12.3.2). 
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Figure 12.3.2: Comparison of spectrum of compound eluting at 5.83 minutes in the extract of sample 
20, with the spectra of the specially constructed library. 
 
As can be seen the spectra are a good match for each other, the quality algorithm which mathematically 
estimates the quality of the match between the two was greater than 90, which is very good (Kavanagh, 
2001). 
 
MDMA (5)/MDA (4) was the only significant substituted amphetamine in 54 of the 100 samples. 
Sample 21 serves as good example of this (see Figure 12.3.3). In this sample MDMA (5) and MDA (4) 
were detected at 9.4 minutes and 8.5 minutes respectively. These retention times matched the retention 
times for the standards and the mass spectra were compared with the spectra in the library.  
  
Figure 12.3.3: GC-MS chromatogram of sample 21, showing both MDA (4) and MDMA (5). 
 
Both spectra were identified as MDA-TFA and MDMA-TFA 
respectively (see Figure 12.3.4) and the quality algorithm 
returned a value exceeding 90 in each case. 
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Figure 12.3.4: The two uppermost Spectra: MDA-TFA spectra compared to spectra eluting at same 
time in sample 21, The two lower Spectra: MDMA-TFA spectra compared to spectra of compound 
eluting at same time. 
 
In all 24% of the samples showed both amphetamine and MDMA/MDA. A typical sample which was 
found to contain both is shown below (Figure 12.3.5) for sample 27. 
 
 
Figure 12.3.5: GC-MS chromatogram of sample 27 extract. The peaks at 5.8 minutes, 8.5 and 9.4 
minutes were identified as amphetamine (3), MDA (4) and MDMA (5) respectively. 
 
The findings indicate that propanamine ring-substituted amphetamines (MDA (4) and MDMA (5)) and 
non-ring substituted amphetamines, and in this case specifically amphetamine were being abused. 
There was no observed occurrence of MDEA (6). There was no detection of MBDB (8) or BDB (7), 
which would indicate that the particular cohort monitored, was not abusing 
methylenedioxybutanamines. Thioamphetamines (4-MTA (9)) were not detected either.  There was one 
incidence of the anorectic, phentermine, in the samples analysed.  A pie chart summarising the results 
is shown below (see Figure 12.3.6). 
Amphetamine (21%) MDMA and Amphetamine (54%)
Amphetamine (24%) Other (1%)
 
Figure 12.3.6: Pie chart summarising results of the analysis of 100 EMIT positive samples by GC-MS 
The fact that there were no BDB (7), MBDB (8) or MDEA (6) present was not surprising as Irish 
Police (An Gardai) records also reflect this observation. It would appear that the majority of ‘’Ecstasy’’ 
seized in the Republic of Ireland in 1998 was almost exclusively MDMA (5) and only a fraction of 
cases involved MDEA (6) and MBDB (8) (An Garda Siochana, 1998).  In that same year there no 
reported seizures of BDB (7). 
 
In Germany MDMA (5) and MDEA (6) seem to be the most significantly abused, with little MBDB (8) 
or MDA (4) being encountered (Sondermann, 1999). It is also reported that 95% of all drugs sold as 
‘’Ecstasy’’ in Germany contain only one compound and that only 5% of formulations appeared as 
mixtures, which may give anecdotal credence to the possibility that the MDA (4) in the samples was of 
metabolic origin. However King et al. (1997) described the significant occurrence of MDA (4), 
MDMA (5) and MDEA (6) in the U.K. with some samples seen as mixtures of MDMA (5) with 
MDEA (6) and MDMA (5) with MDA (4). 
 
It has been shown in the past that 4-MTA (9) cross-reacts with the particular immunoassay system that 
was employed here (Kavanagh, 1999). The absence of 4-MTA (9) was probably due to the limited 
number of seizures in Europe, coupled with the high incidence of 4-MTA (9) associated fatality 
(EMCDDA, 1999), which may have lead to a decline in its use. 
 
It is worthwhile pointing out that the extent of ring-
substituted amphetamine abuse exceeds that of the non-
substituted form. Amphetamine abuse among first-contact 
patients of the drug treatment programme in 1997 and 1998 
in the Dublin area was ca. 1% (O’Brien, 1999). This low 
level of amphetamine abuse has been a feature of the drug 
scene in Ireland since the 1970’s (Corrigan, 1987). The 
extent of ring-substituted amphetamine abuse for first-
contact patients for the same region was 4.8% in 1997 and 
3.7 in 1998 (O’Brien, 1999).  
 
Although not particularly renowned for its abuse potential the appetite suppressant, phentermine, will 
rarely induce euphoria but can cause insomnia (Perrine, 1996). The occurrence of the Phentermine 
sample highlights the potentials for cross-reactivity in immunoassay systems and bolsters the need for 
reliable and confirmatory GC-MS procedures. It has been shown that both amphetamine and MDMA 
(5)/MDA (4) abuse can be confirmed by GC-MS with trifluoroacetyl derivatisation and that such abuse 
is occurring in the clients of the Dublin Methadone programme. 
 
Section 12.4: Conclusion 
A rapid GC-MS procedure incorporating flash derivatisation has been established for a series of 
amphetamines and their analogues which can be used in urinalysis to identify the type of amphetamines 
being abused. It also shows that in one locality in the Republic of Ireland a small group of drug users, 
who would most likely be exposed to similar market trends as the general populace, are being exposed 
to methylenedioxypropanamines which have been around for many years and not to newer analogues 
such as thioamphetamines and butanamines. 
 
Section 13.1: Historical Background 
 
The plant Cannabis sativa L is among one of the world’s oldest and best known plants/illicit drugs. It 
has been used for millennia for its fibre and intoxicating properties (Nahas, 1984). It was known to the 
Chinese and many other ancient civilisations as far back as the second millennium BC, when the plant 
was first cultivated for both its fibre and medicinal properties (Camp, 1936; Nahas, 1984). Although 
the plant certainly originated in Asia, its precise origin has yet to be identified (Nahas, 1984). It is 
thought that there was an early diffusion over a vast area stretching from the Caspian Sea to the 
southern Himalayas then extending into China and western Siberia, where today in the Altai valleys it 
can still be found in its wild state (Crescini, 1971). Cannabis sativa was one of the first non-food 
industrial plants to be cultivated by man (Mignoni, 1997/1998).  Cannabis is currently controlled in 
most countries including the Republic of Ireland, under the terms of the Misuse of Drugs Acts 1977 
and 1984 (Irish Government, 1977; Irish Government, 1984) 
 
Section 13.2: Botany 
 
 
Many botanists believe Cannabis sativa to be a single non-stabilised species and it was thought in 1949 
that there were as many as 100 varieties or races (Bailey, 1949); this number may be far greater today. 
Another opinion exists however that there are three distinct species, Cannabis sativa of temperate 
United States and the rest of the world, Cannabis indica of central Asia, and Cannabis ruderalis, a 
more northern species growing in Russia and Siberia (Schultes, 1980). For the purposes of this thesis 
Cannabis, where referred to, will be considered as being one species, Cannabis sativa L. The many 
varieties of Cannabis sativa L. have been categorised further into three phenotypes which are described 
as the drug-type (containing high levels of psychoactive material), the intermediate–type (intermediate 
levels of psychoactive material) and the fibre-type (containing low levels of psychoactive material).  
The details of this categorisation are discussed in more detail below.  
 
In Latin, the word Cannabis means hemp, and denotes the genus of the hemp family of plants.  The 
species name, sativa, means planted or sown, and indicates the nature of the plant’s growth (Nahas, 
1984). Cannabis sativa is closely allied to Humulus, the genus of the hop plant (curiously enough 
another industrial plant, which looms large in connection with another intoxicant-alcohol). Cannabis 
and Humulus are the only two genera of the family Cannabaceae (order Urticales), but Cannabis is the 
only plant in nature containing the “cannabinoid” chemicals (see chemistry below) (Nahas, 1984).  The 
plant is a herbaceous annual plant, which grows from a seed for a season and dies down; it grows again 
the following spring from its own hardy seed (Metchalfe, 1950). 
 
Cannabis is a dioecious plant, producing in a single sowing an equal proportion of female pistillate 
flowers and male staminate ones (Arnoux, 1966a &1966b).  Hermaphrodite plants with both male and 
female flowers also occur occasionally under unfavourable conditions.  Cannabis sativa also has the 
ability, rarely observed in nature, to reverse its sex after being transplanted.  This phenomenon is 
sometimes referred to as ‘’the confused sexuality of the plant’’ and is thought to depend on the length 
of the daylight exposure. further individual plant parts have the ability to unpredictably change their 
sex as the year goes on (Schaffner, 1923 & 1931). Soil nitrogen levels are also thought to play a part in 
this confusion (Talley, 1934). 
 
The morphological characteristics of this plant are distinct allowing for easy identification. A picture of 
a female plant is shown in Figure 13.2.1.  A slender stalk, 5 –7 cm long supports the characteristic 
palmate leaves, with a narrow groove along the upper side.  Each leaf presents 5 – 11 dark green 
leaflets radiating from the top of the stalk (Nahas, 1984).  The soft-textured leaflets, which may be as 
long as 25cm, are most often narrow and shaped like a lance finely sharpened to a narrow point; the 
edges of the leaflets are regularly dentate like the blade of a saw, with deep ridges running diagonally 
from the centre to the periphery.  The upper side of the leaf is dark green, contrasting with the lighter 
colour of its underside (Nahas, 1984). 
 
The male flower clusters, with their pollen-laden stamina standing out from the leaves on the individual 
flowering branches, consist of five whitish or greenish hairy petals 3 mm long and five pendulous 
stamens.  
 Figure 13.2.1: Female plant of the species Canabis sativa. 
 
The female flower clusters are usually more densely packed and do not extend beyond the leaves. Each 
flower presents a green organ, the bract, a tubular sheath, which surrounds the ovary and out of which 
project two long pollen-catching stigmas.  The bract is covered with hairs of which there are two types; 
capitate stalked or sessile glandular hairs and cystolythic or non-cystolythic covering hairs.  The 
stalkless, circular glands secrete drops of resin.  The bract, after pollination, produces a fruit, which is 
an achene; a hard shell containing a single seed. Female plants in general are taller and stockier than 
their male counterparts. , where the flowers are more tightly packed around the stem. 
 
Both the male and female flowers produce a resin in the trichomes on the bract, which surrounds the 
flower. It is in these trichomes that the bulk of psychoactive biosynthesis occurs. The trichomes contain 
a sticky resin, which is thought to be present as a means of protecting the plants from water loss in hot 
and dry climate (Perrine, 1996). Female plants generally produce more resin than males and hence they 
are considered to be more psychoactive than male plants (Perrine, 1984). 
 
Cannabis is also capable of assuming astonishing variation of shape and size which has often lead to 
doubt being cast about whether there is only one species. A plant grown in India will look very 
different to one grown in America. If there is only one species these responses may be due to 
environmental factors such as soil, climate, human manipulation and also to Cannabis sativa’s genetic 
plasticity. The plant is extremely tolerant of harsh environmental conditions and is known to thrive 
well in any type of soil (Nahas, 1984). 
 
Section 13.3: Chemistry 
 
 
The main chemical constituents of the plant, Cannabis sativa, are the cannabinoids. These compounds 
are unique to Cannabis and have not been found anywhere else in nature. Over 400 chemical 
compounds have been identified in varying quantities in Cannabis; more than 60 of these have been 
identified as cannabinoids (Turner, 1980). Chemically, cannabinoid structures are discernible as a 
terpene joined to an alkyl-substituted resorcinol. However for purposes of nomenclature the Chemical 
Abstracts Service (CAS) views the system as a benzopyran ring rather than a substituted terpene, 
leading to two numbering systems, both of which are widely employed. For the purpose of this thesis 
the benzopyran numbering system is used. Broadly speaking the term cannabinoid refers to the C21-
compounds present in the plant and includes their transformation products and related analogues. 
 
It took many years and unsuccessful attempts to identify the euphoric constituent in Cannabis sativa 
(Perrine, 1996). However, in the 1960’s the main psychoactive constituent was identified as ∆9-
tetrahydrocannabinol (THC) (72) as a result of the work of Gaoni and Mechoulam (1964). Two other 
important cannabinoids, which are found to exist in abundance in Cannabis sativa, are cannabinol 
(CBN) (73) and cannabidiol (CBD) (74). The structures of THC (72), CBN (73) and CBD (74) are 
shown below in Figure 13.31. CBN (73) is not actually biosynthesised by the plant, it is the oxidative 
breakdown product of THC (72) and therefore one would not expect to find it in a fresh plant, but 
rather in an aged plant (Nahas, 1984). CBN (73) and CBD (74) are not known to be euphoriants 
(Nahas, 1984). 
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                                                   Figure 13.3.1: Structures of ∆9-THC (72), CBN (73) and CBD (74) 
 
 
Section 13.4: Pharmacology 
 
 
The pharmacological activity of THC (72) is now known to be mediated through two types of receptors 
whose endogenous ligand is anandamide. The receptors are known as CB1 and CB2. The CB1 receptors 
occur in the brain and mediate for the characteristic effects of cannabis (feeling of relaxation and well 
being, increased visual and auditory perception, analgesia and depression of motor activity) (Nocerino, 
2000). So far the CB2 receptors have only been found outside the central nervous system (Nocerino, 
2000). The pharmacology of the cannabinoid receptors, their agonists and antagonists have been 
extensively reviewed (Adams, 1996; Ameri, 1999; Glass, 1998 & Reggio, 1999). 
 
Section 13.5: Potency and Administration 
 
Cannabis preparations are largely derived from the female plant due to the fact that it is believed to 
produce the highest levels of THC (72) of the two sexes (Perrine, 1996). The cannabinoids are 
distributed throughout the whole plant but the THC (72) content is highest in the flowering tops of the 
plant (which contain the resinous glandular trichomes), declining in the leaves, lower leaves, stems and 
seeds (Martin, 1997/1998). Marijuana or Cannabis herb (‘’weed’’, ‘’spliff’’’, ‘’grass’’ etc.) is prepared 
from the dried flowering tops and leaves of the plant (THC (72) content 0.5%-5.0%) (Martin, 
1997/1998). Hashish (hash, Lebanese Gold, Pakistani black) consists of dried cannabis resin and 
compressed flowers (THC (72) content 7%-14%) (Martin, 1997/1998). Hashish oil, derived directly 
from the plant via solvent extraction and distillation, may contain 15%-50% THC (72) (Martin, 
1997/1998). Sinsemilla is a form of Cannabis, where all male plants are culled from any females early 
in the growth cycle. The females then produce higher levels of THC (72) (Nahas, 1984). This effect 
may be due to the fact that the unfertilised female plants do not have to channel their energies into 
reproduction. Levels of THC (72) up to 20% have been recorded (Adams, 1996). New varieties have 
also appeared on the black market (e.g. ‘’Nederwiet’’, ‘’Skunk’’) which have been specially bred 
through clandestine research to produce high levels of THC (72) (up to 20%) (Adams, 1996). 
 
Cannabis can be eaten or smoked in order to experience its euphoric effects, however it is generally 
smoked as this results in more immediate effects.  Cannabis may be smoked in a ‘’joint’’ which is hand 
made cigarette (with or without tobacco), or in a water pipe (bong) (Hall, 1998).    
 
 
 
 
Section 13.6: Medicinal Properties and Adverse Effects 
 
The discovery of the cannabinoid receptors has paved the way for much research into the synthetic 
manipulation of the cannabinoid backbone in an attempt to discover useful drugs that may be used in 
the treatment of many diseases.  
 
However, cannabis is used in modern medicine for the treatment of emesis in chemotherapy where 
Dronabinol (THC (72)) and Nabilone (a synthetic variant of THC (72)) which has increased water 
solubility) are available on prescription as anti emetics (Perrine, 1996). 
 
As well as being useful anti-emetics, cannabinoids appear to have therapeutic value as antispasmodics, 
analgesics and appetite stimulants and may also have potential in the treatment of epilepsy, glaucoma 
and asthma (Ashton, 1999). The biomedical effects (Martin, 1997/1998; Ashton, 1999; Gurley, 1998; 
Marmor, 1998; McGinn, 1999; Edwards, 1999; Hollister, 1998 & Ling, 2000) and the debate 
surrounding their use (Grinspoon, 1999; Clark, 2000; Morris, 1997 & Gowing, 1998) have been 
studied and reviewed by many authors. 
 
As mentioned, all drugs including cannabis have adverse affects. These effects have been reviewed (Hall, 1998; Ashton, 2000, 
Ashton 2001 & Holdcroft, 2000). Some of the main areas for concern amongst the medical community with regard to adverse 
effects are chronic effects such as immunosuppression, chronic bronchitis, negative reproductive effects, negative behavioural 
effects, dependence syndromes, impaired cognitive function and psychosis (Hall, 1998). Acute effects such as panic attacks, 
anxiety, paranoia, elevated blood pressure and impaired cognitive function have been reported (Hall, 1998). 
 
 
 
 
 
Section 13.7: Cannabis and Chemical Variation. 
 
As mentioned in the botany section above, the many varieties of Cannabis sativa L. are categorised 
further into three chemically different types or phenotypes. There is the drug-type (containing high 
levels of THC (72)), intermediate –type (intermediate levels of THC (72)) and fibre-type (low-level of 
THC (72)).  For the purpose of this thesis hemp will refer to fibre-type cannabis, while herb will be the 
term used to describe intermediate-type and drug-type cannabis. The psychoactive material referred to 
is THC (72). The level of a particular cannabinoid, be it THC (72) or CBD (74) are used to differentiate 
varieties of cannabis which are chemically different (Nahas, 1984).  
 
The three phenotypes are quantitatively defined as follows. 
 
• Drug type (THC (72) > 1% and CBD (74) = 0); plants growing in warm climates:  
Mexico, South Africa 
• Intermediate type (THC (72)  > 0.5% and CBD (74) > 0.5%); plants grown in warm climates 
around the Mediterranean. 
• Fibre type (THC (72)  < 0.3% and CBD (74)  > 0.5%); Plants grown in temperate climates such as 
Ireland, France. 
              
A method of classifying variants according to the following ratio of the identified cannabinoids has 
been suggested (Fetterman, 1971).  
 
      
 
If the ratio is >1.0, the preparation is classified as drug “phenotype” 
It the ratio is <1.0, the preparation is classified as fibre “phenotype.” 
 
However de Meijer et al. (1992) acknowledged the limitations of the approach by Fetterman et al. 
which failed to allow for an intermediate variety. de Meijer et al. (1992) used the following criteria for 
the classification of phenotypes according to cannabinoid content, including provision for an 
intermediate phenotype (Table 13.2). 
 
Phenotype [THC] (%) [CBD] (%) [THC](%) / [CBD] (%) 
Fibre type < 0.5 ≥ 0.5 < 1 
Intermediate type ≥ 0.5 ≥ 0.5  
Drug type ≥ 0.5 < 0.5 > 1 
 
Table 13.2: Phenotype characterisation criteria as defined by de Meijer et al. (1992). 
 
CBN (73) was excluded from the study as the authors used values from fresh plants, which had 
extremely low levels of CBN (73). 
 
The ideal, with regard to research conducted clandestinely for the purpose of illicit drug production has 
been to develop drug-type varieties with ever increasing THC (72) levels (Szendrei, 1997/1998). 
However the other extreme has been to develop fibre type cannabis with low levels of THC (72) and 
high levels of CBD (74) for industrial use (paper, rope etc.) (Szendrei, 1997/1998). Although the 
growth of drug-type Cannabis plants is prohibited, the growth of hemp is permitted by the E.U. and 
practised in the Republic of Ireland under license from the Dept. of Health and Children  (European 
Union, 1989). 
 
There is also an EU subsidy, which is available to farmers interested in growing hemp and since its 
introduction the amount of hemp harvested in the EU has increased from 5,840 hectares in 1980-1982 
to 45,000 hectares in 1999 (Mignoni, 1997/1998). Ireland has been involved in the EU programme 
since 1998 (Maguire, 1999). The main compliance required for the licence is that the THC (72) content 
of the hemp must not exceed 0.3% in order to comply with EU Council Regulations (European Union, 
1984).  
 
 
Section 13.8: Extraction and Detection of Cannabinoids. 
The cannabinoids are easily extracted from plant material or resin using any of a variety of 
organic solvents. The stability of the cannabinoids in different solvents has been reviewed 
(Gough, 1983), however petroleum ether seems to be a suitable choice if one intends to analyse 
the extract soon after extraction. 
 
Thin layer chromatography has also played an important role in the identification of the plant 
Cannabis sativa L. and the products derived from it. With spray reagents such as Fast Blue B 
produce specific colours which also help to identify specific cannabinoids (Segelman, 1976). 
Nowadays techniques such as Gas Chromatography with Flame Ionisation Detection (GC-FID), 
Gas Chromatography with Mass-Spectrometry (GC-MS) and High Performance Liquid 
Chromatography with Ultra-Violet Detection (HPLC-UV) are the main tools used for the 
identification and investigation of Cannabis sativa L. plants and products.  
 
In Cannabis, THC (72) is present as its carboxylic acid (THCA). GC analysis will give the ‘total’ 
THC (72) present, i.e. the THC (72) originally in the sample, together with that formed by 
decarboxylation of the cannabinoid acid at elevated temperatures in the GC (Gough 1983). As 
most Cannabis products are smoked, GC analysis mimics the smoking process and gives a better 
idea of the potency of the crude drug under investigation (Baker, 1981). Otherwise the samples 
have to be derivatised before GC analysis in an attempt to preserve the acids (Turnet, 1974). GC 
has been used to good effect by many workers in the determination of THC (72), CBD (74) and 
CBN (73) (Stephanidouu, 1993, 1998 & 2000; Rasmussen, 1975; Fairbairn, 1974; Rowan, 1977 
and Zeeuw, 1972). The official method for the determination of THC (72) in hemp, as published 
by the EU, is in fact a GC method (European Union, 1989). Originally this method used a packed 
column method and has only recently been upgraded to a capillary column method (European 
Union, 2000). 
 
 
 
 
 
 
 
 
 
GC-MS has also been used in the determination of cannabinoids in the Cannabis sativa L. 
(Yotoriyama, 1992;  Lercker, 1992 and Ross, 2000). 
 
 
HPLC-UV analysis has been used with good effect in the analysis of cannabis especially in the analysis 
of both neutral cannabinoids and their acid derivatives (Baker, 1980; Baker, 1981; DeBruyne, 1994; 
Kanter, 1979; Smith, 1975; Smith, 1976 and Turner, 1982). 
 
DNA testing has also begun to appear in the literature as a means of positively identifying Cannabis 
sativa L. and its derived products (Linacre, 1998, Gigliano, 1998). 
 Section 13.8.1: Quantitation of the Cannabinoids. 
 
Quantitation of THC (72), CBN (73) or CBD (74) via GC-FID is normally achieved via external 
standardisation, using standard solutions of THC (72), CBN (73) or CBD (74) respectively. However 
Poortman-van der Meer and Huizer (1999a) cast doubt on the accuracy of using THC (72) as a standard 
for a number of reasons. Firstly THC (72) is an oil and is supplied as a solution in ethanol, provided at 
a concentration specified by the supplier.  The analyst  has to prepare working standards from this 
solution introducing a possible error. Secondly, THC (72) is unstable and the solutions are generally 
labelled to state that the concentration is approximately 95% (contributing significant uncertainty to the 
measurement). Ideally analysts would be using a standard which is a solid crystalline material that can 
be acquired in high purity. However when one is using a flame ionisation detector then the method 
known as the effective carbon number (ECN) method can be considered as an approach to minimising 
these potential inaccuracies. 
 
This approach was studied extensively by Sternberg et al. (1962) and who claimed that it is possible to 
predict a molecule’s response in a FID detector. As THC (72), CBN (73) and CBD (74) have the same 
number of carbons, their relative response factors should not differ by much. Therefore, if one predicts 
the response for THC (72), CBN (73) and CBD (74) then one could feasibly use either CBD (74) or 
CBN (73) and a correction factor for THC (72) as an indirect standard for the determination of the 
other molecules. CBD (74) and CBN (73) are stable crystalline solids and are therefore very suitable 
for use as indirect standards in the quantitation of THC (72). Poortman-van der Meer et al. (1999a) 
found that the predicted and experimental response factor values for THC (72), CBN (73) and CBD 
(74) were in agreement and hence the use of CBD (74) as a means of quantifying THC (72) was 
justifiable. The following equation applies: 
 
 
Section 13.9: Objectives 
 
The objectives of the work presented here were to determine the levels of THC (72), CBN (73) and 
CBD (74) in samples of cannabis resin and cannabis herb seized and/or grown in the Republic of 
Ireland. The Garda National Drugs Unit supplied the samples to the Department of Pharmacognosy.  
 
The Department of Agriculture, Food and Forestry supplied samples of hemp, grown on farms holding 
licenses from the Department of Health and Children, to grow hemp. The THC (72) content of these 
samples was determined in order to validate compliance with EU regulations (European Union, 1989), 
requiring a content of less than 0.3% THC (72)). The CBD (74) and CBN (73) content were also 
determined in order to determine the phenotype of the Cannabis sativa L. analysed. 
 
The method of analysis was petroleum ether extraction followed by GC-FID analysis. It was hoped that 
for the first time ever a comment could be made on the potency of cannabis seized in the Republic of 
Ireland. From the data generated the phenotype of the cannabis product analysed was determined. 
 
In addition the THC (72) content as estimated using THC (72) itself as the standard, was compared to 
the THC (72) content estimated using CBD (74) as an indirect standard for all of the samples analysed 
and any statistical differences assessed.  
Section 14.1: Instrumentation & Solvents 
 
GC-FID 
 
The GC-FID instrument used in all of the experiments detailed below was a Perkin Elmer Sigma 3 Gas 
Chromatograph with a flame ionisation detector attached.  The column used was a 2 metre glass packed 
column, with a 3% OV-17 stationary phase. Data output from the system was collected with the aid of 
a Shimadzu CR-6A integrator. 
 
Miscellaneous Instruments 
 
All weighing was carried out using a Sartorius BP110 S analytical weighing balance. A generic flask 
shaker was used to agitate samples for long periods of time as required. A Heidolph, Labrota 4000 
rotary evaporator was used to evaporate solvents under reduced pressure as required. A series of 
microlitre syringes were used to measure small volumes of fluid (10 µl, 25 µl and 100µl). 
 
Solvents 
 
All solvents were HPLC grade unless otherwise stated. 
 
Section 14.2: Preparation of standard curves for 
quantitation of THC (72), CBD (74) and CBN (73). 
 
Preparation of analytical standards for preparation of standard curves used in the analysis of samples 
1-18. 
 
Preparation of CBD (74) standard: A 5 mg/ml CBD (74) standard was prepared by dissolving 5 mg of 
CBD (74) (Sigma-Aldrich) in 1 ml of ethanol.  
 
 
 
 
Preparation of THC (72) standard: A working standard of THC (72) was 
prepared by dissolving the 200 µl of 25 mg/ml THC (72) (Sigma-Aldrich) 
in ethanol. The resulting solution was a 5 mg/ml THC (72) standard.  
 
Preparation of Internal Standard solution: A 10 mg/ml internal standard 
solution was prepared by dissolving 10 mg of Androstene-3, 17-dione 
(Sigma-Aldrich) in 1 ml of ethanol.  
 
Preparation of combined standard: The 10 mg/ml internal standard 
solution, and the 5 mg/ml THC (72) standard were used to prepare the 
analytical standards. The details of the volumes of each solution required 
to achieve the desired concentrations of the analytical standards are 
outlined below in Table 14.2.1. The standards were made up in 500 µl 
vials, which were sealed with the septum caps that could be crimped 
closed. The standards were refridgerated until required for analysis. New 
standard solutions were made up every two weeks. 
 
Volume of 5 mg/ml 
THC (72) standard 
Volume of 10 mg/ml 
AD internal standard 
Volume of Blank 
ethanol 
Final Volume Final concentration of 
each cannabinoid 
Final concentration of AD 
internal standard 
20µl 40µl 340µl 400 µl 0.25 mg/ml 1.00 mg/ml 
40µl 40µl 320µl 400 µl 0.50 mg/ml 1.00 mg/ml 
60µl 40µl 300µl 400 µl 0.75 mg/ml 1.00 mg/ml 
80µl 40µl 280µl 400 µl 1.00 mg/ml 1.00 mg/ml 
100µl 40µl 260µl 400 µl 12.50 mg/ml 1.00 mg/ml 
 
Table 14.2.1: Volumes required and concentrations achieved for the preparation of cannabinoid standards 
 
Preparation of analytical standards for preparation of standard curves used in the analysis of samples 
18-87. 
 Preparation of CBD (74) standard: A 5 mg/ml CBD (74) standard was prepared by dissolving 5 mg of 
CBD (74) (Sigma-Aldrich) in 1 ml of ethanol.  
 
Preparation of CBN (73) standard: A 5 mg/ml CBN (73) standard was 
prepared by dissolving 5 mg of CBN (73) (Sigma-Aldrich) in 1ml of 
ethanol.  
 
Preparation of THC (72) standard: A working standard of THC (72) was 
prepared by dissolving the 200 µl of 25 mg/ml THC (72) (Sigma-Aldrich) 
in ethanol. The resulting solution was a 5 mg/ml THC (72) standard.  
 
Preparation of Internal Standard solution: A 10 mg/ml internal standard 
solution was prepared by dissolving 10 mg of Androstene-3, 17-dione 
(Sigma-Aldrich) in 1 ml of ethanol.  
 
Preparation of combined standard: The 10 mg/ml internal standard 
solution, and the 5 mg/ml THC (72) standard were used along with the 5 
mg/ml CBN (74) and the 5 mg/ml CBD (73) standards to prepare the 
combined analytical standards. The details of the volumes of each solution 
required to achieve the desired concentrations of the analytical standards 
are outlined below in Table 14.2.2. The standards were made up in 500 µl 
vials, which were sealed with the septum caps, which were closed by 
crimping. The standards were refrigerated until required for analysis. 
New standard solutions were made up every two weeks. 
 
Volume of 5 
mg/ml THC (72) 
standard 
Volume of 5 
mg/ml CBD (74) 
standard 
Volume of 5 
mg/ml CBN (73) 
standard 
Volume of 10 
mg/ml AD 
internal standard 
Volume of 
Blank ethanol 
Final 
Volume 
Final 
concentration of 
each cannabinoid 
Final concentration 
of AD internal 
standard 
20µl 20µl 20µl 40µl 320µl 400 µl 0.25 mg/ml 1.0 mg/ml 
40µl 40µl 40µl 40µl 280µl 400 µl 0.50 mg/ml 1.0 mg/ml 
60µl 60µl 60µl 40µl 240µl 400 µl 0.75 mg/ml 1.0 mg/ml 
80µl 80µl 80µl 40µl 200µl 400 µl 1.00 mg/ml 1.0 mg/ml 
100µl 100µl 100µl 40µl 160µl 400 µl 1.25 mg/ml 1.0 mg/ml 
 
Table 14.2.2: Volumes required and concentrations achieved for the preparation of cannabinoid standards 
 
Preparation of individual 0.5 mg/ml standards of THC (72), CBD (73), CBN (74) and AD  
 
One in ten dilutions of the previously prepared 5 mg/ml standards of THC (72), CBD (73), CBN (74) 
were prepared by dissolving 100 µl of respective standard in 900 µl of ethanol. A 5 mg/ml solution of 
standard AD was prepared by making a one in twenty dilution of the 10 mg/ml standard with ethanol. 
Chromatographic Conditions 
 
The chromatographic conditions used are outlined in Table 14.2.3 below.  
Parameter Value 
Column Type Glass Packed 
Column Length  2 metres 
Column i.d. 2 mm 
Column o.d. 6 mm 
Stationary Phase  3% OV-17 
Support Phase Chromosorb G-AW-DMCS, 80-100 mesh. 
Mobile Phase Nitrogen 
Mobile Phase Flow Rate 30 ml/min 
Oven Temperature 235°C 
Injector Temperature 265°C 
Detector Temperature 265°C 
Injection Volume 1 µl 
Chart Speed  2 mm/min 
 
Table 14.3: Chromatographic conditions used for the analysis of the Cannabinoid standard solutions. 
 
Analysis 
Each of the individual solutions containing either 5 mg/ml THC (72), CBD (74) or CBN (75) were 
analysed in duplicate in order to determine chromatographic data for each of the standards. The 
analytical standards (0.25 mg/ml, 0.50 mg/ml, 0.75 mg/ml, 1.00 mg/ml and 1.25 mg/ml of THC (72), 
CBD (74) and CBN (73)) were analysed in duplicate as required during the course of the work. The 
results obtained are discussed in section 15. 
 
 
 
  
 
 
Section 14.3: Preparation and Analysis of Cannabis products using GC-FID. 
 
It is worth noting at this point that the method outlined below for the extraction of cannabinoid material 
from hemp is the same as that set down by the E.U. Commission Regulation No 1164/89 (Annex C). 
 
Origin of Cannabis products. 
The Garda National Drugs Unit (GNDU) provided the herbal samples and the resin samples. The 
Department of Agriculture, Food and Forestry provided the hemp samples. 
 
Preparation of Cannabis products. 
All cannabis products (hemp, resin, and herb) were firstly dried in an oven at 40°C until constant 
weight. The products were then powdered in a mortar and pestle. The resulting triturates were reduced 
to semi-fine powders with the aid of a 1,000 meshes per cm2 sieve as required. The powders were 
transferred to a sealed glass vial, which was stored in the dark until further processed. The samples 
were generally extracted and analysed by GC-FID within 48 hours of powdering. 
 
Preparation of analytical solutions. 
A 1mg/ml androsten-3,17-dione (I.S.) was prepared by dissolving 100mg of androsten-3,17-dione in 
100 ml of ethanol. This solution was used for the reconstitution of cannabis residues after extraction 
(see section 14.2.4). 
 
Extraction of cannabis products. 
The amount of powder taken for extraction depended on the type of Cannabis product (resin, hemp or 
herb) under analysis. The weights taken for each are shown in Table 14.3.1 (below). 
 
  
 
 
Cannabis Product Amount taken (mg) for 
extraction 
Resin 100 mg 
Herb 50 mg 
Hemp 2000 mg 
 
Table 14.3.1: Amounts of powdered Cannabis product taken for extraction. 
 
The extraction followed the same path in the case of each product-type. The required amount of 
product was accurately weighed out into a plastic weighing boat (see Table 14.3.1). The contents of the 
weighing boat were quantitatively transferred to a 250ml ground glass stoppered conical flask with the 
aid of 5 ml of petroleum ether. A further 30ml of petroleum ether was added and the flask was 
stoppered. This was carried out in duplicate for each sample. The flasks were then shaken mechanically 
for 30 minutes in the case of resin and herb. The flasks were shaken for 24 hours in the case of hemp 
samples. Once the extracts had been shaken for the required amount of time they were taken from the 
shaker and filtered into a 10 ml round bottomed flask. The solvent was then evaporated under reduced 
pressure using a rotary evaporator. The round bottomed flasks were allowed to cool before having the 
residue reconstituted in Petroleum Ether.  
 
In the case of herb and resin extractions, residues were reconstituted in 2 ml of 1.00 mg/ml androsten-
3,17-dione internal standard . In the case of hemp extractions, residues were reconstituted in 10 ml of 
1.00 mg/ml androsten-3,17-dione internal standard. Solutions were refrigerated until required for 
analysis. 
 
 
 
 
 
  
 
 
Chromatographic Conditions 
 
The chromatographic conditions are as follows (see Table 14.3.2).  
Parameter Value 
Column Type Glass Packed 
Column Length  2 metres 
Column i.d. 2 mm 
Column o.d. 6 mm 
Stationary Phase  3% OV-17 
Support Phase Chromosorb G-AW-DMCS, 80-100 mesh. 
Mobile Phase Nitrogen 
Mobile Phase Flow Rate 30 ml/min 
Oven Temperature 235°C 
Injector Temperature 265°C 
Detector Temperature 265°C 
Injection Volume 1 µl 
Chart Speed  2 mm/min 
 
Table 14.5: Chromatographic conditions used for the analysis of the Cannabis product extracts. 
 
Analysis 
Extraction residues of resin, herb and hemp which had been reconstituted in the appropriate volume of 
1 mg/ml androstene-3,17-done were analysed in duplicate under the chromatographic conditions 
outlined. The results are discussed in section 15. 
Section 15.1: Assessment of suitability of GC-FID method 
for the analysis of the cannabinoids. 
 
The objective of the work presented here was to quantify the three key cannabinoids (THC (72), CBN 
(73) and CBD (74)) in samples of cannabis resin and herb supplied by the Garda national drugs unit 
and in hemp supplied by the Department of Agriculture, Food and Forestry. The analytical method, 
employed for this task utilised GC-FID. The method chosen for the analysis was an official method of 
the EU for the analysis of THC (72) in hemp (European Union, 1989).  Many other workers (Turner, 
1984 & Parker, 1974) have used a similar method not only for THC (72) analysis, but also for CBN 
(73) and CBD (74) in cannabis resin and cannabis herb. The method was set up and assessed for system 
suitability (resolution, peak tailing, efficiency and linearity), the results of which follow.  The official 
EU method has been modified by using a capillary column method in the last year (European Union, 
2000), and would presumably be considered a better method. Time did not permit a comparison of the 
original and revised protocols but the future work in this area would have to be conducted using the 
revised method.  
                                                                                                 
When the analysis began the only standard available was THC (72). Subsequently a CBD (74) standard 
became available. According to Poortman-van der Meer et al. CBD (74) is a more useful standard as it 
can be used as a standard to quantitate CBD (74) and also as a surrogate standard in the accurate 
quantitation THC (72) and CBN (73)(1999a). 
 
The chromatographic parameter values are presented in Table 15.1.1, and are the averages of six 
replicate injections of a 0.5 mg/ml standard, where the relative standard deviations were calculated to 
be less than 4% in all cases. The peaks were identified by injection of standard solutions containing 
individual components (e.g. THC (72) in ethanol etc.). The peak area ratios of CBD (74), THC (72) 
and CBN (73) with respect to the area of AD, for six replicate injections of the 0.5 mg /ml standard are 
shown in Table 15.1.2. 
 
  
Peak Peak 
Identity 
tR mins tR Relative to 
AD 
Capacity 
Factor 
Resolutionpeaks Asymmetry Theoretical 
Plates 
1 CBD (74) 7.68 mins 0.37 29.71 -- 1.0 943.22 
2 THC (72) 10.41 mins 0.50 40.66 2.741,2 1.0 1735.55 
3 CBN (73) 12.96 mins 0.62 50.85 2.552,3 1.1 1194.95 
4 AD 20.84 mins -- 82.35 3.943,4 1.1 1736.72 
 
Table 15.1.1: Chromatographic parameters for six replicate injections of 0.5 mg/ml combined THC (72), CBN (73), CBD (74) 
and 1.0 mg/ml androstene dione standard. 
 
 
Cannabinoid CBD (74) THC (72) CBN (73) 
Peak Area Ratio 0.48 0.38 0.45 
 
Table 15.1.2: Peak area ratios of CBD (74), THC (72) and CBN (73) with respect to the area of AD, for six replicate injections of 
the 0.5 mg/ml standard. 
 
A typical chromatogram of the combined standard is shown in the Figure 15.1.1 below for the 0.5 
mg/ml combined standard, which also contained androstene dione at a level of 1.0 mg/ml AD. 
 
 
 
 Figure 15.1.1: 0.5 mg/ml THC (72), 0.5 mg/ml CBD (74) and 0.5 mg/ml CBN (74) combined standard which also contained 
androstene dione at a level of 1.0 mg/ml AD, in ethanol. 
 
The first compound to elute from the mixture after the solvent front, in the example chromatogram 
shown in Figure 15.1.1, was the CBD (73), which eluted at circa 7.68 minutes (relative retention w.r.t. 
AD was 0.37). The next compound to elute was the THC (72), which had a retention time of 10.5 
minutes (0.50 relative to the internal standard, AD). The final cannabinoid to elute was the CBN (73), 
eluting at a retention time of 13.07 minutes (0.62 relative to androstene dione). The final peak to elute 
was the androstene dione peak itself, which eluted at 21.02 minutes. The resolution was adequate in the 
case of all of the peaks, as the calculated value exceeded 2 units in each case, which allowed adequate 
separation and easy integration (Dolan, 2000). The peak tailing was acceptable as the values were 
below 1.2 units  (Snyder, 1997). The capacity factors seemed high (see Table 15.1.2), when compared 
with previous work presented in this thesis for HPLC analysis, however one must be mindful that the 
non-retained volumes in GC can be much lower with such high flow rates. On visual inspection of the 
example chromatogram (Figure 15.1.1) it is clear that the peaks have eluted within an acceptable time. 
Although one can see peak broadening for the AD peak, integration of the peak was achieved without 
difficulty. The column efficiency values seemed low for packed column GC, as one would expect values  
in the region of 4000-5000 plates per 2 metre column (Baugh, 1993 ).  
 
15.1.1: Assessment of the precision of the method. 
  
The precision of the method was assessed by analysing the retention times and peak areas for the six 
replicate injections. The relative standard deviation for the peak areas and retention times are shown 
below in Table 15.1.1.1. 
 
Parameter Peak 1 (73) Peak 2 (72) Peak (74) Peak 4 (A.D.) 
tR R.S.D 0.03 % 0.01 % 0.02 % 0.01 % 
Area R.S.D. 2.78 % 2.41 % 1.76 % 2.12 % 
 
Table 15.1.1.1: Relative standard deviations of peak area and retention time for CBD (74), THC (72), CBN (73) and AD.  
 
As can be seen in all cases the relative standard deviations were low (< 3%) and so the method was 
considered to be precise for the analysis of the cannabinoids.  
 
15.1.2: Assessment of the selectivity of the method. 
 
The selectivity of the method was not assessed as it was an official method published by the European 
Union (European Union, 1989). 
 
15.1.3: Assessment of the linearity of the method. 
 
The linearity of the method for each of the standards is illustrated with the combined THC (72), CBD 
(74) and CBN (73) at the levels 0.25 mg/ml, 0.50 mg/ml, 0.75 mg/ml, 1.0 mg/ml and 1.5 mg/ml (each 
containing AD at 1.0 mg/ml). The data used to construct a standard curve is shown in Table 15.1.2.1, 
below, and the standard curve is shown in Figure 15.1.2.1. The averaged peak area ratio for duplicate 
injections was calculated for each peak in the chromatograms, relative to the AD peak. The peak area 
ratio values were plotted against concentration and are shown in Figure 15.1.2.1 below. The R2 value 
was used to assess the linearity between a group of points on a graph and will have a value close to 
one when a set of data show a linear relationship. The R2 values calculated for each of the fitted 
trendlines using Excel was 0.9993 in the case of CBD (74), 0.9992 in the case of THC (72) and 0.9996 
in the case of CBN (73). This high degree of linearity is excellent, however as one can see the slope of 
the THC (72) is somewhat lower, 0.0008, than the value, 0.001, recorded for both the CBD (72) and 
CBN (73) curves.  
 
Concentration (mg/ml) CBD peak area ratio THC peak area ratio CBN peak area ratio 
0.25 0.258 0.207 0.249 
0.50 0.52 0.427 0.506 
0.75 0.782 0.634 0.764 
1.00 1.052 0.85 1.007 
1.25 1.281 1.036 1.242 
 
Table 15.1.2.1: Peak area ratios for cannabinoid standard curve. 
 
The example shown is not an isolated incident, the slope of the THC (72) standard curves were 
consistently lower than the slopes of the other two standard curves for the CBD (74) and CBN (73). 
 
Cannabinoid Standard Curve (P lot of peak area versus 
cannabinoid concentration (mg/L)) 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 500 1000 1500 2000
Concentration (mg/L)
P
ea
k 
A
re
a 
R
at
io
CBD 
THC
CBN
Linear (THC)
Linear (CBN)
Linear (CBD )
 
Figure 15.1.2.1: Cannabinoid standard curve for THC (72), CBN (73) & CBN (74). 
 
This was a cause for concern, as the contribution of Poortman-van der Meer and Huizer (1999a) 
suggested that the responses for all three should be quite similar (i.e. one would expect similar slope 
values). It was decided that the oily liquid nature of the THC (72) standard was most likely the cause in 
this instance, as the CBN (73) and CBD (74) were solid and thus were more easily prepared to 
concentration with known weights of the relevant standard. The THC (72) standard was purchased 
from Sigma-Aldrich and had already been prepared to a particular concentration (25 mg/ml). Further 
the label states that purity of this unstable standard is approximately 95% which is poor when one 
considers that this is supposed to be a primary standard, which may be used for the quantitation of a 
drug. There is simply too much room for error hence the CBD (74) would be used to estimate the THC 
(72) concentration, where possible. It is obvious this was not possible for samples 1-19, as the only 
standard curve prepared during the analysis of those samples was based on the THC (72) standard. The 
standard curves prepared for THC (72) analysis of sample 20 onwards were adjusted using the 
following formula (Poortman-van der Meer, 1999a) (Equation 15.1.2.1). 
 
 
 
Using the CBD (74) as a replacement standard for THC (72) should have provided a more accurate 
result.  How this was done is illustrated below for the curve shown in Figure 15.1.2.1.  The actual data 
that was recorded for each of the three standards over the concentration range investigated is shown in 
Table 15.1.2.1 (above). 
 
By inserting the peak area ratio data for CBD (74) and THC (72) into equation 15.1.2.1 at each specific 
concentration a corrected set of concentrations for the peak area ratios of THC (72) is calculated. The 
values calculated here are shown in Table 15.1.2.2.  
 
 
 
 
 
Corrected THC (72) 
concentration (mg/ml) 
Observed peak area ratio for THC 
(72) 
0.201 0.207 
0.411 0.427 
0.609 0.634 
0.810 0.85 
1.013 1.036 
 
Table 15.1.2.2: Data for corrected THC (72) standard curve. 
 
A standard curve is plotted showing the uncorrected THC (72) data (Table 15.1.2.1) and the corrected 
THC (72) data (Table 15.1.2.2). The corrected THC (72) standard curve is shown in red. (See Figure 
15.1.2.2).  
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Figure 15.1.2.2: Standard curve for THC uncorrected and corrected. 
 A plot of the corrected THC (72) data and the CBD (74) and CBN (73) data is shown below. The 
trendlines for CBD (74) and THC (72) are superimposed (See Figure 15.1.2.3). 
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Figure 15.1.2.3: Corrected cannabinoid standard curve for THC (72), CBN (73) & CBN (74). 
 
If one compares Figure 15.1.2.2 and Figure 15.1.2.3 one can clearly see that the slope of the THC 
standard curve has increased and the response is brought closer to that of the CBN (73) and the CBD 
(74) as one would expect. The slopes of the corrected THC (72) curve, the CBN (73) curve and the 
CBD (74) curves are 0.001 in all cases. 
 
This correction was applied to all standard curves used for the quantitation of THC (72) from sample 
20 onward (72). As mentioned above no CBN (73) standard curve was available for samples 20-29 
however by measuring the peak area ratio for the CBN (73) peak and inserting it into equation 15.1.2.2, 
a corrected standard curve for CBN (73) could be derived. 
 
 
 
A THC (72) standard curve was prepared for use during the analysis of samples 1-19, but no CBD (74) 
or CBN (73) standards were available when those samples were being analysed. The amount by which 
the corrected curves for THC (72) deviated from the actual value provided a crude correction of the 
THC (72) content in these samples. It was considered futile to try to predict the CBN (73) and CBD 
(74) contents of these samples, as the error in the values would very likely be large. 
 
 
Section 15.2: Cannabinoid content of the Cannabis products 
 
15.2.1 Cannabinoid content of Hemp. 
 
The hemp grown under licence from the Department of Health and Children was analysed for content 
of THC (72), CBN (73) and CBD (74). In all 21 samples were analysed, 13 harvested in 1998 and 8 
harvested in 1999. The samples were grown in the counties Cavan, Roscommon, Sligo, Clare, Kerry, 
Mayo and Tipperary. The varieties selected for cultivation were all registered EU varieties of Cannabis 
sativa. The main variety, which was grown, was Fedora 19 but there was also one case of Ferimon and 
one case of Futura. All of these varieties are well known fibre type plants, producing low levels of 
psychoactive drug (Mignoni, 1997/1998). The plants were harvested in September/October each year. 
Quantitation of the cannabinoids in the sample was achieved using a standard curve derived from all 3 
cannabinoids which were individually identified on the basis of retention time relative to the internal 
standard included in the re-constitution solution (see Section 14.2). A typical chromatogram obtained 
with a hemp sample is shown below (see Figure 15.2.1.1 A). 
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Figure 15.2.1.1: Typical chromatograms for hemp (A), resin (B) and herb (C). 
A peak area ratio for each cannabinoid with respect to the AD peak was calculated. The peak area 
ratios for the respective cannabinoids were interpolated from the respective graphs. In the case of THC 
(72) the standard curve was corrected using CBD (74) standard curve data, according the equation of 
Poortman-van der Meijer et al. (1999a) and the peak area ratio for the THC (72) (relative to AD) was 
interpolated from the corrected graph. The method for correcting the THC (72) data has been outlined 
in detail above. Once interpolated, a value in mg/L was returned, this value was converted in % 
cannabinoid via the following equation (Equation 15.2.1.1): 
 
 
Equation 15.2.1.1: Calculation used to estimate percent cannabinoid. 
 
The content of THC (72), CBD (74) and CBN (73) for the 21 samples of hemp analyzed are shown in 
Table 15.2.1.1 below. Samples 68-76 were supplied and analysed as part of the 1999 years harvest. 
Samples 77-88 were supplied and analysed as part the 1998 harvest. 
 
Sample Number Variety % THC (72) % CBN (73) % CBD (74) 
68 Fedora 19 0.05 0.08 0.80 
69 Fedora 19 0.03 0.06 0.95 
70 Fedora 19 0.06 0.12 1.22 
71 Fedora 19 0.17 0.08 1.68 
72 Ferimon 0.08 0.13 1.68 
73 Fedora 19 0.18 0.06 1.19 
74 Fedora 19  0.01 0.09 1.26 
75 Futura 0.03 0.08 0.58 
76 Fedora 19 0.01 0.02 1.29 
77 Fedora 19 B.L.O.Q* 0.15 2.00 
78 Fedora 19 B.L.O.Q* 0.07 2.86 
79 Fedora 19 0.05 0.03 1.70 
80 Fedora 19 B.L.O.Q* 0.04 1.41 
81 Fedora 19 0.04 0.07 0.78 
82 Fedora 19 0.06 B.L.O.Q* 1.80 
83 Fedora 19 0.02 0.04 2.15 
84 Fedora 19 0.27 B.L.O.Q* 2.72 
85 Fedora 19 0.01 0.10 1.99 
86 Fedora 19 B.L.O.Q* B.L.O.Q* 2.67 
87 Fedora 19 B.L.O.Q* B.L.O.Q* 1.13 
88 Fedora 19 0.12 B.L.O.Q* 1.89 
 
Table 15.2.1.1: THC (72), CBN (73) and CBD (74) contents of hemp grown in the Republic of Ireland 1998-1999 (* B.L.O.Q. 
refers to the fact that the cannabinoid was below the limit of quantitation). 
As can be clearly seen from the results (see Table 15.2.1.1) the THC (72) content for the hemp was 
never greater than 0.3% which is the limit set down by the EU (1984). Therefore all of the farmers who 
had grown the hemp for industrial purposes in the Republic of Ireland satisfied the licence and it would 
appear that no drug type plants were being grown on these farms on the strength of the above results. 
Some of the values were below the level of quantitation (B.L.O.Q.). The average amount of THC (72) in 
the samples was 0.06% THC (72) with a range of 0.01% to 0.27%. The level of CBN (73) was also 
quite low in most cases with the average of 0.06% (range 0.02% to 0.15%) calculated. CBD (74) was 
the major cannabinoid and was found at a average concentration of 1.61% CBD (74), calculated for 
the 21 samples analysed. The range of CBD (74) content was found to be 0.18% CBD (74) to 2.86% 
CBD.  
 
Hemp normally has levels of CBD (74) greater than 0.5% (Nahas, 1984). Stefanidou et al. found that of 
29 herbal cannabis plants analysed 16 were hemp, with an average CBD (74) content of 0.20% (range 
0.0004% to 1.43%) (1993). In a study by de Meijer et al., out of 97 accessions of Cannabis sativa 
evaluated for cannabinoid content, 60 were considered to be of the fibre type (1992). The average THC 
(72) content was found to be 0.22%, with a range of 0.06% to 0.42% THC (72). The average CBD (74) 
content was found to be 1.18%, with a range of 0.55% to 2.19% CBD (74). Among the 60 samples 
which were analysed were Futura (average THC=0.23%, average CBD=1.49%, n=2), Ferimon 
(average THC=0.17%, average CBD=1.16%, n=1) and Fedora 19 (average THC=0.26%, average 
CBD=1.41%, n=1).  When one compares data of de Meijer et al. (1992) and Stefanidou et al. (1993) to 
the data presented here it is clear that the CBN (73) and THC (72) levels were lower than the averages 
found by de Meijer et al.  Further the average CBD (74) content of hemp grown in the Republic of 
Ireland is higher than that of the 60 accessions evaluated by de Meijer et al. (1.18% CBD versus 1.61% 
CBD). A bar chart graph of CBD (74) content versus variety and origin (Irish hemp or hemp analysed 
by de Meijer et al. (1992)) is shown below for the three varieties grown in the Republic of Ireland (see 
Figure 15.2.1.2). As can be seen from the chart, the CBD (74) content of the Ferimon and the Fedora 
varieties were comparable, while the CBD (74) content for the Futura variety was lower for Irish 
hemp. 
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Figure 15.2.1.2: A bar chart graph of CBD (74) content versus variety an origin (Irish hemp or hemp analysed by de Meijer et al. 
(1992)) for the three varieties grow in the Republic of Ireland. 
 
15.2.2 Cannabinoid content of Herbal Cannabis 
 
There were very few herb samples submitted for analysis by the Garda National Drugs Unit (n=5) 
compared to the resin samples (n=62). This indicates that resin is the prevalent form of cannabis being 
abused in the Republic of Ireland. This would also have been the case in the U.K., but in recent times 
clandestine cultivation of herbal cannabis has increased dramatically (Bone, 1997/1998), and it may 
not be long before an increased amounts of in Irish grown herbal cannabis appear on the market. 
Three of the samples (Early ’98, Rosslare ’97 and Dutch ’97) were seized from individuals attempting 
to enter the State in Rosslare ferry port. Another sample referred to here as ‘’skunk’’ was seized in 
Dublin in 1998. The final sample, which was analysed, was seized again in Dublin but in this case the 
plant was being cultivated domestically. This sample was presented in a plastic bag bearing a label 
which read ‘’Cannablitz’’ As with the hemp analysis all of the samples were analysed after the 
adoption of the cannabinoid standard containing THC (72), CBN (73) and CBD (74). The correction 
procedure for the THC (72) standard curve was also applied. The values obtained from the standard 
curves were converted into % cannabinoid as per section 15.2.1.The results for the individual for the 
five samples analysed are shown below (see Table 15.2.1.2). A typical chromatogram of a herbal 
sample is shown in Figure 15.2.1.1 C, above. 
 
 
 
Sample Number Name/Origin %THC (72) %CBN (73) %CBD (74) 
40 Early ‘98 9.54 0.72 B.L.O.Q.* 
41 Rosslare ‘97 4.78 0.68 B.L.O.Q.* 
41A Skunk 9.48 B.L.O.Q.* B.L.O.Q.* 
42 Dutch ‘97 5.86 1.52 0.48 
43 Cannablitz 1.36 0.33 0.18 
 
Table 15.2.1.2: THC (72), CBN (73) and CBD (74) contents for herbal samples analysed. 
 
Although the sample size is small it is of interest that the THC (72) content ranged from 1.36% to 
9.54%. The average THC content (72) is 6.20% (standard deviation 3.44), and the CBN (73) content is 
much lower at 0.65% (standard deviation 0.57), which indicates that the samples are not to old or have 
been very well preserved (Ross, 1997/1998). The Dutch ’97 sample, had a high level of CBN (73) 
(1.52%) compared to THC (72) (5.86%). The CBD content was low, as one would expect for drug-type 
herb with an average level of 0.13% (standard deviation 0.21).  Traditional herbal cannabis would 
generally contain 0.5-5.0% (Martin, 1997/1998). It is obvious that three of the samples, Early ’98, 
Dutch ’97 and ‘’Skunk’’ exceed the level suggested.  Hence, these can only be described as either 
Sinsemilla-type (there was no evidence of seeds in any of the plants) or Nederweed-type, as these types 
of plants are the only ones capable of generating so much THC (72) (Adams, 1996).   
 
The ‘’Cannablitz’’ had a low level of THC (72) in comparison to the other samples. All the other 
samples were received as intact flowering tops and leaves. The Cannablitz on the other hand had been 
processed and was coarsely powdered. It contained a lot of stalk which would have diluted the sample 
somewhat as the stalk of the cannabis plant does not contain a high level of THC (72). However it 
seems less likely that Cannablitz was Sinsemilla or Nederweed and more likely that it was some 
traditional variety of cannabis herb. Some work carried out on the THC (72) content of cannabis seized 
in the Republic of Ireland in 1981 suggested that no high THC (72) content varieties were encountered 
at that time (O’Brien, 1981) as the average THC content of eight herbal samples analysed was 1.36 
(range 0.18%-2.9%). Hence, the above results provide proof that high THC (72) content varieties of 
cannabis are now available in the Republic of Ireland. Also if one aggregates the %THC (72) and the 
%CBN (73) one gets an idea of the initial levels of THC (72). In this case the average goes from 6.2% 
(THC only) to 6.85% (THC +CBN). This is high when compared to the average content of traditional 
marijuana observed by Elsohly et al. (2000) over the period 1980-1997 (rising from 1.5 % THC in 
1980 to 4.2% in 1997). THC (72) contents of up to 11.53% have been recorded for Sinsemilla over the 
same period (Elsohly, 2000). Niesink reported that the average THC (72) content in Dutch herb was 
7.5%, which compares well with our observations (Niesink, 2000). King reported that the THC (72) 
content of the flowering tops of herb, seized in the U.K. in 1999, was 9.6%, which is high when 
compared to the average reported here (20101). This average compares well with the THC (72) 
contents of the Early ’98 and the Skunk samples.   
 15.2.3 Cannabinoid content of Resin 
 
In all 62 samples of resin were analysed. The results are presented in three sections. 
1. Samples 30-39 & 44-67 (THC (72), CBD (74) and CBN (73) standard curves prepared)  
2. Samples 20-29 (Only THC (72) and CBD (74) standards curves prepared) 
3. Samples 1-19 (Only THC (72) standard curve prepared) 
 
Cannabinoid content of samples 30-39 & 44-67. 
 
A typical chromatogram for a resin sample is shown in Figure 15.2.1.1 B. The peak area ratios for the 
CBD (74) and CBN (73) were obtained straight from the graph and converted into % values as per 
section 15.2.1. The THC (72) curve was corrected as per section 15.1.  The results of percentage 
(corrected) THC (72), percentage CBN (73) and percentage CBD (74) for samples 30-39 and 44-67 
are shown below (Table 15.2.3.1). 
 
 
 
 
 
 
 
 
 
 
Sample No. %THC (72) % CBN (73) % CBD (74) Sample No. % THC (72) % CBN (72) % CBD (72) 
30 3.05 3.20 1.41 51 0.40 0.45 1.51 
31 2.61 0.78 2.01 52 5.52 1.02 2.66 
32 0.44 1.08 0.07 53 0.54 1.96 1.62 
33 1.65 2.40 0.56 54 0.53 2.52 1.23 
34 0.70 2.70 1.89 55 0.68 1.04 1.49 
35 1.07 3.10 2.16 56 0.84 2.47 2.11 
36 0.58 2.82 2.20 57 0.84 2.07 2.13 
37 2.37 1.37 2.45 58 2.04 2.07 1.20 
38 5.15 1.14 2.66 59 0.38 2.93 2.28 
39 0.44 2.16 1.72 60 0.68 2.34 2.16 
44 0.21 1.15 1.18 61 0.32 3.78 3.24 
45 0.80 2.73 1.94 62 0.40 2.66 1.67 
46 0.88 2.93 2.03 63 0.88 3.34 4.40 
47 1.07 2.63 2.20 64 0.83 2.12 11.54 
48 0.31 0.65 0.48 65 0.36 2.25 1.50 
49 1.40 4.59 4.29 66 0.68 0.74 1.42 
50 0.50 1.77 1.85 67 1.96 2.59 2.11 
 
Table 15.2.3.1 : Cannabinoid content of samples 30-39 and 44-67. 
 
Cannabinoid content of samples 20-29. 
 
For these samples, the THC (72) standard curve was corrected using the CBD (74) standard curves 
and the CBN (73) values were predicted using the CBD (74) standard curve. The results of percentage 
(corrected) THC (72), percentage CBN (73) and percentage CBD (74) for samples 20-29 are shown 
below (Table 15.2.3.2). 
 
Sample Number %THC (72) % CBN (73) % CBD (74) 
20 3.84 0.86 2.00 
21 2.20 1.89 2.10 
22 2.33 2.68 2.05 
23 2.64 2.31 2.49 
24 1.48 1.72 1.54 
25 0.44 2.16 2.30 
26 0.50 3.19 3.12 
27 1.34 1.95 1.84 
28 2.02 2.02 2.01 
29 0.72 1.65 1.61 
 
Table 15.3.2.2: Cannabinoid content of samples 20-29. 
 
 
 
 
 
THC content of samples 1-19. 
As previously mentioned it was only possible to determine the amount of THC (72) in these samples, as 
only a THC (72) standard curve was prepared during the analysis of these samples. The deviation 
between the uncorrected THC (72) estimations of samples 30-39 & 44-67 and the corrected THC (72) 
values was found to be 22.9%. Subtracting the two values (corrected and uncorrected) from each other 
and dividing by the number of samples gave this average. The actual THC (72) contents as calculated 
by the THC (72) standard curves were multiplied by 1-0.229 (0.771) in order to correct these figures. 
This is very crude but in the absence of a reliable standard curve the only option was to correct the 
values on the basis of more reliable historical data. The corrected THC (72) contents for the resin 
sample 1-19 are shown in Table 15.3.2.3. 
 
Sample Number % THC (72) Sample Number % THC (72) 
1 6.22 11 1.54 
2 0.19 12 3.85 
3 0.87 13 3.62 
4 4.26 14 2.56 
5 2.53 15 3.12 
6 3.72 16 3.83 
7 2.76 17 3.13 
8 2.21 18 1.02 
9 4.13 19 1.88 
10 1.49   
 
Table 15.3.2.3: corrected THC (72) content of samples 1-19. 
 
Cannabinoid content of Resin samples seized in the Republic of Ireland. 
 
The average THC (72) content found in all samples of cannabis resin analysed was calculated, and 
found to be 2.11% (standard deviation, 1.45%, range 0.4%-8.08%). The average amount of CBN (73), 
excluding samples 1-19, was found to be 2.13% (standard deviation 1.14%, range 0.31%-4.59%). 
Finally the average amount of CBD (74), excluding samples 1-19, was found to be 2.19% (standard 
deviation, 1.65%, range 0.07%-4.38%). The level of THC (72) reported in resin samples varied from 
7%-14% (Martin, 1997/1998), however Adams et al. (1996) claimed that values from 2%-20% have 
been recorded. The level of THC found in resins was low in comparison to reported values. Conversely 
the CBN (73) levels (2.13% average) suggested that the samples had aged significantly (Fairbairn, 
1976). Aggregation of the percentage THC (72) and CBN (73) content perhaps better reflects the 
original average THC (72) content present when the resin was first produced.  In these circumstances 
average THC (72) content in the resin at the time of preparation would be 4.24% which seems 
reasonable when this figure is compared to those recorded by Elsohly (2000) in the USA. He reported 
that the average THC (72) content of resin analysed during the period 1980-1997 was 5.52% and the 
combined CBN (73) and THC (72) content was 7.00% in the USA for the same period. Resin samples 
analysed by the Forensic Science Service in the U.K. in 1999 were found to have an average THC (72) 
content of 5.0%, which again is high when compared with the values reported here (King, 2001). There 
was no CBN (73) data available for these samples (King, 2001). 
 
The CBD levels reported here were also high (2.19% (standard deviation, 1.65%, range 0.07%-
4.38%)) when one considers the fact that the resin samples contained a reasonable amount of THC 
(72). This observation may indicate that the resin was actually collected from an intermediate type 
plant. This theory will is investigated further in the following section.  
 
It is notable that the work of O’Brien et al. 1981 found lower levels of CBD (1.04%) and THC (0.9%) 
for a number of resin samples analysed, than are reported here. The level of CBN found in the same 
samples was 1.4%, which again is lower, but the high levels of CBD would suggest that the resin 
samples analysed by O’Brien et al. may also have been from an intermediate type variety of Cannabis 
sativa. 
 
15.3 Phenotype ratio of cannabis hemp, herb and resin seized in the Republic of Ireland. 
 
The phenotype ratio concept, as described in the introduction, was applied to the samples of herb, 
hemp and resin (excluding sample 1-19). The formula that was suggested by Fetterman (1971) was 
applied here where the following equation allows the determination of a phenotype (Equation 15.3.1). 
 
 
Equation 15.3.1 
 
The criteria of de Meijer et al. (1992) were used for the classification of phenotypes according to 
cannabinoid content, including provision for an intermediate phenotype (Table 15.3.1). Note that de 
Meijer et al. excluded CBN (73) as the samples analysed by this group were all fresh, however it is 
acceptable to include CBN (73) in our case. 
 
Phenotype %THC + %CBN %CBD %THC+%CBN / %CBD 
Fibre type < 0.5 ≥ 0.5 < 1 
Intermediate type ≥ 0.5 ≥ 0.5  
Drug type ≥ 0.5 < 0.5 > 1 
 Table 15.3.1: Criteria for the classification of phenotypes according to cannabinoid content (de Meijer et al. 1992). 
 
Giroud et al. (1999) used the same formula as Fetterman and de Meijer. However Giroud, et al. 
calculated the logarithm (base 10) of equation 15.3.1 in order to simplify the graphical interpretation 
of the data he presented.   The equation now changes to 15.3.2 
 
Equation 15.3.2 
 
Now, if one uses equation 15.3.2 the criteria shown in table 15.3.1 must be changed to take the 
logarithm into account. The criteria of de Meijer et al. now change to the criteria shown in Table 
15.3.2. 
 
Phenotype %THC + %CBN %CBD Log(%THC+%CBN / %CBD) 
Fibre type < 0.5 ≥ 0.5 < 0 
Intermediate type ≥ 0.5 ≥ 0.5  
Drug type ≥ 0.5 < 0.5 > 0 
 
Table 15.3.2: Log10 of criteria for the classification of phenotypes according to cannabinoid content (de Meijer et al., 1992). 
 
A plot of %THC +  %CBN versus the result of equation 15.3.2 (log (%THC +%CBN /%CBD) is very 
useful in visually comparing the phenotype of the subjects under analysis .  If we look firstly at the plot 
for the hemp samples (see Figure 15.3.1).  
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Figure 15.3.1: Phenotype plot for hemp samples 
 
One can see from the plot that all of the sample points in Figure 15.3.1 are less that zero on the y-axis 
(log (%THC +%CBN /%CBD). This indicates that the samples are of the fibre type (see Table 15.3.2). 
It is noteworthy that all of the hemp samples had CBD  (74) levels above 0.5%, satisfying the %CBD 
criterion outlined in Table 15.3.2. 
 
The resin samples are also plotted in this way and are shown in Figure 15.3.2, below. 
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Figure 15.3.2: Phenotype plot for Resin samples 
 
One can see from Figure 15.3.2 that all of the resin samples have greater than zero on the y-axis (log 
(%THC +%CBN /%CBD) except one. Further all samples contained levels of CBD (74) greater than 
0.5 %. The combination of both of these criteria indicates that the samples are intermediate-type. The 
one sample which does not fit into any of the three categories outlined in Table 15.3.2 could be 
considered unusual, it must be derived from a variety closely related to hemp as it had a high levels of 
CBD (74) (1.51%). 
 
Note that if the CBD (74) values were below the limit of quantification as was the case in 3 of the herb 
samples or if there was no measurable amount of both THC (72) and CBN (73) then those samples 
were omitted. The phenotype plot of the two herbal samples that could be included is shown below 
(Figure 15.3.3). 
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Figure 15.3.3: Phenotype plot for Resin samples 
 
The other three herbal samples had such low levels of CBD (74) (below the limit of quantitation) that 
there would be no denominator for equation 15.3.2.  However the fact that there was no quantifiable 
CBD (74) and that the levels of THC (72) were high (9.54%, 4.78% and 9.48%) indicates that these 
samples were indeed of the drug-type variety. 
 
The combined plot of Figures 15.3.1, 15.3.2 and 15.3.3, for herbal, hemp and resin samples 
respectively is shown below (Figure 15.3.4). 
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Figure 15.3.4: Plot phenotype ratio for herbal, hemp and resin samples 
 
 
 
15.4: The THC content of Joints. 
 
Buchanon et al. (1998) estimated the amount of cannabis resin and the amount of cannabis herb in 
‘’joints’ seized by the Irish Gardai over the period 1980 to 1996 (1998). It was found that the average 
amount of cannabis resin found in hand made cigarettes was 102 mg, while the amount of herb was 
found to be 260 mg (Buchanon, 1998). If one applies the amounts of THC (72) quoted in the 
introduction then the following ranges are likely to be administered by the cannabis smoker (see Table 
15.3.5). 
 
Cannabis product Range of THC (72), in a ‘’Joint’’, according to the 
estimates of Buchanon et al. (1998) 
Cannabis Herb 0.51 mg – 5.1 mg 
Cannabis Resin 18.2 mg –36.4 mg 
Skunk/Sensimilla Up to 52 mg 
 
Table 15.3.5: The estimate THC (72) content range in ‘’joints’’ based on the results of Adams et al. (1996), Buchanon et al. 
(1998) and Martin et al. (1997/1998). 
 
Hall et al. (1998) claim on the basis of Australian research that a typical joint may contain from 0.5 g 
to 1.0 g (of Herb presumably) resulting in a content of THC (72) between 35 mg- 70 mg for traditional 
herb and up to 100 mg for ‘’Skunk’’ /Sinsemilla type drug. 
 
As one can see from the Table 15.3.5 the THC (72) content could be quite varied. However it is thought 
that only a small amount of cannabis is required (e.g. 2-3 mg of available THC (72)) to produce a brief 
pleasurable euphoria (high), but more may be needed to satisfy a regular user (Hall, 1998). The THC 
(72) delivered varies between 20% and 70% (Hall, 1994), its bioavailabilty ranging from 5%-24% 
(Adams, 1996). 
 
Using the THC  (72) levels presented here an estimate of the amount of THC (72) likely to be 
experienced in the Irish situation can be estimated. The estimated amount of THC (72) in a joint 
containing 260 mg of herbal cannabis would be 16.2 mg, but could range from 3.5 mg- 21.84 mg. The 
amount of THC (72), which is likely to be found in a ‘’joint’’ prepared using cannabis resin, would be 
4.3 mg, but could range from 0.40 mg- 8.2 mg. When one compares this to the value of 16.2% THC in a 
joint containing herbal cannabis, one can see that the difference in dose is very large. These high doses 
may increase the likelihood of the precipitation of some of the acute adverse effects mentioned in the 
introduction to this chapter, especially among naive or first time users (Hall, 1999).  It is noteworthy 
that there is no information available on the amount of either herb or resin used when individuals 
attempt to smoke cannabis using a pipe, hence no estimation can be made as to the amount of THC 
(72) administered via this route in the Republic of Ireland. 
 
15.5: Conclusion 
 
Hemp samples grown under license from the Department of Health and Children satisfy the criteria of 
the licence (%THC <0.3%) and all the samples were deemed to be of the fibre-type phenotype. High 
potency varieties of cannabis herb are being traded on the black market in the Republic of Ireland, and 
all samples analysed would appear to be of the drug phenotype. The resin samples analysed would all 
appear to be of the intermediate phenotype and do not seem to have a %THC content which is 
comparable with samples analysed in the USA but not with samples analysed in the Netherlands. The 
work presented here goes only part of the way to estimating the potency of cannabis products seized 
and/or grown in the Republic of Ireland. Further work is needed in order to both improve the quality if 
the data presented here but also as a means of monitoring changes (if any) in the potency of cannabis 
products seized and/or grown in the Republic of Ireland 
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